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SUMMARY
SUMMARY
The value of thrombolytic therapy in the treatment of 
acute myocardial infarction is now unchallenged following 
the publication of large scale clinical trials showing an 
impressive reduction in mortality. Intravenous 
administration of a thrombolytic agent in the early hours 
of myocardial infarction is established practice in all 
hospitals, from district generals to specialized cardiac 
centres. The aim is to obtain a patent artery, improve 
left ventricular function and decrease mortality. The 
effectiveness of intravenous therapy obviates the need for 
acute angiography and intracoronary administration, but a 
definitive statement concerning whether reperfusion has 
occurred cannot be made.
The 12 lead ECG undergoes well recognised dynamic changes 
in the early phase of myocardial infarction. Successful 
lysis, either induced or spontaneous, will modify these 
changes. Whether these modifications can be quantified 
and used as simple non invasive tests of reperfusion, 
myocardial salvage and infarct size has caused much 
speculation. To have such a simple, widely available, 
reproducible and inexpensive tool would be highly 
desirable in a clinical setting. This thesis has 
addressed these questions.
The first study demonstrated the rapid fall .in ST segment 
elevation occurring in response to thrombolysis, and
18
introduced a measurement which expresses this fall as a 
proportion of the admission value. This is termed the 
Fractional Change and can be applied to either 24 hour 
tape recordings or to the 12 lead ECG. A Fractional 
Change Value  ^ 0.5 occurring by 2-3 hours following
therapy is highly specific and sensitive for reperfusion. 
The next study examined whether an electrocardiographic 
marker of infarct size, the QRS score, was attenuated in 
patients achieving successful reperfusion compared with a 
historical cohort of patients with infarctions given no 
therapy other than simple analgesia. Only patients with 
anterior infarcts were studied, and although both groups 
had similar areas of myocardium at jeopardy on admission, 
the group of patients achieving successful reperfusion had 
a significant reduction in the QRS score at 48 hours 
compared to the control group.
These initial studies showed that dynamic changes in the 
ECG can reflect both reperfusion and myocardial salvage, 
but are limited in that they were performed in relatively 
small numbers, and the ECG measurements were made and 
tabulated manually. A method for digitizing 12 lead ECG's 
with subsequent computer storage of data for comparative 
analysis has been developed, and incorporates an automatic 
QRS scoring system. The developmental work involved in
19
setting this system up and its subsequent validation with 
inter- and intra-observer variation studies is presented 
in Chapter 5.
This system was then used to follow the sequential ECG 
changes in a prospective angiographically controlled, 
double blind randomised trial of 128 patients comparing 
anistreplase with streptokinase. The 90 minute patency 
rates for both drugs were found to be the same 
(anistreplase 55%, streptokinase 53%) . Coronary 
angiography performed at 90 minutes post therapy allowed a 
detailed correlation between ECG changes on admission and 
acute coronary anatomy. The findings of this particular 
study showed that the height of ST segment elevation does 
not bear any relation to the age of the infarct, that 
there is a high incidence of reciprocal change early in 
the course of infarction, and that this is not related to 
coexisting disease or remote ischaemia, but is likely to 
be an electrocardiographic mirror phenomenon.
Examining the resolution of ST segment elevation and 
depression showed that it was the rate of fall which 
discriminates patent from non patent arteries, and that 
using a Fractional Change Value of 0.5 to detect 
reperfusion, calculated at 2 hours post treatment from a 
single lead showing maximal ST segment elevation, gave the 
best sensitivity (81%) and specificity (60%), when 
compared with a number of different parameters. In
20
addition, it appears that the presence of collaterals 
supplying the infarct area could result in a high 
Fractional Change Value despite no antegrade perfusion. 
This study also confirmed that achievement of a patent 
artery early (i.e. before 90 minutes) significantly 
attenuated Q wave development, R wave loss and the QRS 
score in anterior infarction, but did not affect 
electrocardiographic markers of infarct size when applied 
to inferior infarcts.
In summary, this thesis provides a detailed study of the 
electrocardiographic changes taking place in acute 
myocardial infarction, especially as a consequence of 
treating with thrombolysis, quantitates these changes and 
shows where they may be used in a clinical setting as non- 
invasive tests to aid patient management.
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CHAPTER 1 - INTRODUCTION
SECTION A. THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION 
SECTION B. ELECTROCARDIOGRAPHY IN ACUTE MYOCARDIAL INFARCTION
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A. THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION
1 . 1 PATHOPHYSIOLOGY OF THROMBOSIS IN ACUTE MYOCARDIAL 
INFARCTION
The rationale of giving thrombolytic therapy to patients
with acute myocardial infarction requires the presumption
that the coronary occlusion has been caused by thrombus
formation. Medical opinion appears to have turned full
circle regarding this subject. Herrick first described
thrombotic coronary occlusion in patients with acute
myocardial infarction in 1912. Over the following decades
the belief that thrombotic occlusion occurred as a result
and not the cause of the infarction, was popularised by
the work of Branwood and Montgomery, (1956) and Roberts
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and Buja (1972). Radiolabelled I fibrinogen was 
administered to patients with acute infarction 47 hours 
after the onset of symptoms, and subsequent post mortem 
examination revealed the intracoronary thrombus to be 
radioactive in all but 1 patient, providing further 
evidence for coronary thrombosis being a secondary 
phenomenon (Erhardt et al., 1973).
This work however was refuted by De Wood et al. (1980) in
his classical paper where coronary angiography was 
performed in a total of 322 patients within 24 hours of 
the onset of acute myocardial infarction. This group 
showed a decreasing percentage of total coronary occlusion 
from onset of symptoms, being 87.3% between 0 and 4 hours,
23
85.3% between 4 and 6 hours, 68.4% between 6 and 12 hours 
and 64.9% between 12 and 24 hours. The main acute 
arteriographic finding indicating thrombus was identified 
as persistent staining of intraluminal material by the 
contrast agent. In addition, a subgroup of patients 
underwent surgical revascularization and thrombus was 
recovered in 8 8 % of patients by an intraoperative Fogarty 
catheter, confirming in an in vivo model the importance of 
thrombus in acute myocardial infarction. In addition, 
this study suggested the existence of a spontaneous 
reperfusion rate by showing a decreasing incidence of 
thrombotic occlusion as the time from onset of symptoms to 
angiography increased. This is of particular importance 
when assessing reperfusion rates of different thrombolytic 
agents. Since this work, many patients have undergone 
emergency angiography within a few hours of onset of 
myocardial infarction for confirmation of diagnosis, and 
in some cases for administration of therapy. The findings 
confirm the high percentage of thrombotic total coronary 
occlusions early in the process of infarction (Table 1).
24
Trial
No. of 
Pts. Time from onset
Percent­
age Total 
Occlusion
Rentrop et al. 
(1981 )
29 (not given - R waves 
and pain still 
present)
76%
Anderson et al. 
(1983)
24 <4 hrs 83%
Kennedy et al. 
(1983)
250 < 1 2 hrs 8 6 %
TIMI Phase I 
(1985)
316 <7 hrs 74%
Simoons et al. 
(1985)
136 <4 hrs 82%
Blanke et al. 
(1985)
130 < 1 2 hrs 69%
Williams et al. 
(1986)
47 <7 hrs 78%
TABLE 1: PERCENTAGE TOTAL THROMBOTIC OCCLUSION AT
ANGIOGRAPHY IN EARLY STAGES OF ACUTE MYOCARDIAL 
INFARCTION
1.2. POTENTIAL FOR MYOCARDIAL SALVAGE
Over the same period as described above, several other 
groups were working to devise means of limiting the extent 
of myocardial damage. In Herrick's original paper (1912) 
he hypothesised that the "hope for damaged myocardium lies 
in the direction of securing the supply of blood, so as to 
restore as far as possible its functional integrity". The 
first evidence for reversibility of myocardial damage was 
presented by Tennant and Wiggers (1935). They showed in a 
dog model that reperfusion following temporary occlusion 
resulted in restoration of myocardial function. Later, 
work by Reimer et al. (1977) established the wavefront 
phenomenon of ischaemic cell death, again in a dog model. 
By varying the time of total circumflex occlusion from 40 
minutes to 3, 6 , 24 and 96 hours, they showed a time 
dependent increase in degree of myocardial necrosis. 
Subendocardial tissue showed necrosis very quickly, but a 
subepicardial zone of tissue remained viable, and 
therefore available for salvage for at least 3, and up to 
6 hours. Salvage of jeopardised myocardium with 
betablockers (Maroko et al., 1971; Rasmussen et al., 1977) 
and hyaluronidase (Maroko et al., 1972) was subsequently 
shown.
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One of the difficulties in dealing with animal models is 
whether the model will translate adequately for 
application to man. Nevertheless, following on from the 
conclusions derived from the above studies, various 
reports were published in the late 70's showing beneficial 
effects in man from hyaluronidase (Maroko et al., 1977), 
intra-aortic balloon pumping (Leinbach et al., 1978) and 
betablockers (Yusuf et al., 1980; The International 
Collaborative Study Group 1984).
These interventions attack the problem from 2 angles - 
firstly trying to reperfuse the occluded artery, and 
secondly, by reducing myocardial oxygen consumption.
These two different mechanisms of action have led to 
combination therapy being tried, with apparent synergy in 
the dog model (Lo et al., 1985). Nevertheless, the most 
attractive form of treatment is to remove the initial 
insult by lysing the thrombotic coronary occlusion, and it 
is to this end that much research has focused over the 
last two decades.
The first report of intravenous thrombolytic therapy being 
administered in acute myocardial infarction was by 
Fletcher et al. in 1959, using streptokinase. Reperfusion 
data for the 2 2 patients treated in this way is not 
available, but a low mortality and morbidity rate 
suggested that intravenous streptokinase was. safe and 
beneficial in this situation. Nevertheless, it took a
27
further 17 years before reports appeared showing 
successful lysis of coronary thrombi in acute myocardial 
infarction using the intracoronary route of administration 
(Chazov et al., 1976; Rentrop et al., 1979). Since then, 
many studies have been performed using both intravenous 
and intracoronary routes of administration, showing both 
efficacy and reduction in mortality, confirming the place 
of thrombolytic therapy given early in acute myocardial 
infarction.
1.3. THROMBOLYTIC AGENTS
A further area of intense research over the past decade 
has been the search for an ideal thrombolytic agent. The 
requirements for this drug would be, clot specificity with 
a high fibrin affinity and little fibrinogenolytic 
activity, ease of administration with a rapid onset of 
action with sustained local activity, and it should be 
non-allergenic. The three main drugs, streptokinase, 
anisoylated plasminogen streptokinase activator complex 
(anistreplase) and tissue Plasminogen Activator (tPA), 
will be described with particular reference to the above 
qualities. Published patient studies utilizing these 
drugs will be compared with respect to reperfusion, 
mortality and left ventricular function. No mention is 
made of urokinase or pro-urokinase, as this thesis does 
not contain work relating to these agents.
28
1.3.1. Streptokinase
As the first thrombolytic agent available, most clinical 
experience has been with streptokinase. It is a single 
chain protein (molecular weight 47,000 daltons) which is 
produced by Group C beta-haemolytic streptococci. Its 
action is to combine with the circulating proenzyme 
plasminogen and the resulting complex is capable of 
converting more plasminogen molecules to active plasmin 
with subsequent clot lysis. Due to previous streptococcal 
infections, patients may have a variable amount of 
circulating antibody to streptokinase. This needs to be 
neutralised before streptokinase has a therapeutic lytic 
effect, especially if given intravenously, as opposed to 
the more direct intracoronary route. In practice however, 
standard dosage regimens are used following the work of 
Verstraete et al. (1966) which showed that a dose of 1.25 
million I.U. streptokinase intravenously will neutralise 
circulating antibodies and cause systemic fibrinolysis in 
more than 97% of the population. Administering 
streptokinase locally via a coronary catheter reduces the 
total dose which needs to be given (about 250,000 I.U.), 
but even this reduced dose has been shown to have 
significant effects on circulating fibrinogen levels, 
resulting in a systemic lytic state. Cowley et al. (1983) 
showed a 70% reduction in fibrinogen levels in 8 8 % of 
patients receiving a mean of 201,000+24,000 I.U. 
streptokinase via the intracoronary route. Although 
bleeding complications are reported, they tend to be
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associated with femoral puncture sites for angiography or 
venepuncture sites (Simoons et al., 1985).
As streptokinase is a foreign protein which can stimulate 
an antibody response, there is a theoretical risk of an 
allergic reaction following intravenous administration. 
Typically this is covered prophylactically by giving 
hydrocortisone and chlorpheniramine. However, the 
multicentre GISSI study (1986) did not require the 
administration of prophylactic steroid and recorded the 
incidence of anaphylactic shock at only 0.1%.
1.3.2. Anistreplase
Anistreplase is an anisoylated plasminogen streptokinase 
complex in which the active serine site on plasminogen is 
acylated with P-anisoic acid conferring chemical 
protection from the normal plasma inhibitors, alpha
2
antiplasmin and alpha macroglobulin. The streptokinase
2
plasminogen complex is still able to bind to fibrin
through its lysine binding site. Once bound, hydrolysis
causes deacylation and semi-selectively activates
anistreplase at the clot surface. However, in doses of more
than 10 units not all plasmin generated is neutralized by
circulating alpha antiplasmin, and a systemic
2
fibrinogenolytic state ensues (Ferres, 1987). The 
deacylation half-life is 40 minutes (Smith et al., 1981) 
with a plasma clearance half-life of 70 minutes (Matsuo et
30
al. , 1981). Compared with the shorter half-life of 
streptokinase of 18 minutes (Martin, 1982) these 
pharmacokinetic properties allow for a single bolus dose 
rather than a prolonged infusion regimen. An overview of 
the early patient studies with anistreplase is presented by 
Hillis and Hornung (1985) and illustrates the difficulties 
in achieving a balance between an acceptable reperfusion 
rate and limited systemic fibrinogenolysis. Dosing up to 
15 units resulted in initial successful reperfusion, but a 
high early reocclusion rate (Hillis et al, 1983). The 
standard intravenous dose of alteplase is now accepted as 
30 units which is inevitably associated with a degree of 
systemic fibrinogenolysis. Been et al. (1986) showed that 
at this dose the mean fibrinogen level fell to a third of 
the predosing level at 1 hour with few patients having a 
fibrinogen level below 0.5 g/L. Thus, initial trials have 
shown anistreplase to be effective in obtaining 
reperfusion, and to be advantageous in that it is given as 
a single bolus dose. The theoretical risk of anaphylaxis 
remains with anistreplase but similar to the GISSI 
findings with streptokinase, the recent AIMS study (Aims 
Trial Study Group, 1988) reported anaphylaxis in 2 of 502 
patients (0.4%). Prophylactic steroids were not used 
routinely.
1 .3.3. Tissue Plasminogen Activator
Although these serine proteases, called tissue plasminogen 
activators were known to exist as far back as 1947 (Astrup
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and Permin), the low yield of these substances from human 
tissues delayed progress, until in 1982 Collen et al. 
reported the isolation and purification of human tissue 
type plasminogen activator (t-PA) from a melanoma cell 
line. A year later Pennica et al. (1983) cloned the gene 
responsible for the synthesis of recombinant t-PA (rt-PA) 
and expressed it using E.Coli. Thus, sufficient 
quantities were produced to evaluate its lytic activity 
and to provide treatment for patients with acute coronary 
occlusion. The attraction in developing this agent for 
widespread use was that it has several properties 
considered advantageous to a thrombolytic drug. As it is 
a naturally occurring compound, it lacks antigenicity, and 
it has been termed clot selective, thus supposedly 
avoiding the induction of a systemic lytic state. The 
half-life is short, in the order of 5 minutes (Garabedian 
et al., 1986), allowing manipulation to achieve 
haemostatic control if required for invasive procedures. 
Tissue plasminogen activator owes its clot selectivity to 
its binding properties. In circulation it does not bind 
avidly to plasminogen, but has a high affinity for fibrin, 
to which it binds at specific sites in the kringle 
structures. Plasminogen binds avidly to this t-PA fibrin 
complex, and is thus activated at the clot surface. Any 
plasmin which escapes will be inactivated by alpha
2
antiplasmin.
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The ability of t-PA to lyse thrombi without producing a
systemic lytic state was shown first in animals (Van de
Werf et al., 1984a) and then in humans, where 6 out of 7
patients with evolving myocardial infarction were shown to
reperfuse without depleting levels of fibrinogen,
plasminogen and alpha antiplasmin (Van de Werf et al.,
2
1984b). Despite encouragingly high levels of reperfusion 
obtained initially with intravenous infusions of rt-PA, 
the problem has been that a high percentage of patients 
reocclude or suffer further infarction. Collen et al. 
(1984) reported an initial reperfusion rate of 75% after 
intravenous infusion of 0.5-0.75 mg/Kg rt-PA. Patients in 
this study who had been randomised to placebo were then 
given intracoronary rt-PA, 9 out of 13 patients achieving 
reperfusion. There was very little change in fibrinogen 
levels, but there were 5 early reocclusions. Gold et al.
(1986) reported a reocclusion rate of 45% in patients with 
persistent high grade (>80%) stenoses. Prolonging the 
infusion of rt-PA over 4 hours maintained patency. In 
contrast, work from the European Co-operative Group for t- 
PA (Verstraete et al., 1987) reported a reocclusion rate 
of 8% within 24 hours, and there was no difference between 
patients receiving a maintenance intravenous infusion of 
30 mg rt-PA over 6 hours and those who did not. Work 
arising from the TIMI study (Rao et al., 1988) compared 
the degree of systemic fibrinogenolysis induced by 1.5 
million I.U. streptokinase to that caused by 80 mg of rt- 
PA. Fibrinogen fell by a mean of 33% 5 hours following
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rt-PA compared to 58% after streptokinase. Similarly, 
plasminogen fell by 57% after rt-PA and 82% after 
streptokinase, suggesting less systemic effect.
Verstraete et al. (1985b) showed a fall in fibrinogen 
levels to 52% of pre infusion levels folowing a dose of
0.75 mg/Kg. It is now thought that this systemic lytic 
activity may in fact be desirable to reduce the 
reocclusion rate.
One of the disadvantages of rt-PA is that it remains very 
much more expensive than either streptokinase or 
anistreplase. Of its claimed advantages, clot specificity 
is now thought to be less important for reasons outlined 
above. It is non allergenic, and it has been suggested 
that it is the drug of choice when administering a second 
dose of thrombolytic therapy to a patient who has 
previously received streptokinase especially if within the 
past year.
1 .4 AIMS OF TREATMENT 
1.4.1. Reperfusion
Restoring blood supply to the myocardium by lysing 
coronary thrombus is the rationale behind giving 
thrombolytic therapy. Reperfusion is assessed 
angiographically and various scoring systems (TIMI Trial 
1985; Verstraete et al., 1985a) have been employed to 
quantify the degree of reperfusion. Unfortunately these
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two scoring systems are not directly comparable, and the 
doses of agents used varies between studies. Similarly, 
reperfusion rates will vary depending on the time delay 
following the onset of symptoms to the initiation of 
treatment, the drug given and the method of 
administration. In addition, it is important to ascertain 
whether a study is reporting a patency rate or a true 
reperfusion rate. The latter requires that a pre­
treatment angiogram is performed to document occlusion 
prior to treatment. Performing angiography only after 
thrombolytic therapy has been started will give a slightly 
higher incidence of open arteries as it does not take into 
account the incidence of spontaneous reperfusion reported 
by De Wood et al. (1980). These are termed patency rates, 
and are higher than reperfusion rates by about 15-20%. 
Figure 1 summarises reperfusion and/or patency rates from 
the major trials which have used different agents. Some 
of the smaller clinical trials are included to illustrate 
the problem of assessing drug efficacy when interpreting 
results for different series with differing protocols and 
small numbers.
As the length of time increases between onset of pain and 
administration of thrombolytic therapy, the reperfusion 
rate decreases (Smalling et al., 1982). Anistreplase was 
initially assessed in small patient numbers and an 
excellent reperfusion rate reported (Been et al., 1985; 
Kasper et al., 1986). Timmis et al. (1987) studied the
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same number of patients using the same dose, but by 
extending the time window from 3 hrs to 6 hrs, the 
reperfusion rate dropped to 56%. When assessed in a much 
larger multicentre trial (Anderson et al., 1988) the 
reperfusion rate using anistreplase seems to have settled 
at 51% within a 6 hour time window.
An overall mean intracoronary reperfusion rate of 7 5% with 
streptokinase has remained the "gold standard" against 
which all of the agents and routes of administration are 
compared. Against this is the time saved if intravenous 
therapy can be administered soon after admission, rather 
than wait for the cardiac catheterisation laboratory to be 
set up. With the advent of effective intravenous 
administration, coronary angiography is no longer required 
to administer treatment, and is a non realistic means of 
determining if reperfusion has occurred in large patient 
groups outwith cardiac centres to whom thrombolysis will 
now be available. Non invasive methods of detecting 
reperfusion are required, and research has focused on 
utilizing the so-called "reperfusion arrhythmias", 
creatine kinase release curves and changes in the ST 
segment to determine reperfusion non invasively. The 
latter topic is discussed fully in chapter 3.
The value of arrhythmias in identifying reperfusion 
remains controversial, as, in the setting of acute
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myocardial infarction, the incidence of ischaemia-induced 
arrhythmias is increased. Reperfusion associated 
arrhythmias have been described in both animal models and 
clinical practice (Penkoske et al., 1978; Goldberg et al., 
1983a). Pre-treatment with lignocaine and atropine 
confuses the issue and has been given routinely in many 
studies.
Nevertheless, two arrhythmias are thought to be fairly 
indicative of reperfusion. Firstly, accelerated 
idioventricular rhythm has been shown to be significantly 
more common in patients achieving reperfusion with 
streptokinase than in a control group (Cercek and Horvat, 
1985). Secondly, the development of bradycardia and 
hypotension, the Bezold-Jarisch reflex, is associated with 
reperfusion of the infero-posterior myocardium (Koren et 
al., 1986). The sensitivity and specificity of these 
arrhythmias for predicting reperfusion is not yet known, 
but it is generally accepted that they are benign 
arrhythmias which rarely require treatment. Of interest 
is the observation that life-threatening arrhythmias such 
as ventricular fibrillation show a lower incidence if 
thrombolytic therapy is given (Simoons et al., 1985).
Restoration of anterograde coronary arterial flow is 
associated with an early peak of creatine kinase. This 
"wash-out" phenomenon is seen irrespective o.f whether flow
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has been re-established by thrombolysis (Blanke et al., 
1984a) or by spontaneous reperfusion (Ong et al., 1983) 
and is therefore not specific for drug induced reperfusion 
(Gore et al. , 1987). It is however a useful non-invasive 
marker, and the specificity and sensitivity of this 
technique has been addressed recently by Garabedian et al. 
(1988). This group compared a conventional 
radioimmunometric assay of plasma CK-MB with a rapid 
endpoint CK-MB immunofunctional assay (<15 minutes 
analysis time). Plasma CK-MB was estimated at the end of 
a 90 minute t-PA infusion and an increase from pre­
treatment values of >2.5 fold for an LAD lesion and >2.2 
fold for an RCA lesion was taken as evidence of 
reperfusion. The rapid analysis using the 
immunofunctional assay performed well with a sensitivity 
of 83%, and a specificity of 100% when compared to 
angiographic findings. The performance of this method has 
yet to be confirmed prospectively in a larger patient 
group.
CK-MB, although thought to be relatively specific for
myocardium, only comprises about 15% of the total
myocardial CK. CK-MM makes up the remaining 85% and its
release into blood exhibits three bands on electrophoresis
known as isoenzyme isoforms MM , MM and MM (Roberts,
1 2 3
1987). The isoform MM is released during reperfusion,
3
and is converted to MM and then to MM . Morelli et al.
2 1
(1987) showed that the MM :MM activity ratio is a
3 1
38
sensitive measure of reperfusion with peak levels
occurring much earlier in patients achieving reperfusion.
Certainly the isoform MM shows more dynamic temporal
3
changes, and may be of future use in documenting early 
reocclusion.
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1.4.2 Left Ventricular Function
A further objective end-point in assessing efficacy of 
thrombolytic treatment is to measure left ventricular 
function which can be done in several ways. Left 
ventricular angiography is invasive, and although patients 
have usually undergone cardiac catheterisation in the 
acute phase, it is more difficult to obtain serial 
recordings. Radionuclide angiography is non invasive and 
reproducible, allowing several measurements over a given 
time period. Echocardiography has also been used with the 
advantage that it is non invasive and easily repeatable 
(Anderson et al., 1983). Its disadvantages are that not 
all patients can be studied with the accuracy required to 
measure ejection fraction. Infarct sizing can also be 
carried out by Thallium 201 scintigraphy, which will show 
changes in perfusion following thrombolysis (Smalling et 
al., 1982).
There are several confounding variables to bear in mind 
when interpreting left ventricular ejection fraction in 
patients with acute myocardial infarction treated with 
thrombolytic therapy. Firstly, Schwarz et al. (1985) 
showed that there is spontaneous improvement in left 
ventricular ejection fraction in patients with acute 
myocardial infarction not treated with thrombolytic 
therapy. . This change took place between admission and two 
weeks, and correlated with a degree of residual flow 
(either anterograde or via collaterals) to the infarct
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related segment. The mean change in ejection fraction for 
patients with residual flow was 6.9^2.3% vs -2.2+1.7% for 
patients without (p<0.01). This illustrates the problem 
if trials are not controlled. The improvement seen over a 
two week period suggests the phenomenon of stunning and 
Braunwald and Kloner (1982) suggested that the assessment 
of efficacy of any intervention designed to limit 
myocardial damage should be delayed for at least two 
weeks. They also purported that the basic mechanism 
behind stunning is thought to be ATP depletion.
Reperfusion wash-out of ATP metabolites, which would 
otherwise be recycled for ATP manufacture, means that 
there is a prolonged resynthesis for nucleotide 
precursors.
Secondly, it is not enough to look at global ejection 
fraction, but to relate this to changes in regional wall 
motion , Rogers et al. (1984) showed that in patients with 
"no flow" to the infarct zone and an unsuccessful 
reperfusion, the fall in global ejection fraction seen 
over a two week period was due to a reduction in movement 
of the non infarct zone. This is thought to be due to an 
initial hyperkinesis of the non infarct area which is not 
sustained.
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Despite theoretical work suggesting that a significant 
improvement in left ventricular function could be expected 
only if thrombolytic therapy was administered within 3 
hours, early reports (Reduto et al., 1981; Smalling et 
al. , 1982) did show improvement in global ejection 
fraction despite delays before treatment of 9 hours and 18 
hours respectively. Although both trials provided control 
groups, they were not randomised. The randomised trials 
of Anderson et al. (1983) and Khaja et al. (1983) 
published conflicting results. The Western Washington 
Group were not able to show an improvement in left 
ventricular function in their intracoronary streptokinase 
trial (Ritchie et al., 1984), but showed a reduction in 
infarct size and increase in left ventricular ejection 
fraction in patients randomised to intravenous 
streptokinase (Ritchie et al., 1988). This improvement was 
limited to patients with anterior infarction treated 
within 3 hours of symptom onset. They attributed the 
difference in their results to the fact that the patients 
receiving intravenous therapy were treated on average 
about 1 hour earlier, 52% being randomised within 3 hours 
of symptom onset, compared with only 22% randomised in the 
same interval in the intracoronary group (Ritchie et al.,
1988). A summary of the larger randomised trials is shown 
in Figure 2. These results confirm that administration of 
thrombolytic therapy early in the course of myocardial
42
infarction results in an improvement in left ventricular 
ejection fraction, and that this improvement may be more 
marked in specific subset of anterior infarction.
There appears to be a dichotomy between improvement in 
left ventricular function and mortality results. The ISAM 
Study Group (1986) showed an improvement in ejection 
fraction, but in this large group of 1,741 patients, they 
were unable to show an improvement in mortality, either in 
the short or long term (Shroder et al., 1987). Large 
scale multicentre studies such as ISIS 2 (1988) have shown 
benefit in mortality if treatment is commenced within a 24 
hour time window. It would be unlikely looking at the 
results of Ritchie et al. (1988) that this benefit could 
be attributed to an increase in ejection fraction. There 
may be as yet some unidentified factor which contributes 
to improvement in mortality rates, but has no relation to 
left ventricular function per se. This may be due to a 
reduction in the propensity to arrhythmias, the 
accompanying systemic lytic state, a decrease in plasma 
viscosity, or reperfusion itself which may have a 
beneficial effect in preventing infarct expansion.
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1.4.3. Mortality Data
In the early 70's and 80's many small trials were 
conducted using streptokinase in acute myocardial 
infarction. Although these trials were randomised and 
placebo controlled, most of them did not show 
statistically significant changes in mortality (May et 
al., 1983). In order to assess the net benefit of this 
treatment Stampfer et al. (1982) reported on pooled 
results from randomised trials in which intravenous 
streptokinase had been used. They showed that intravenous 
streptokinase therapy reduced mortality over the 
subsequent few weeks by about 20%. In a similar manner 
Yusuf et al. (1985) pooled data from 33 randomised trials 
using both intracoronary and intravenous routes of 
administration, for both streptokinase and urokinase. An 
overview from this data indicated that intravenous 
treatment produces a highly significant reduction in the 
odds of death (22%4L5%, p<0.001).
With improvement in treatment for cardiac failure and 
arrhythmias, the mortality rate for acute myocardial 
infarction dropped even before the introduction of 
thrombolytic therapy. Norris reported a fall in hospital 
mortality rates from 17% in 1968 (Norris et al., 1969) to 
13% in 1977-79 (Norris and Sammel, 1980) and to 10% in 
1982-84 (Norris et al., 1984). Thus, to show a 
significant reduction in mortality attributable to 
thrombolytic therapy, large scale trials are required.
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The results of GISSI published in 1986 showed an 18% 
reduction in mortality comparing intravenous streptokinase 
to controls in over 11,000 patients. Other trials 
followed, and are shown in Figure 3. The mortality rates 
shown are overall rates for all age groups and all time 
windows before initiation of therapy. Once these are 
subdivided and analysed, it becomes clear that the 
hospital mortality rate for patients <70 years receiving 
intravenous thrombolytic therapy within 3-4 hours after 
the onset of myocardial infarction is about 5% (Norris and 
White, 1988). Comparing this with the placebo mortality 
rates shown, raises the question as to whether placebo 
controlled trials are ethical. Following publication of 
ISIS 2 (1988), most large thrombolytic trials now use 1.5 
million I.U. streptokinase and aspirin as standard 
therapy, against which all other agents are compared.
The 47% reduction in mortality seen in the AIMS study 
group (1988) prompted termination of the trial early, 
recruiting 1,000 rather than the planned 2,000 patients. 
Criticism was levelled at this practice in a Lancet 
editorial which suggested that stopping early may have 
exaggerated the benefit (Anonymous, 1988). However, it 
does not negate a substantial reduction in mortality, and 
the recent publication of longterm mortality shows 
continued benefit at 1 year (AIMS Trial Study Group,
1990).
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Streptokinase and anistreplase have both been shown to 
substantially reduce mortality. It was only recently that 
the results of the ASSET trial (Anglo-Scandinavian Study 
of Early Thrombolysis) confirmed that t-PA also reduces 
mortality by 26% (Wilcox et al. , 1988). As yet it would 
appear that none of the agents is any better at reducing 
mortality than the others. The somewhat impressive 47% 
reduction with anistreplase seen in the AIMS study 
probably reflects the more stringent entry criteria 
required in this trial. If the subset of ISIS 2 patients 
fulfilling the AIMS criteria are examined, the reduction 
in mortality using streptokinase is 43%.
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B. ELECTROCARDIOGRAPHY IN ACUTE MYOCARDIAL INFARCTION
1 .5 HISTORICAL REVIEW AND CURRENT OF INJURY THEORY 
The decision to treat a patient with thrombolytic therapy 
requires that an accurate diagnosis of acute myocardial 
infarction is made based on the clinical history and an 
admission ECG. Myocardial infarction is diagnosed by the 
electrocardiographic parameters of ischaemia, injury and 
necrosis, thought to be represented by T wave changes, ST 
segment elevation and Q wave formation respectively. The 
T wave changes are non specific and may be transient and 
therefore missed in man unless the ECG is recorded at the 
time of occlusion (Fisch, 1988). Q waves reflect necrotic 
tissue, and therefore it is the manifestation of injured, 
but potentially salvageable myocardium demonstrated by ST 
segment elevation that highlights patients suitable for 
thrombolytic therapy.
It was Pardee who first described ST segment elevation as 
a clinical electrocardiographic feature of coronary 
occlusion as far back as 1920 in an observational study 
describing a 38 year old chauffeur with an acute inferior 
infarction. The first experimental work dealing with ST 
segment change was published in 1928 by Otto. Since then 
it has been the subject of intensive investigation used 
both as a tool for the diagnosis of acute myocardial 
infarction, and for following the effect of ..interventions 
intended to limit infarct size.
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There are two main theories to explain deviation of the ST 
segment from the isoelectric line. Both depend on a flow 
of current between healthy myocardium and the ischaemic 
area; the so called "current of injury". In the "diastolic 
current of injury" theory, the injured myocardial surface 
becomes electrically negative and surrounding healthy 
muscle has a positive surface charge. A continuous 
current flows even during electrical diastole from healthy 
tissue to injured tissue, and is recorded as a depressed 
TQ segment, automatically corrected in ECG machines back 
to the isoelectric line. During systole when the whole 
heart is depolarised no current of injury flows and the ST 
segment returns to baseline, but is interpreted as ST 
segment elevation.
In the "systolic current of injury" theory, true elevation 
of the ST segment is proposed in that the injured 
myocardium has a positive surface charge relative to 
healthy depolarised tissue, either due to early 
repolarisation (Samson and Sher, 1960) or an inability to 
depolarise initially (Eyster et al., 1938). This will 
result in a flow of current from injured tissue to 
healthy, but still depolarised tissue, creating true ST 
segment elevation.
Support for the "diastolic current of injury" has been 
provided by Prinzmetal et al. (1961) who documented 
partial depolarisation of ischaemic cells during diastole
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associated with ST segment elevation in epicardial leads. 
Also Vincent et al. (1977) demonstrated depressed TQ 
segments in epicardial leads following coronary occlusion 
and Cohen and Kaufman (1975) used the magnetocardiogram to 
pick up the injury current in closed chest dogs with 
coronary occlusions, demonstrating a depressed baseline, 
providing further evidence for the "diastolic current of 
injury" theory.
1 .6 SENSITIVITY AND SPECIFICITY OF THE 12 LEAD ECG IN THE 
DIAGNOSIS OF ACUTE MYOCARDIAL INFARCTION
Not all patients presenting at casualty with acute
myocardial infarction demonstrate electrocardiographic
changes, and as many as 20% may have a normal tracing
(Behar et al., 1977). Other studies have shown overall
sensitivity rates using the admission ECG in patients
subsequently proven to have acute myocardial infarction of
66% (Gunraj and Rajapakse, 1974) and 51% (McGuinness et
al., 1976). These two studies showed much higher
sensitivity rates when serial ECG's were used - 93% and
83% respectively. Decision making about administration of
thrombolytic therapy however cannot wait for serial ECG's
to be performed. Rude et al. (1983) addressed this
problem in screening 3,697 patients with greater than 30
minutes of chest pain for eligibility for entry to the
MILIS trial (Multicenter Investigation of the Limitation
49
of Infarct Size). The diagnosis of acute myocardial
infarction was made if one or more of the following
criteria were met:
1. New or presumably new, Q waves >„30 m.sec and 0.2 m.v
deep in at least 2 contiguous leads (i.e. II, III,
AVF, or V -V or I and AVL).
1 6
2. New or presumably new ST segment elevation or 
depression of ^0.1 m.V. in at least one of the above 
lead combinations, or
3. Complete left bundle branch block.
Using these criteria the diagnostic sensitivity was 81% 
and the specificity 69% resulting in a predictive value of 
72%. When combined with the MILIS exclusion criteria 
(i.e. age >75, symptoms >18hrs duration, cardiogenic shock 
etc.) the overall rate of confirmed myocardial infarction 
was 86%. Bren et al. (1987) in a later review further 
subdivided these ECG criteria showing a 75% sensitivity 
and 77% specificity for ST segment elevation or depression 
and a diagnostic sensitivity of only 46% and specificity 
of 91% when using ST segment elevation alone. He 
commented that when applied to inclusion or exclusion 
criteria for thrombolytic trials, many patients may be 
excluded from entry because of the lack of sensitivity of 
ST segment elevation.
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1 . 7 THE 1 2 LEAD ECG, INFARCT LOCATION AND ARTERIOGRAPHIC 
FINDINGS
Initially ECG accuracy in localising acute myocardial 
infarction was assessed by comparing ECG findings with 
post mortem results. Myers et al. in a series of post 
mortem examinations published between 1948 and 1949 
correlated the 12 lead ECG with evidence of myocardial 
necrosis. Their findings remain the basis of infarct 
localisation today, but various modifications and 
additions are now included to deal with both right and 
left bundle branch block (Besoain-Santander and Gomez- 
Ebensperguer, 1960; Dressier et al., 1950a&b). An 
accepted nomenclature for site of infarction according to 
electrocardiographic leads showing sequential changes is 
shown in Table 2. These studies by their very nature pre­
select the study group. They may therefore not represent 
adequately, all patients sustaining an acute myocardial 
infarction. A similar post mortem study from Canada 
(McQueen et al., 1983) suggested that the ECG was 
frequently unhelpful in diagnosisng acute transmural 
myocardial infarction due to the incidence of bundle 
branch block or paced rhythm. Again only patients 
succumbing to the disease were studied and by implication 
have a higher rate of complications which would include 
conduction changes and heart block. Using radionuclide 
techniques by technetium pyrophosphate imaging of the 
myocardium in acute infarction addressed the problem in a 
more typical group of patients (Yasuda et al., 1982). The
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sensitivity and specificity of 12 lead ECG's localising 
the acute infarct to one of five left ventricular wall 
segments were determined. This study screened 34 patients 
and gave an overall accuracy of localisation of 86% which 
was further increased when 4 patients with left bundle 
branch block were excluded. The sensitivities and 
specificities for 12 lead ECG localization for each of the 
five ventricular segments and the ECG lead criteria used 
are shown in Table 3.
The correlation of ECG findings with obstructive coronary 
lesions demonstrated angiographically in acute myocardial 
infarction has been studied by Blanke et al. (1984b). The 
sensitivity, specificity and predictive value for 
different sites of infarct were reported and are shown in 
Table 4.
With the introduction of thrombolytic therapy many trials 
have performed coronary angiography to document the 
obstructed coronary artery early in the course of 
myocardial infarction prior to treatment, irrespective of 
whether the intracoronary or intravenous routes of 
administration are used (Timi Study Group, 1985; Simoons 
et al ., 1985). This has allowed further correlation 
between the admission ECG and arteriographic findings. 
These studies have confirmed the earlier work of de Wood 
et al. (1980), in that patients studied up to 6 hours 
after the onset of pain, as many as 14% may have
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incomplete coronary artery occlusion. The ability to 
identify this subgroup using the admission ECG may have 
implications regarding whether to administer thrombolytic 
therapy or not, as it is already known that this group do 
better than their counterparts with complete occlusion 
(Schwarz et al., 1985). Conflicting evidence exists in 
the literature regarding the ability of the ECG to 
highlight this good prognostic group. Rentrop et al. 
(1981) could find no difference in the degree of ST 
segment elevation between patients with complete and 
incomplete occlusions, but von Essen et al. (1985) 
reported that if the sum of ST segment deviation in leads 
I, II and III was < 0.2 mV, this was useful in 
highlighting a small group of patients (3/56) with 
incomplete occlusion. Ross, (1985) on behalf of the TIMI 
Study Group found that he could not differentiate between 
these groups based on the degree of ST segment change.
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t
R WAVE
D E V E L O P M E N T  |
Q WAVE  
D E V E L O P M E N T
POSTERIOR
II III AVF
INFER IOR
V1 V2 , V3 V4 V5 V6 I AVI-
a n t e r i o r HIGH
L A T E R A L
A N T E R O S E P T A L
i
L A T E R A L  
—  >
A N T E R O L A T E R A L
y
EXTENSIVE ANTERIOR
IN ADDITION
APICAL INFARCT II, III, AVL and any one of V1 - V4
TABLE 2: NOMENCLATURE FOR SITE OF INFARCTION ACCORDING TO 
ELECTROCARDIOGRAPHIC LEADS SHOWING SEQUENTIAL 
CHANGE
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LV wall 
segment
Leads 
designating 
infarct site*
Sens­
itivity
Spec­
ificity
Anterior wall V1-V4 86% 89.5%
Lateral wall V5-V6 73.7% 80%
High lateral wall I, AVL 80% 87.5%
Inferior wall II, III, AVF 87.5% 100%
True posterior wall V1 , V2 83.3% 86.4%
* Leads required to show sequential change of infarction -
i.e. development of Q waves, loss of R wave voltage,
ST-T changes or development of R waves in V1 V2 in true 
posterior infarctions.
(Yasuda et al., 1982).
TABLE 3: THE SENSITIVITY AND SPECIFICITY OF THE 12 LEAD 
ECG IN LOCALIZING ACUTE INFARCTION TO 5 LEFT 
VENTRICULAR SEGMENTS
ECG Site of 
Infarction
Obstructed
Coronary
Artery
Sens­
itivity
Spec­
ificity
Pre­
dictive
Value
ANTERIOR 
(I, V1-V4)
LAD 90% 95% 96%
INFERIOR 
(II, III, AVF)
RCA or Cx 53% 98% 94%
POSTERIOR/LATERAL 
R>S V1/AVL V4-V6
RCA or Cx 20% 100% 100%
INFERIOR 
(II, III, AVF)
RCA 56% 97% 88%
POSTERIOR/LATERAL 
R>S V1/AVL V4-V6
Cx 24% 98% 75%
ECG diagnosis of infarction required Q waves or ST segment 
elevation in at least 2 of the lead groupings shown. 
(Blanke et al., 1984b).
TABLE 4: SENSITIVITY, SPECIFICITY AND PREDICTIVE VALUES OF 
ECG CLASSIFICATION OF INFARCT SITE CORRELATED 
WITH ANATOMICAL SITE OF CORONARY OCCLUSION.
1 .8 EVOLUTION OF INFARCT PATTERN
Before the electrocardiographic changes occurring in 
response to reperfusion following thrombolysis can be 
assessed, it is mandatory to know what changes evolve in 
patients with acute infarction not receiving 
interventional therapy. The typical pattern of evolving 
myocardial infarction is for the ST-T and T wave changes 
to occur (discussed in section 1.5) and to be followed by 
development of Q waves and symmetrical T wave inversion. 
There is considerable inter-patient variability in the 
time course of these sequential changes as demonstrated by 
Thygesen et al. (1979). There is remarkably little 
literature giving absolute quantification in timing of 
these evolving ECG changes, and in the most recent edition 
of "Heart Disease" (Braunwald, 1988) a textbook of 
cardiovascular medicine, QRS evolution is discussed only 
in reference to hand drawn diagrams originally published 
by Lepeschkin, (1951). This diagram suggests that acute 
QRS changes are limited to the first day after the onset 
of myocardial infarction.
In serial 72 point mapping studies, Selwyn et al. (1977 & 
1978) characterised the natural history of both Q waves 
and ST segments. In 47 patients with uncomplicated acute 
myocardial infarction the sum of ST segment elevation (J^  
ST elevation) was shown to slowly decrease over a period 
of 1 week. A progressive fall in mean JjST s.egment 
elevation expressed in percentages of 17%, 12% and 15%
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occurred between the time points 4-8, 8-12 and 12-24 hours 
respectively. The largest fall of 34% occurred between 1 
and 4 hours. However, this fall depended on only 8 
patients being admitted within the 1 hour time bracket, 
compared with 28 in the 1-4 hour bracket. Despite small 
numbers, it does suggest that this may reflect hyperacute 
changes occurring early in the phase of infarction which 
then resolve quickly. A later study (Selwyn et al., 1978) 
which looked at 45 uncomplicated anterior myocardial 
infarctions demonstrated Q wave formation within 2 hours 
of onset of chest pain, the sum of all Q waves, ]TQ, on 
the precordial map increased significantly at 6 and at 1 2  
hours, but thereafter plateaued and did not change over 
4 days. elevation steadily dropped with the
biggest fall occurring over 1 2 hours - 18 patients were 
recruited within 2 hours of onset of symptoms in this 
group and the large fall of 34% reduction in ST segment 
height between 1 and 4 hours seen in the first study was 
not repeated here. The number of positions on the 72 lead 
map showing ST segment elevation correlated well with the 
number of positions showing Q waves at 24 hours, but only 
the precordial sum of ST elevation at 45 minutes (n=8 ) 
correlated withJ^Q at 24 hours. Thus, ST segment 
elevation would appear to be a qualitative, rather than 
quantitative marker for subsequent Q wave development.
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Certainly Q wave formation appears to be complete within 
1 2 hours of onset of pain, and to remain static over at 
least 4 days.
Zmyslinski et al. (1979) described a biphasic pattern to 
the natural evolution of ST segment changes following 
anterior myocardial infarction. The changes he describes 
were comparable whether using either the six precordial 
leads from a 12 lead ECG or 35 leads from an 
electrocardiographic map. There was a significant 
decrease in ^ S T  at 7-12 hours following onset of chest 
pain (-1.13+0.38 mV) but this then increased at 25-48 
hours. These patients did not have pericarditis. Values 
were shown to return to base line within 8 days.
Long-term recovery of the ECG has been described by 
Montague et al. (1986), using 120 lead body surface maps 
over a period from day 5 to 6 months post myocardial 
infarction in 23 patients (12 anterior, 11 inferior). The
ECG parameters measured were different from work already 
described as they represent computed time intervals 
acquired from a signal averaged lead. The Q zone (QZ) 
integral represents the area under the first half of the 
QRS curve. The Q wave (QW) integral represents the area 
under the QRS curve from the initial negative deflection 
until it returns to baseline. The units are expressed in 
uV.s. In anterior infarctions, the Q zone integral 
improved from -34hh20 to -24_+13 uV.s at 6 months and the^Q
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2 2 
wave from -160+122 x 10 to -120+90 uV.s x 10 over the
same time period. In the inferior infarction group there
was a significant improvement over the same time period in
2
the wave from -91+_40 uV.s x 10 to -6 8 + 24 uV.s x
2
10 . There was no such change in QZ. This work suggests 
that there is continued gradual recovery in the ECG 
following infarction over a period of at least 6 months, 
and would appear to be heterogenous in different clinical 
groups, although the small numbers in either group here 
may not be totally representative of the normal infarct 
population.
In a small percentage of patients, the Q wave may
disappear completely, leaving a normal ECG. Pappas (1957)
found that out of 742 cases of myocardial infarction, 14 
cases normalised their ECG's. This change took between 2 
and 18 months except for one patient who developed a 
normal ECG within one month. Nine patients had 
anteroseptal infarction, 4 had posterior infarction and 1 
had both.
An extension to the 6 month follow up by Montague et al. 
(1986) is provided by Richter et al. (1987) with data 
arising from the Goteberg Metoprolol Trial (Hjalmarson et 
al. , 1981). Sixty patients with proven anterior 
myocardial infarction had 24 lead precordial maps
performed at day 4, 3 months, 6 months and 1. year. R and
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Q wave amplitudes were measured for each lead, and then 
summed to give J^R andJ^Q. The increased from a mean
value of 95 mm on day 4 to 114 mm at 3 months, 122 at 6 
months and a small, but further increase to 128 mm at 1 
year. The sum of Q waves decreased from a mean value of 
102 mm on day 4 to 75 mm at 3 months, 6 8 mm at 6 months 
and 57 mm at 1 year. Half of this group were receiving 
metoprolol up to the 3 month period, thereafter the study 
was stopped and most patients were given open metoprolol. 
The results between the two groups for ^ R  and up to 3
months were not different. In conclusion, it would appear 
that the ECG has the facility to show continued 
improvement up to 1 year following myocardial infarction. 
The reason for this is not clear, but may reflect 
shrinkage of the necrotic area so that the overlying 
electrode only picks up the depolarization wave forms due 
to healthy tissue (Holland & Arnsdorf, 1977).
1 .9 DEVELOPMENT OF SCORING SYSTEMS
The above techniques depend on sophisticated precordial 
mapping systems which are not available to every 
physician. The standard 12 lead ECG remains the 
cornerstone for clinical detection and location of 
infarction as it is universally available, reproducible, 
non invasive and inexpensive. Following the hypothesis 
that electrocardiographic changes occurring during 
myocardial infarction reflect the degree of necrosis, 
various scoring systems have been developed for estimation
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of infarct size using the 12 lead ECG. A summary of the 
development and description of these scoring systems is 
given below:
1.9.1. The Selvester Score
Studies examining the depolarisation pathways in both dogs 
(Scher & Young, 1956) and the isolated human heart (Durrer 
et al., 1970) provided Selvester and his associates with 
the necessary knowledge to devise computer simulations 
which produced vectorcardiographic loops resembling those 
seen in normal individuals (Selvester et al. , 1965). This 
group simulated the human heart in a mathematical model 
using computer analog techniques which divided the heart 
into 20 segments, 4 for right ventricle, 7 for septum and 
9 for left ventricle. By removing segments corresponding 
to necrotic areas seen in pathological studies in humans, 
revealed similar simulated vectocardiographic loops as 
seen in these patients. Later, the same group (Selvester 
et al., 1967) devised a digital computer model using 20 
dipoles - each representing an area of the heart, and 
simulated vectorcardiograms of myocardial infarctions were 
produced. This model showed good correlation between not 
only the vectorcardiographic data, but also 
electrocardiographic data; both from the 12 lead ECG and 
the the total body surface map. Surface maps derived from
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this model simulated those seen in normal subjects 
(Taccardi, 1963) even when torso and lung simulations were 
added (Selvester et al., 1968).
From these computer simulations, both quantititative and 
qualitative criteria were produced to form a 32 point 
scoring system to determine infarct size based on 57 
criteria. Each point was designed to represent 3% of the 
left ventricle, and depends on Q and R wave durations, R 
and S wave amplitudes and ratios, the presence of late R 
waves and early R notches. This scoring system was 
devised using ECG's in a group of Caucasian men aged 40-49 
years. When applied to a bigger, more disparate group of 
normal subjects (Hindman et al. , 1985) it was felt that 
the scoring system had to be at least 95% specific for the 
identification of myocardial infarction. Fifty-one out of 
the 57 criteria met this required standard, of the 6 that 
failed, 3 were modified and 3 were eliminated, leaving a 
54 criteria/32 point complete system. This allowed normal 
subjects over the age range 20-69 to score 3 points before 
diagnosing myocardial infarction with 95% specificity.
This low scoring in normals requires that screening 
criteria for diagnosis of myocardial infarction be used 
prior to performing a score, so that false positives are 
excluded. Anderson et al. (1982) have proposed such a 
system.
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Wagner then developed and evaluated a simplified version
of the above, known as the Simplified Selvester Score
(Wagner et al., 1982). Qualitative data such as slurs and
notches were not evaluated due to difficulties encountered
in defining rules for these wave forms which could be
universally applied by doctors to large numbers of ECG's.
Also ignored were absolute amplitudes of wave forms due to
variation in the normal population. Thirty-seven criteria
taken from 10 leads (I, II, AVL, AVF, V -V ) give rise to
1 6
a 29 point system and when applied to a group of 349
normal subjects, 93% scored 0 or 1 point, 5% scored 2
points, 2 % scored more than 2 points and only 1 subject
scored 4 points. This gives 98% specificity for
diagnosing an infarct when a score of more than 2 is
obtained. Of the 37 criteria, only 2 did not reach
individual specificities of .^95%, R/S n<1.5 in V achieved
4
92% specificity, and R/S s<3 in V achieved 92%
5
specificity. These criteria were than modified to R/S 1^
in V and R/S 4:2.0 in V yielding specificities of 98% and 
4 5
97% respectively. This then forms the basis of the
simplified scoring system which has been used in
subsequent studies, and is shown in Table 5. Each
criteria achieved at least 91% intra and inter observer
agreement.
The above scoring system has been evaluated in various 
ways. Post mortem studies in patients succumbing to a 
first myocardial infarction with no other complicating
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features such as right or left ventricular hypertrophy, 
right or left bundle branch block, or anterior or 
posterior fascicular block showed highly significant 
correlations between the QRS score and percentage 
infarction of the left ventricle r=0.8, r=0.74 and r=0.72 
for anterior, inferior and posterolateral infarcts 
respectively (Ideker et al., 1982; Roark et al., 1983;
Ward et al., 1984). The evolution of QRS scores over 3 
days following the admission of 82 patients with acute 
inferior myocardial infarction was demonstrated by 
Anderson et al. 1983. This shows that 53% of the study 
group had a score of 0 on admission, but increased their 
scores over the next two days. These workers interpreted 
their results as meaning that Q waves evolve over 2-3 
days, and suggest that interventional therapy designed to 
salvage myocardium may still be effective if administered 
after the first few hours. In this paper however there is 
no information made available regarding over what time 
scale from onset of pain the patients were admitted, and 
further comment regarding evolution of Q waves and QRS 
scores is unjustified.
Testing the hypothesis that left ventricular function 
depends on the extent of necrosis which in turn is 
dependent on the QRS score has led several groups to 
attempt to predict left ventricular ejection fraction 
using the QRS score. A summary of regression lines and
65
correlation coefficients for each group of workers is 
shown in Table 6 . With the exception of de Pace et al. 
(1982) the regression lines are all fairly similar - this 
is surprising when the different methodologies, different 
patient groups and time scales in each study are taken 
into account. In particular, Seino et al. (1983) 
performed radionuclide ventriculography within 48 hours of 
admission, and related this ejection fraction to 1 2 lead 
electrocardiographs taken at 3 and 7 days, and found no 
correlation at 3 days, but a significant r value of -0.72 
at 7 days. Left ventriculography so early in the course 
of myocardial infarction although previously shown to be a 
reasonable prognostic indicator (Shah et al., 1980) may be 
complicated by hypercontractility of non injured segments 
up until at least 5 days post infarct (Montague et al., 
1986). The phenomenon of stunned myocardium may cloud the 
issue further. De Pace et al. (1982) performed 
radionuclide ventriculography at 2 weeks and correlated 
his result with a 12 lead ECG performed at the same time. 
This gave a weaker, but still significant correlation in 
acute infarcts (r=-0.61), but this group was unable to 
repeat this when studying a group of old infarcts 
retrospectively. Palmeri et al. (1982) in contrast 
followed their group of patients for at least 1 year and 
found better correlations which were reproducible (r=- 
0.88) .
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Unfortunately this QRS scoring system did not perform well 
when applied to a much bigger group of patients (n=285) 
two weeks following myocardial infarction (Fioretti et 
al. , 1985). A similar correlation to that of de Pace et 
al. (1982) of -0.61 was determined between QRS score and 
radionuclide ejection fraction, but the spread of data 
either side of this line was large (standard error of 
estimate = 11%). It was concluded that the QRS score is 
less accurate than ejection fraction in predicting late 
survival following infarction.
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SIMPLIFIED SELVESTER SCORE
Max.
Lead Duration Amplitude Ratio Points
I Q 30 msec (1 ) R/Q s< 1 ( 1 ) 2
II Q >✓ 40 msec ( 2 ) 2
Q >✓ 30 msec ( 1 )
AVL Q >✓ 30 msec ( 1 ) R/Q s< 1 ( 1 ) 2
AVF Q >✓ 50 msec (3) R/Q s< 1 ( 2 ) 5
Q >✓ 40 msec (2 ) R/Q s< 2 ( 1 )
Q >✓ 30 msec (1 )
V1 Any Q ( 1 ) R/S >✓ 1 ( 1 ) 4
R > 40 msec (2 )
R > 40 msec (1 )
V2 Any Q or R « 2 0 msec ( 1 ) 4
R >/ 60 msec (2 )
R 50 msec ( 1 ) R/S > 1.5 (1)
V3 Any Q <or R ^ 30 msec ( 1 ) 1
V4 Q 2 0 msec (1 ) R/Q or R/S n< 0 .5 (2) 3
R/Q or R/S « 1 ( 1 )
V5 Q >✓ 30 msec ( 1 ) R/Q or R/S « 1 (2 ) 3
R/Q or R/S « 2 ( 1 )
V 6 Q >✓ 30 msec ( 1 ) R/Q or R/S « 1 (2 ) 3
R/Q or R/S s< 3 ( 1 )
29
TABLE 5: THE 37 CRITERIA AND 29 POINT SYSTEM FOR THE 
SIMPLIFIED SELVESTER SCORE
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Study
Correlation
Coefficient
Regression Analysis 
Prediction of E.F. using 
QRS Score
Palmeri et al. -0 . 8 8 EF = 60-3.0 x QRS Score
De Pace et al. -0.61 EF = 45-2.0 x QRS score
Young et al. -0.60 EF = 61-2.5 x QRS score
Roubin et al. -0.81 EF = 66-3.3 x QRS score
Seino et al. -0.72 EF = 60-2.2 x QRS score
TABLE 6: SUMMARY OF PUBLISHED WORK CORRELATING QRS SCORE 
WITH LEFT VENTRICULAR EJECTION FRACTION
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1.9.2. Cardiac Infarction Injury Score (CHS)
This score designed by Rautaharju et al. (1981) was based 
on 707 subjects, 387 with myocardial infarction, and 320 
without evidence of infarction. A training and test group 
were selected and various ECG parameters examined to 
detect the best classifiers of infarction against non 
infarction. This group showed by statistical modelling 
that the classical criteria used in decision making from 
the Minnesota Code (Blackburn et al. , 1960) were suboptimal 
and were rejected. The resulting CIIS expresses the 
likelihood of an infarction on a continuous scale using 
eight binary (single threshold), three ternary (two 
threshold) and four non thresholded features, each 
individually weighted to produce the CIIS scores. For 
practical visual coding of ECG's, 12 observations are made 
in check list fashion using 9 standard leads, II, III,
AVR, AVF, V1-V5 and 2 inverted leads -AVR, -AVL which were 
found to improve the diagnostic accuracy of the score.
The CIIS detected myocardial infarction with a sensitivity 
of 85%, and a specificity of 95%. It appears to perform 
best on infarcts that are 1 week to 1 month old, but in 
the group of patients who have had an infarct more than 1 
year old, for a specificity of 98%, sensitivity dropped to 
only 80%. The authors felt that the place of the CIIS 
would be in large epidemiological studies to pinpoint a 
deterioration in the ECG due to new ischaemic events, and 
did not address whether it would be an accurate predictor 
of infarct size. Young et al. (1983) found that not only
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did the CIIS not predict reliably the presence of 
infarction, but that there was a poor correlation 
coefficient between the score and the ejection fraction 
(r=-0.49).
1.9.3. Askenazi
In an attempt to relate changes in the 12 lead ECG with 
ejection fraction, this group studied 73 patients with 
ischaemic heart disease, all of whom underwent left 
ventriculography (Askenazi et al., 1978). The patients 
were separated into four groups (normal, anterior, 
inferior, and a combined anterior and inferior group) 
depending on the presence or absence of abnormal Q waves 
( ^40 m.secs duration and >,0.2 mV amplitude). The sum of 
R waves, was calculated from leads I, AVL and V1-V6
and the number of abnormal Q waves, nQ, determined. 
Separating the patients into the four groups described and 
calculating nQ for each ECG showed no correlation with 
either the basal or augmented ejection fraction. There 
was however a positive correlation betweeny^R and both the 
basal (r=0.61) and augmented (r=0.77) ejection fraction. 
The highest correlation coefficient (r=0.82) was between 
R and the augmented ejection fraction in patients with an 
anterior myocardial infarction.
71
1.9.4. Arditti
As the 12 lead ECG has fewer leads representing the 
inferior aspect of the heart compared to the anterior 
surface, it is not surprising that Palmeri et al. (1982) 
found a lower degree of correlation between the simplified 
Selvester QRS score and ejection fraction when dividing 
his patients into groups according to site of infarct 
(r=-0.69, -0.87 and -0.8 for inferior, anterior and 
combined infarcts respectively). Arditti et al. (1985) 
devised a very simplified scoring system for use in 
inferior infarcts using only the R/Q ratio in lead II. 
Previous work by Schamroth (1975) had shown that the 
terminal R wave in lead II accurately reflects the 
potential of non infarcted myocardium. The patients were 
arbitrarily divided into those with R/Q >2 (Group 1),
R/Q >1 (Group 2), R/Q S<1 (Group 3). The relation of 
these groupings to left ventricular ejection fraction was 
assessed both by radionuclide ventriculography and 
echocardiography. The mean lead II R/Q ratio for each of 
the groups is as follows: Group 1, 7.22+ 4.81, Group 2, 
1.27+ 0.26, and Group 3, 0.12+0.17. This difference 
between groups significant at the 0.1% level. Patients in 
Group 1 had a low wall motion score of 1.5+1.4, and a 
normal left ventricular ejection fraction (LVEF) 
(60.2+8.9%). Group 2 had a higher wall motion score of 
5.25+2.44 (P<0.001 vs Group 1) and a lower LVEF 
(51.2+16.5% NS vs Group 1) and Group 3 had the highest 
wall motion score of 6.16+2.54 (P<0.001 vs Group 1 and
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P<0.05 vs Group 2) and a low LVEF of 51.5 ±9.4% (NS vs 
Group 2, but P<0.005 vs Group 1).
Although extremely simplistic in approach and quick to 
perform, the scoring system would appear to be really only 
useful in placing patients into relatively wide groupings 
which may have prognostic implications, but does not allow 
a definite estimate of an individuals ejection fraction or 
infarct size.
1.9.5. Frank Lead Orthogonal Electrocardiograms 
Various groups have used the Frank lead system of XYZ to 
develop scores which would relate to left ventricular 
function. Howard et al. (1976) concluded that the 
vectorcardiogram is superior to the electrocardiogram in 
the diagnosis of obstructive coronary artery disease and 
left ventricular contraction abnormality. Gottwik et al. 
(1978) showed that Q and R voltages from leads XY and Z 
provided information leading to an accurate estimation of 
ejection fraction, but this work was later refuted 
(Luwaert et al., 1983; Young et al., 1983). As 
vectorcardiography is not performed routinely in patients 
being admitted to Stobhill, the advantages and 
disadvantages of such a technique are not further 
discussed here.
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1.9.6. Conclusion
Of all the scoring systems discussed, that of Selvester 
modified by Wagner seems to have been most intensively 
studied and validated, both with respect to pathologic 
infarct size, left ventricular function following 
myocardial infarction and most recently has been shown to 
be of prognostic value in patients with coronary artery 
disease (Bounous et al., 1988).
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CHAPTER 2 - GENERAL METHODOLOGY
75
2.1 INTRODUCTION
This chapter describes the Coronary Care Unit at Stobhill 
General Hospital, and the facilities which have been 
developed to enable thrombolytic therapy to be 
administered and angiography to be performed early in the 
course of acute myocardial infarction. Protocol design is 
discussed with special reference to inclusion and 
exclusion criteria, and the various studies which have 
provided the patient and electrocardiographic data which 
form the work of this thesis are described. Details 
concerning the collection of electrocardiographic data are 
given.
2.2. CORONARY CARE UNIT AND DIRECT ADMISSION POLICY
Stobhill General Hospital provides the cardiological 
services for the North-East portion of Glasgow and serves 
a population of 220,000. The Coronary Care Unit has six 
beds and is situated geographically in the middle of the 
Medical block. Between 800 and 900 patients are admitted 
annually. The Coronary Care Unit operates a direct 
admission policy for General Practitioners which 
facilitates the early admission of patients with suspected 
acute myocardial infarction. The admission of patients 
via a "back-door" leading directly to the Coronary Care 
Unit, and therefore bypassing Casualty, reduces the intra­
hospital delay. Patients admitted this way have a
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clinical history, examination and ECG performed in an 
adjacent assessment area, and are then admitted to the 
Coronary Care Unit or to a General Medical ward, as 
considered appropriate by the Coronary Care Registrar.
To further reduce the delay between onset of symptoms and 
admission to Coronary Care, a direct telephone link which 
bypasses the hospital switchboard was established at the 
beginning of 1987. The General Practitioners in the area 
had previously identified getting through to the hospital 
switchboard, with subsequent referral calls, both to 
Casualty and the medical receiving team, as time 
consuming. Letters with the direct telephone number 
prominently displayed were circulated to practices within 
the Stobhill catchment area. A General Practitioner using 
the direct line calls through to the Coronary Care Unit, a 
nurse on duty takes the details and accepts the referral, 
letting the medical staff know of the imminent admission. 
The impact this method has had on the suitability of 
patients for thrombolysis has been reported by Burns et 
al. (1989). The direct telephone link with a back-door 
admission policy reduced the delay by a mean of 55 
minutes, doubling the number of patients admitted within a 
3 hour time window.
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2.3. ACUTE ANGIOGRAPHY
The admission assessment area is also used as a procedures 
room, allowing coronary angiography to be performed within 
the Coronary Care Unit. There are no other 
catheterisation facilities at Stobhill, routine 
investigational work is performed at Glasgow Royal 
Infirmary. The methodology used at Stobhill to enable 
acute angiography to be performed could be translated to 
every District General Hospital at very little extra cost. 
The Stobhill system and one year's experience with it's 
use has been previously published (Hillis et al., 1986).
A mobile x-ray image intensifier with a television display
(Siremobil 2N/2H) was already used for the insertion of
temporary pacemakers. It has a circular arm, allowing
rotation about the horizontal axis, enabling the standard
angiographic views to be performed. To visualize the
o o
right coronary artery a 60 LAO and 30 RAO are performed,
and for the left anterior descending and circumflex 
o o o
arteries, a 10 RAO, 30 RAO and 60 LAO are routinely
taken. Linking this unit to a heavy duty video cassette
recording system (JVC CR-8200E) allows permanent recording
of coronary arteriograms and left ventriculograms.
Each angiogram is performed by a consultant aided by a 
registrar. The Coronary Care nursing staff assist with 
the procedure, usually one nurse at staffing level or 
above being present. Screening with the image intensifier
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is provided by a radiographer, and an ECG technician is 
present to record pressure tracings.
A conventional Seldinger technique is used, and a no.7 
sheath (Hemaquet, USCI International) inserted. Following 
acute angiography, this sheath is flushed with heparin and 
left in situ for 24 hours, allowing, in some instances a 
second arteriogram to be performed 24 hours after therapy. 
The sheath is removed once the coagulation has returned to 
normal. Antibiotics (cephalexin 500 mg tid) are given as 
prophylaxis over the time of the sheath being in situ.
2.4. CLINICAL TRIALS
Stobhill Coronary Care Unit has been active in 
administering thrombolytic therapy under the direction of 
Dr. W.S. Hillis since 1982. Up until November 1988, none 
of the lytic agents were licensed for treatment in acute 
myocardial infarction, and their use prior to this time 
necessitated administration according to the guidelines of 
approved clinical trials. All trials conducted in 
Stobhill Coronary Care Unit and referred to in this thesis 
were approved by the local research and ethical committee.
Thrombolytic therapy is administered under the 
responsibility of the Consultant Cardiologist on duty for 
Coronary Care. Two or three Registrars/Research Fellows 
are on call to assess patients, obtain informed consent,
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and administer treatment, as well as to participate in 
acute angiography and the taking of blood for research 
purposes. I have personally been involved in such a rota 
since August 1984. This system provides 24 hour cover, 7 
days a week. A previous report by Hillis et al. (1986) 
showed that 40% of acute infarcts were admitted outwith 
the normal working hours of 9 am to 5 pm. Patient 
recruitment is thus maximised. Radiography, ECG and 
audiovisual services also provide an on call system, 
facilitating emergency out-of-hours angiography.
2.4.1.Patient Selection
All patients presenting to the Coronary Care Unit with a 
suspected diagnosis of acute myocardial infarction are 
considered for thrombolytic therapy if they have the 
following criteria:-
1) onset of cardiac pain of }30 minutes duration and 
4.6 hours by time of admission to the Coronary Care 
Unit.
2) confirmatory electrocardiographic evidence of 
myocardial infarction (ST elevation 1^ mm in at least 
2 standard limb leads or 2 mm ST elevation in at 
least 2 precordial leads).
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Exclusion criteria are chosen to avoid the known potential 
side-effects of lytic agents. Thus, although details may 
vary from protocol to protocol, exclusion criteria 
precluding entry to thrombolytic trials are as follows:
1 ) cerebrovascular disease
2) documented or suspected active peptic ulceration 
within the past 6 months
3) history of bleeding diathesis
4) extreme hypertension (i.e. >200/120 mmHg)
5) severe renal or hepatic disease
6) menstruating or potentially pregnant females
7) prolonged cardio-pulmonary resuscitation or insertion 
of central venous lines via the subclavian route prior 
to treatment
8) proliferative diabetic retinopathy
In trials requiring emergency angiography, a further 
exclusion criteria would be if the patient had severe 
peripheral vascular disease, although this does not per se 
constitute an absolute contraindication to thrombolytic 
therapy.
Informed consent was obtained in all patients, and the 
procedure explained to accompanying relatives where 
possible. An example of the patient information sheet and 
accompanying consent form are shown at the end of appendix 
I. Description of individual trials providing the 
database for this thesis are attached below..
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2.4.2.Intracoronary Streptokinase Trial
Patients were recruited for this trial conducted in an
open fashion between December 1981 and March 1983.
Patient selection was according to criteria already 
outlined. Acute angiography was performed and the 
obstructed artery visualized. Isosorbide dinitrate (2 mg) 
was administered into the coronary artery to relieve 
spasm. Prior to the intracoronary infusion of 
streptokinase, 100 mg hydrocortisone and 10 mg 
chlorpheniramine were administered intravenously. 
Streptokinase was then infused selectively or sub- 
selectively in a dose of 250-500,000 units over 30-45 
minutes. The presence or absence of reperfusion was 
determined visually at the end of the procedure. In some 
cases mechanical perforation of the thrombus was 
performed. Patients were returned to the Coronary Care 
Unit following this procedure, and subsequently 
heparinized.
2.4.3.Intravenous Anistreplase Trial
The aim of this study, performed in an open fashion, was 
to determine a patency rate following a dose of 
anisoylated plasminogen streptokinase activator complex 
(30 U anistreplase). Patients were recruited according to 
the criteria already defined. After informed consent was 
obtained from each patient, 30 U anistreplase was infused 
through a peripheral line over 5 minutes. Hydrocortisone 
100 mg, and 10 mg chlorpheniramine were given
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prophylactically in each case. Coronary angiography was 
carried out at 90 minutes following therapy, although was 
postponed if the patient's haemodynamic status or cardiac 
rhythm was unstable. Pre-treatment angiography was not 
performed, and therefore it is a patency rate and not a 
reperfusion rate which is derived. Following successful 
thrombolysis, the patients were anticoagulated using 
heparin and warfarin. The results for 94 patients have 
previously been reported (Hillis et al. , 1987).
2.4.4.Streptokinase/Anistreplase Comparison 
This is a double-blind randomised protocol, designed to 
assess any differences in patency rates between 30 U 
intravenous anistreplase and 1.5 million I.U. intravenous 
streptokinase in patients 410 years old with an acute 
myocardial infarction of less than 6 hours duration. One 
hundred and twenty eight patients were recruited, and the 
study ran between April 1987 and December 1988. Coronary 
angiography was performed at 90 minutes and again at 24 
hours utilising the femoral sheath which had been left in 
situ. A full protocol description is listed in appendix 
I.
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2.5. ELECTROCARDIOGRAPHIC DATA COLLECTION
12 lead ECG's are performed in the Coronary Care unit by
nursing staff trained in electrocardiography. The
tracings are performed during quiet respiration in the
o
semi-supine position with the back rest at 20 from the
horizontal. The standard chest positions are marked on
admission to Coronary Care with an indelible marker to
ensure reproducibility (Table 7). All ECG's are performed
using a Hewlett Packard Page Writer Cardiograph (Model
4700A) which provides a one-page recording. Each ECG is
marked with a calibration signal (10 mm = 1 mV), lead
annotation, lead switching marks and the recording speed.
Diagnostic 12 lead ECG's are always recorded at 25 mm/sec.
Multiple leads are acquired simultaneously from the
patient in standard lead groups (i.e. I, II and III, AVR,
AVL and AVF, V , V , V and V , V , V ). These lead 
1 2 3 4 5 6
groups are smoothly switched, providing continuous rhythm
across the 10 second record. A continuous lead II is
recorded along the bottom of the tracing. The machine has
a memory function which provides exact duplicates of the
recording, allowing copies to be stored in nursing
proformata, case record forms, and to be used for research
purposes.
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Bipolar leads
I Derived from electrodes on the right arm and left
arm
II Derived from electrodes on the right arm and 
left leg
III Derived from electrodes on the left arm and the 
left leg
Unipolar leads 
AVR Augmented unipolar right arm lead
AVL Augmented unipolar left arm lead
AVF Augmented unipolar left leg lead
V Fourth intercostal space to right of sternum
1
V Fourth intercostal space to left of sternum 
2
V Midway between V and V
3 2 4
V Mid clavicular line over 5th intercostal space
4
V Anterior axillary line at same level as lead V
5 4
V Mid axillary line at same level as leads V
6 4 
and V
5
TABLE 7: STANDARD LEAD PLACEMENTS FOR 12 LEAD 
ELECTROCARDIOGRAPHY
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CHAPTER 3
USE OF THE ST SEGMENT AS A NON INVASIVE MARKER
OF REPERFUSION
8 6
3.1. LITERATURE REVIEW
Since Pardee (1920) described ST segment elevation as a 
feature of acute coronary occlusion, many experimental and 
clinical studies have attempted to use this functional 
electrocardiographic marker as an index of ischaemic 
injury, and to assess the efficacy of pharmacological 
interventions to reduce myocardial infarct size such as 
the administration of beta-adrenoceptor blocking compounds 
(Gold et al., 1976) and hyaluronidase (Maroko et al., 
1977). With the first reports of intracoronary 
thrombolysis came the observation that reperfusion was 
accompanied by rapid resolution of ST segment elevation 
(Rentrop et al., 1981; Mathey et al., 1981). Ganz et al. 
(1981) showed resolution of ST segment elevation back to 
baseline occurring over a 2 hour period from time of 
reperfusion. However, these trials were all uncontrolled 
and were descriptive rather than quantitative. 
Interpretation of subsequent papers is made somewhat 
difficult due to variation in methodology. The rapid 
sequential change in ST segments occurring with 
reperfusion has been demonstrated by either standard 
electrocardiography or multilead precordial mapping 
systems in an angioplasty setting (von Essen et al.,
1985). Differing conditions between trials leaves the 
area somewhat confused.
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The first two controlled trials to be reported in 1983 
were in agreement. Anderson et al. (1983) in his 
randomised study of intracoronary streptokinase showed 
that by summing the ST segment elevation in all infarct 
leads, or by using a single lead (maximal ST segment 
deflection), that these measurements were similar in both 
groups prior to treatment, but there was a significant 
fall in the streptokinase treated group over a period of 3 
to 6 hours (p<0.01). Blanke et al. (1983) confined his 
study to anterior infarctions and measured J^ST elevation 
in leads V1-V6. Twelve lead electrocardiograms were 
performed prior to coronary angiography and at a mean of 
3, 12, 24 and 48 hours following angiography. J^ST V1-V6 
was not different between the groups prior to treatment, 
but after intracoronary streptokinase the treated group 
showed a mean fall of some 60% at 3 hours, compared with 
only 13% in the control group. There remained a 
difference in J^ST V1-V6 between the two groups even at 
follow up. However, their results show very wide standard 
deviations, suggesting wide inter-patient variability.
These results were in contrast to the work of Timmis et 
al. (1982) who described ST segment changes in their group 
of patients given intracoronary streptokinase. Using a 
single lead with maximal ST segment elevation they showed 
an almost identical change post infusion (from 
approximately 0.29 mv to 0.2 mv) irrespective of whether 
the patient had reperfused (n=27) or not (n=8). The
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values for the control group were not given, and 
measurements were made immediately following streptokinase 
infusion. Similarly Ross, (1985) reporting on behalf of 
the TIMI group stated that by monitoring ST segment 
elevation (mean of 2 contiguous leads showing injury) it 
was impossible to identify patients who had achieved 
succcesful clot lysis from those who had not.
A further method of looking at ST segment change is to use 
an on-line mapping system with several precordial leads 
(von Essen et al., 1985). Although this group reported on 
this technique to detect recurrent ischaemia in patients 
receiving thrombolytic therapy, and its use during 
angioplasty, its main use was to monitor R waves to 
determine myocardial salvage. This same group found that 
by measuring "ST shift", (the summation of ST elevation 
and depression in limb leads I, II and III), this gave a 
simple electrocardiographic index which helped identify 
reperfusion. In 43 out of 56 patients the infarct-related 
artery was recanalised, and the summated ST shift 
decreased from a mean of 0.68+0.32 mV pre treatment to 
0.09+0.12 mV post treatment. In 13 patients who did not 
achieve reperfusion, the ST shift was 0.44+0.29 mV pre 
treatment and 0.44+0.36 mV post treatment. Again standard 
deviations are large and suggest prediction of reperfusion 
on an individual basis may be difficult.
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The studies described above are primarily observational, 
and it was Krucoff et al. (1986) who first attempted to 
use the change in the ST segment on a predictive basis to 
identify reperfusion. The method they used was continuous 
ST segment monitoring by Holter tapes, and the measurement 
they made was the time to ST "steady state" which was 
defined as "the first 30 minutes when the ST level was 
equally or less deviated than the final steady state 
level". In 19 out of 36 patients who reperfused (after 
intracoronary streptokinase) the ST steady state was 
achieved at a mean of 55+32 minutes, and in patients who 
did not reperfuse, the mean time to steady state was 
211+141 minutes. Achievement of steady state within 100 
minutes after streptokinase indicated successful 
reperfusion with 89% sensitivity and 82% specificity.
Prediction of reperfusion on an individual non-invasive 
basis would seem desirable as the intravenous route for 
administration of thrombolytic therapy increases. Which 
of the different methodologies described above would be 
most accurate is not yet known. From previous work, the 
12 lead ECG has been shown to be more useful than anterior 
precordial mapping in diagnosing and following serial 
changes in patients having sustained an inferior 
myocardial infarction (Madias et al., 1975). Leinbach et 
al. (1978) further confirmed that both the rate and degree 
of ST segment fall could be followed accurately by single 
leads reflecting the zone of maximum ECG injury. Using
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conventional 12 lead electrocardiograms is attractive as 
they are widely available and easily applicable within the 
community and district hospital settings. Disadvantages 
with this technique is that the ST segment may be altered 
by factors other than coronary occlusion, such as 
pericarditis (Thadani et al., 1971), metabolic 
abnormalities including hyperkalaemia (Levine et al.,
1956) and where repolarisation abnormalities due to 
development of bundle branch block may not reflect 
ischaemia (Sodi-Pollares et al., 1963). The use of a 
ventricular pacemaker will also invalidate ST segment 
analysis.
3.2. AIM OF STUDY
The aim of this study was to analyse ST segment changes 
using both the 12 lead electrocardiogram and Holter 
monitor in patients during thrombolysis, with a view to 
detecting a simple, sensitive, widely applicable technique 
to detect successful reperfusion non invasively.
3.3. PATIENTS AND METHODS
Forty-five patients were studied, age range, 39-75 years, 
mean age 58.5 years. Twenty-three anterior infarctions 
(18 M, 5 F) and 22 inferior infarctions (16 M, 6 F) were 
included with a mean time to admission following onset of
91
pain of 2.7 + 1.6 hours. All patients were treated within 6 
hours of symptom onset. Individual patients details are 
shown in appendix II.
Thrombolytic therapy was given according to the current 
Coronary Care protocol. Seventeen patients received 
streptokinase by the intracoronary route, and 28 received 
intravenous anisoylated plasminogen streptokinase 
activator complex (anistreplase 30U). The division of 
patients into these groups was purely temporal, and not 
affected by clinical severity on admission. Inclusion and 
exclusion criteria and protocol design for both treatment 
groups are described in Chapter 2 and will not be further 
discussed here.
3.4. ECG ANALYSIS
3.4.1. HOLTER Monitoring
On admission to the Coronary Care Unit, 24 hour continuous
ECG monitoring was commenced using an Oxford Medilog II
system. The ECG electrodes were placed in a modified V5
position. The tapes were analysed using a Reynolds
Medical Pathfinder with an ST segment trend analysis. ST
segment elevation was measured as a pre treatment control
value, M , and a second value, M , was made 2 hours 
1 2 
following intracoronary and 3 hours following intravenous
thrombolytic therapy. The post therapy value was
calculated as a proportion of the control value and this
index was expressed as the "Fractional Change". If
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complete reversal of ST segment elevation occurs, then the 
Fractional Change value becomes 1 or a number near to 1 
(Fig. 4a). If the ST segment remains elevated to the same 
degree, the Fractional Change value will be zero or a 
number near zero. If increased ST segment elevation 
occurs due to infarct extension, then the Fractional 
Change value will become negative (Fig. 4b).
3.4.2. 12 Lead Electrocardiograms
Conventional 12 lead electrocardiograms were performed on 
admission, and at a mean of 302+141 min following 
admission. The lead with most ST segment elevation was 
identified and taken for serial analysis. Measurements 
were made manually with calipers and ST segment elevation 
was measured at the J point taking the PR segment as the 
isoelectric line. The Fractional Change was calculated in 
the same way as detailed for the Holter Monitor. In both 
groups of ECG data, the calculation of Fractional Change 
was performed by one observer (the author) blindly, 
without knowledge of the angiogram results.
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3.5 STATISTICAL ANALYSIS
Linear discrimination was performed on an ICL2980 main 
frame computer using the programme BMDP (P7M) (Brown, 
1977). The patients were randomly subdivided using a 
random numbers generator into two groups, one a training 
group for devising a rule, and a second test group for 
checking the rule.
Sensitivity measures the ability to detect true cases
which have reperfused, and is expressed by the number of
reperfusions detected on non invasive grounds as a
percentage of angiographically documented reperfusions.
Specificity measures the ability to detect true cases
which have not reperfused, and is defined by the number of
true non reperfusions determined on non invasive grounds
as a percentage of angiographically determined non
reperfusions e.g.
Number of true reperfusions 
(by ECG criteria)
Sensitivity = _____________ ___________________  x 100%
Total No. of true reperfusons 
(by angiography)
Number of true non reperfusions 
(by ECG criteria)
Specificity =  ____________________________  x 100%
Total No.of non reperfusons 
(by angiography)
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3.6 RESULTS
Analysis was performed on ECG recordings obtained in 39 
subjects, 6 were excluded from analysis. In 4 patients 
there was incomplete collection of data due to technically 
inadequate Holter Monitor tapes, 1 subject had left bundle 
branch block precluding ST segment interpretation, and 1 
patient had inadequate visualisation of the coronary 
arteriogram. The remaining 39 patients were randomly 
split into a training group (n = 22) and a test group (n - 
17). Figure 5 shows scatter diagrams of Fractional Change 
results for these two groups, both for Holter tapes and 12 
lead ECG's. The coronary arteriographic patency rate was 
high (79.5%). As ST segment elevation is not completely 
reversed following coronary artery reperfusion, several 
arbitrary values of ST segment reduction were examined 
including 0.25, 0.5 and 0.75. A Fractional Change value 
of .^0.5 appeared most useful in separating those cases who 
had reperfused from those who had not. Table 8 gives the 
specificity and sensitivity for detecting reperfusion 
using this technique applied both to training and test 
groups. Using the Fractional Change derived from the 
Holter tape gave 100% specificity, both for the training 
group and for the test group. Sensitivity was also high 
at 88% and 93% respectively. Using the Fractional Change 
derived from the 12 lead ECG resulted in 100% specificity 
for the training group but only 67% specificity for the
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test group. This fairly large drop actually reflects the 
small numbers of non reperfusions in the test group (n=3) 
and the fact that only one was misclassified. Sensitivity 
remained high at 94 and 93% respectively.
Linear discrimination was then employed using a BMDP
programme to devise a rule which would lead to maximum
separation of the two groups i.e. reperfusions and non
reperfusions. This programme utilised the following
electrocardiographic parameters as variables: FCH
(Fractional Change with Holter monitoring), FC (Fractional
Change with 12 lead ECG), M (height of ST segment on
1
admission) and M (height of ST segment following
2
therapy). From these the following classification 
functions were derived for the training group:-
1) Using FCH
Reperfusion = -3.31 = (2.42 x FCH) + (1.45 x M ) -
1
(1.36 x M )
2
Non reperfusion = -8.48 - (4.74 x FCH) - (1.03 x M ) +
1
(3.72 x M )
2
2) Using FC
Reperfusion = -2.80 + (1.21 x FCH) + (1.28 x M ) -
1
(0.87 x M )
2
Non reperfusion = -7.01 + (-3.09 x FCH) - (0.57 x M ) +
1
(2.64 x M )
2
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To use these classification functions, the Fractional
Change value (either from 24 hour tapes or 12 lead ECG's)
and the height of the ST segment on admission and
following therapy must be known. These values are
inserted in the appropriate formula, both for reperfusion
and for non reperfusion and whichever value is greater
designates the group to which the patient belongs. Thus,
for a patient with a FCH of 0.65, M = 3.5 and M =1.7,
1 2 
the values of 1.03 and -8.84 are calculated for the
reperfusion and non reperfusion classifications
respectively. As 1.03 is greater than -8.84, these
findings are consistent with reperfusion on non invasive
grounds.
Using this form of discriminant analysis resulted in 
complete correct separation of the two groups in the 
training group (sensitivity 100%, specificity 100%) with 
sensitivity being maintained when applied to the test 
group, but the specificity dropping to 33% only. This 
dramatic fall in specificity is explained somewhat by the 
small numbers in the test non reperfusion group (n = 3) 
and the fact that only one of the non reperfusions was 
correctly identified.
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FIGURE 4 : CALCULATION OF FRACTIONAL CHANGE FROM HOLTER 
MONITOR RECORDINGS. Typical examples of ST 
segment analysis from Holter Monitor recordings 
in patients receiving intracoronary 
thrombolysis, in a successful reperfusion A, and 
a non reperfusion B. Real time is represented 
on the X axis in 15 minute intervals.
Measurement M1 is made on admission prior to 
treatment and M2, 2 hours post treatment. The 
Fractional Change value is calculated using the 
formula M1-M2 - M1 and therefore the Fractional 
Change value for A is (3.9-0.6) - 3.9 = 0.85 and 
the Fractional Change value for B is (0.8-3.6) - 
0.8 = -3.5.
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FIGURE 5: SCATTER DIAGRAMS OF FRACTIONAL CHANGE VALUES 
BOTH FOR HOLTER MONITOR AND FOR 12 LEAD ECG
ECG Parameter
Specificity
%
Sensitivity
%
Training Group 
(n = 22)
100 88
FCH .
- Test Group 
(n = 17)
100 93
Training Group 
(n = 22)
100 94
FC
Test Group 
(n = 17) 67 93
FCH - Fractional Change calculated from Holter Recording 
FC - Fractional Change calculated from 12 lead ECG
TABLE 8: SPECIFICITY AND SENSITIVITY OF USING A
FRACTIONAL CHANGE VALUE OF »0 . 5 TO DENOTE 
REPERFUSION
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3.7 DISCUSSION
These results confirm the usefulness of ST segment 
analysis as a non invasive predictor of coronary artery 
patency following thrombolytic therapy in patients with 
acute myocardial infarction. This technique can identify 
patients who may require further pharmacological regimes 
to prevent coronary artery reocclusion, or who may require 
subsequent invasive investigation with a view to 
performing coronary angioplasty or bypass surgery for 
residual arterial stenoses. Of interest is the fact that 
a simple rule of a Fractional Change value of ^0.5 
denoting reperfusion is more specific, but not as 
sensitive as using the more complex classification 
functions derived from linear discrimination. This 
Fractional Change Value of 0.5 (or 50%) compares well with 
the percentage change in ST segments of >55% reported by 
von Essen et al. (1985) occurring over the first hour in 
all patients achieving reperfusion following intracoronary 
streptokinase. Blanke et al. (1983) reported a mean fall 
of 60% in ST segment levels in his treatment group over 
the same time period as we studied. The work presented in 
this chapter confirms that a change in the ST segment 
measured in a single lead of >,50% within 3 hours of 
thrombolytic therapy is associated with reperfusion.
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The Fractional Change derived from the Holter monitor was 
more specific, but not quite as sensitive when compared to 
the Fractional Change calculated from the 12 lead ECG.
The lack of sensitivity was due to 2 patients scoring a 
Fractional Change Value of zero while angiography had 
shown them to have reperfused. These 2 patients had 
inferior myocardial infarction, and it may be that the 
standard lead positions used may have been inadequate to 
show myocardial injury in the inferior wall of the heart.
The results of this study suggest that the simple 
calculation of the Fractional Change derived from ST 
analysis of a single lead showing injury either by 
continuous ECG monitoring or the 12 lead ECG gives a value 
which is of predictive use to determine whether 
reperfusion has occurred or not.
Continuous electrocardiographic monitoring has the 
advantage of incorporating a computerised assessment of 
the ST segment change with less subjective variability, 
although it is more complex and time consuming to analyse. 
The 12 lead ECG can be used quickly for bed-side 
assessment which becomes important when clincal decisions 
regarding further management and drug regimes are being 
decided.
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The method of choice for clinical application depends on 
acceptable values of sensitivity and specificity. These 
levels may change depending on the purpose for which they 
are being used. Following successful coronary artery 
reperfusion, reocclusion has been reported in up to 40% of 
cases. Pharmacological regimes have recently been 
developed to prevent reocclusion. A test with a high 
sensitivity of detecting reperfusion will be of value in 
deciding which patients require specific follow on 
therapy. Comparison of reperfusion rates following 
administration of different thrombolytic agents would 
require a high specificity. While an attempt has been 
made to validate the rule by using a training and test 
group, the small sample sizes that this technique 
generates leads to wide errors in estimation of confidence 
intervals for sensitivity and specficity, and the 
application of these results to large population groups is 
required.
Coronary artery reperfusion can ony be definitively shown 
by coronary angiography, and in those patients treated by 
intracoronary infusion, the time of reperfusion was 
confirmed during the invasive procedure. In those cases 
treated by the intravenous route, no pre-treatment 
angiogram was performed, but the patency was confirmed 
angiographically within the time-scale during which the 
ECG1 s were performed. Although some of thes.e patients may 
not have a total occlusion at the time of their
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presentation (de Wood et al., 1980), all patients had the 
same clinical and electrocardiographic entry criteria, and 
presumably had critical reductions in coronary artery flow 
at time of presentation.
The methodology has shown no difference between the 
results obtained with different thrombolytic compounds, 
being similar with both conventional streptokinase and 
anistreplase. This suggests that this functional marker 
reflects the consequences of obtaining adequate coronary 
artery perfusion rather than a specific action of an 
individual compound, and is therefore applicable to the 
assessment of other pharmacological agents such as tissue 
plasminogen activator and urokinase.
The high percentage of patients in the non reperfusion 
group who showed an increase in ST segment elevation 
resulting in a negative Fractional Change raises the 
question of whether this may reflect reocclusion rather 
than just non-reperfusion. By definition, reocclusion 
requires that the vessel initially reperfused, and this 
would be represented by a biphasic curve in the ST segment 
printout. Over the time window examined no patient 
demonstrated this phenomenon, and in addtion, no patient 
had recurrence of chest pain to suggest reocclusion. 
Application of this technique may however be useful if 
studied over a longer time period.
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In summary, Fractional Change can be obtained from a 
single lead using Holter Monitoring techniques or from 12 
lead ECG's utilising the lead most indicative of
myocardial injury. It appears to be a useful non invasive
marker of treatment outcome, and a value of -^0.5 predicts 
a patent artery within the time-scale of this study.
Using a more sophisticated classification function, will 
increase sensitivity at the expense of specificity.
Future work may derive classification functions with 
better discriminatory power by adding additional variables 
such as creatine phosphokinase release or the presence or 
absence of reperfusion arrhythmias.
Criticism of this study arises from the relatively small 
numbers involved, especially those who do not reperfuse. 
The usefulness of a Fractional Change measurement to 
detect reperfusion non invasively needs to be tested
prospectively in a larger patient group.
A
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CHAPTER 4
ELECTROCARDIOGRAPHIC EVIDENCE OF MYOCARDIAL SALVAGE
FOLLOWING THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION
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4.1. LITERATURE REVIEW 
Having shown the ST segment to be a dynamic functional 
marker reflecting change in ischaemia or reperfusion, the 
next step was to investigate if Q and R wave amplitude 
changes, considered to be the electrocardiographic markers 
of necrosis, would reflect the degree of myocardial damage 
following thrombolysis. Work by Blumenthal et al. (1975) 
and Beller et al. (1977) looking at experimental 
occlusions with subsequent reperfusion, suggested that the 
development of these electrocardiographic markers may lag 
behind the anatomical evidence of necrosis. Ganz et al.
(1981) suggested that the evolution of Q wave formation 
and R wave loss was "perfusion-dependent". This classic 
paper shows accelerated development of Q waves associated 
with diminution of the R wave, 20 minutes following 
reperfusion in a dog model and 2 hours following 
reperfusion in a patient study. These workers suggested 
that had reperfusion not occurred, then these changes 
would have taken very much longer to evolve. This rapid 
evolution of ECG changes following reperfusion was 
confirmed by Goldberg et al. (1983b). Thus, somewhat 
paradoxically, reperfusion is thought to accelerate ECG 
changes of necrosis, the hypothesis being that the total 
amount of Q wave development and R wave diminution is 
reduced.
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Several studies have sought to prove this hypothesis, and 
similar to the results with ST segment changes, not all 
are in agreement. Direct comparison between studies is 
complicated by differing methodologies and patient 
treatment groups. Blanke et al. (1983) looked only at 
anterior myocardial infarction, and measured the sum of R 
waves ( ^ R  V1-V6), and the number of Q waves (nQ V1-V6) on 
the 12 lead ECG in patients receiving intracoronary 
streptokinase and in a control group. There did not 
appear to be an early accelerated change in ^ R  V1-V6 or 
nQ V1-V6 in the treatment group, the changes seen 
parallelling those in the control group. However, after 
12 hours^R V1-V6 increased in the streptokinase group 
along with a reduction in nQ V1-V6. The control group 
values did not change. This partial regrowth in R waves 
following reperfusion has also been described by Goldberg 
et al. (1983) and in patients with acute myocardial 
infarction not receiving interventional therapy by 
Montague et al. (1986). This latter paper emphasizes the 
need for controlled studies.
Anderson et al. (1983) showed a significant difference in 
relative R wave loss between controls and patients given 
intracoronary streptokinase 10 days after treatment. The 
streptokinase group also showed a significant reduction in 
nQ at day 1 and day 10. When this group reported their 
randomised trial of intravenous and intracoronary 
streptokinase a year later (Anderson et al., 1984) they
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were able to confirm a significant attenuation in R wave 
loss following treatment (compared to historical controls) 
but were unable to show any difference in Q wave 
evolution.
Following the evolutionary changes in a single lead 
showing maximum ST segment shift, Timmis et al. (1982) 
were unable to show any significant difference in Q or R 
waves following intracoronary streptokinase regardless of 
whether or not the patient achieved successful 
recanalization. This assessment was made within 1 day. 
When the same group looked at "minimaps" (I, AVL, V1-V6 
for anterior infarcts, II, III, AVF for inferior infarcts) 
prior to discharge, they were able to show a trend to a 
smallery^Q and slightly greater^Jl if recanalization was 
sustained in anterior infarcts in comparison to patients 
in whom streptokinase had failed or in controls. None of 
these changes were statistically significant, and indeed 
the control group of inferior infarcts appeared to show 
greater R wave preservation.
Von Essen et al. (1985) limited their study group to 
patients with anterior myocardial infarction and performed 
a 48 electrode map immediately following the 
administration of intracoronary streptokinase (patients 
treated within 8 hours) and again at 4-6 months. Vessel 
patency was assessed angiographically, and the patients
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divided into 4 subgroups; Group A - incomplete occlusion 
at initial angiography, Group B - successful persistent 
reperfusion, Group C - successful reperfusion with 
subseguent reocclusion and Group D — non reperfusion.
They were able to show a significant increase in ^ 
between early and late maps in Groups A and B, a decrease 
in for Group C and no significant change for Group D
(Table 9).
These studies suggest that achieving reperfusion (either 
spontaneous or following intervention) does result in 
accelerated evolution of the ECG which then undergoes a 
dynamic change, reflecting what is thought to be 
myocardial salvage. The time for this change to occur is 
not clear, and would seem to be temporally unrelated to 
any measured change in left ventricular function, or 
indeed mortality data. As with the ST segment literature, 
absolute changes in R and Q waves are small and standard 
deviations are large.
A single measurement encompassing all R and Q wave data 
from a 12 lead ECG would be of use in monitoring those 
changes occurring following treatment. The simplified QRS 
score designed by Wagner et al. (1982) and further 
assessed in post-infarction patients by Palmeri et al.
(1982) is based on R and Q wave amplitudes and durations.
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This scoring technique is fully discussed in Chapter 1. 
Published studies using this score in thrombolytic trials 
give conflicting results.
Koren et al. (1985) studied 53 patients given intravenous 
streptokinase, and showed that there was no difference in 
QRS score irrespective of whether the infarct-related 
artery was reperfused or not (7.5+5.6 vs 5.2+3.4 NS). It 
was only when this group examined the influence of time to 
treatment, and re-divided the patients into those 
receiving therapy within 1.5 hours and from 1.5-4 hours, 
were they able to show a significant attenuation of the 
QRS score in the group treated early (5.6^4.9 vs 8.6+5.5, 
p<0.01). Distinction was not made between site of infarct 
and 21% of the patients in the early group had non Q wave 
infarctions, compared to 9% in the late group. Pre­
treatment angiography was not performed, and the incidence 
of incomplete occlusion is not known.
Comparison between QRS scores in patients with 
reperfusion, and those without were published a year later 
by Mikell et al. (1986). 131 patients were included, 100
of which reperfused. The QRS scores were not different 
between the two groups (6.0jf3.2 vs 6.4+4.2) despite a 
significant higher ejection fraction being recorded in 
those that reperfused (53hh 13% vs 46+15%, p<0.05). The 
ECG sampling time was not fixed in this study, occurring 
at a mean of 4.9+7 days post treatment.
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Despite earlier work which suggests there is a reduction 
in Q wave formation, and an increase in R wave amplitude 
following successful treatment with thrombolytic therapy, 
there is no convincing evidence that these changes can be 
translated into significant reductions in the simplified 
QRS score, which in turn can relate to left ventricular 
function.
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Gp n 2 >Post SK
(mV)
4-6 months P value
A 11 18.1 23.2 0.04
B 25 12.4 16.2 0.006
C 8 14.0 9.8 0.003
D 10 11 .8 10.7 NS
Group A = incomplete occlusion
Group B = reperfusion
Group C = reperfusion followed by reocclusion 
Group D = non reperfusion 
From von Essen et al. (1985)
TABLE 9: RESULTS OF^^R FROM 48 LEAD PRECORDIAL MAPS
FOLLOWING STREPTOKINASE.
4.2. AIM OF STUDY
This study investigates the sequential changes occurring 
in conventional 12 lead electrocardiograms during acute 
anterior myocardial infarction. It compares the functional 
electrocardiographic changes occurring in control subjects 
with the changes in those who have obtained coronary 
artery reperfusion following thrombolytic therapy. The 
aim is to investigate by using the admission 
electrocardiogram as an index of myocardial injury, 
whether there is a predictable reduction in 
electrocardiographic indices of myocardial infarct size 
measured at 48 hours post treatment in patients obtaining 
successful reperfusion.
4.3 PATIENTS AND METHODS
Three patient groups were studied. All groups entered the 
study, within 6 hours of the onset of cardiac pain and had 
confirmatory electrocardiographic evidence of acute 
anterior myocardial infarction (>2 mm ST elevation in at 
least 2 precordial leads). Patients were excluded if they 
had sustained a previous myocardial infarction or had 
electrocardiographic changes which invalidated ST segment 
and Q wave analysis, including bundle branch block or 
pacemaker dependence.
Group 1 comprised historical controls who sustained an 
acute anterior myocardial infarction, but received no 
therapy other than conventional analgesia. They were
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admitted prior to the introduction of routine thrombolytic 
therapy. All patients admitted to the Coronary Care Unit 
have prospective proformata filled out detailing patient 
identification, clinical features on presentation, 
examination findings, treatment administered and final 
diagnosis. These data are recorded on punch cards and 
stored in a mainframe computer. All electrocardiographic 
and haemodynamic tracings performed are stored separately 
as hard copy. This policy allows a review of coronary 
care admissions and facilitates division of patients into 
subsets for research purposes. The control group chosen 
for this study had no complications requiring specific 
cardio-active agents, nor received routine administration 
of any drugs which might influence myocardial infarct 
size, specifically betablockers, calcium channel blockers 
or nitrates. The ECG changes measured therefore represent 
those occurring in a patient group with acute anterior 
myocardial infarction without cardiogenic shock or 
haemodynamic decompensation.
Group 2 consisted of patients who received thrombolytic 
therapy using the agent of our then current thrombolysis 
protocol. Both groups are similar with respect to age, 
sex and time to presentation (Table 10). Group 2 received 
either intracoronary streptokinase (n=13) or an 
intravenous bolus dose of anistreplase (n=20) according to 
the protocols outlined in chapter 2. Coronary artery
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patency was determined by selective coronary 
arteriography, performed during therapy in the 
intracoronary cases or 60-90 minutes following 
administration of the intravenous therapy. The coronary 
arteriograms were read independently by two of the 
cardiologists not involved in the individual patient 
study. The patency of the infarct-related vessel was 
decided according to the European classification 
(Verstraete et al., 1985a). A vessel was considered 
patent if the distal part of the infarct related artery 
filled within 3 cardiac cycles. It was considered 
unethical to perform emergency angiography in the Group 1 
patients who received only opiate analgesia, and therefore 
the incidence of coronary artery occlusion at time of 
admission and of spontaneous reperfusion is unknown (De 
Wood et al., 1980).
Group 3 consisted of 22 patients (19 male, 3 female, age 
range 31-68, mean age 53.6 years) receiving either 1.5 
M.U. streptokinase over 1 hour or 30 U anistreplase over 5 
minutes. Reperfusion was assessed angiographically at 90 
minutes after the start of treatment in all cases. 
Individual patient data for all three groups is listed in 
appendix III.
4.4 ECG ANALYSIS
Following admission to the Coronary Care unit, 12 lead 
electrocardiographs were performed using a Hewlett Packard
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Cardiograph 4700A as discussed in Chapter 2. ECG's were 
measured manually using hand held calipers. The ST 
segment area was calculated for each lead showing ST 
elevation (1 mm in the limb leads or 2 mm in the 
precordial leads taken at the J point) and measured as the 
area above the isoelectric line from the J point to the 
end of the T wave. The scores for all leads were summed 
as an index of myocardial injury or ischaemia reflecting 
potential infarct size, 2 > .
A second electrocardiograph was taken at 48 hours 
following the onset of symptoms and a measurement of the 
evolved infarct size was made using the QRS scoring system 
described by Wagner et al. (1982) which has been 
previously discussed.
4.5 STATISTICAL ANALYSIS
Results are expressed as mean values +SD. Statistical 
analysis was undertaken using the Students unpaired 't1 
test to compare groups. Linear regression was performed 
using the statistical package VASP on a Nodecrest 
computer, and an F test applied to test the regression 
lines. Prediction intervals of QRS scores for the test 
group patients (Group 3) were calculated based on the data 
from the known reperfusion data. This predicts the level 
of QRS score that would be expected if the patient 
reperfuses.
115
4.6 RESULTS
Figure 6 shows a representative electrocardiograph on
admission a, and at 48 hours b, from which the ^ S T
segment area and the QRS scores respectively were
calculated. The degree of ischaemia on the
electrocardiogram at presentation was similar in both
groups ,7^ST area group 1 m = 115+60 mm , group 2 m =
2
126^+77 mm (N.S). This indicates that both groups had 
comparable myocardial ischaemia and potential infarct 
size. Of the patients in group 2 who received 
thrombolytic therapy, 11/13 receiving intracoronary 
streptokinase achieved successful reperfusion, and 19/20 
receiving intravenous anistreplase were found at 
angiography to have a patent infarct-related vessel (LAD) . 
At 48 hours the evolved infarct size as assessed by the 
QRS score was significantly lower in those patients 
obtaining reperfusion (mean QRS=4.1+2.5) compared with the 
control group (mean QRS=7.8±2.6) (p<0.01). The 
relationship between myocardial ischaemia at admission £  
ST area) and eventual infarct size is shown for both the 
control group and those patients achieving reperfusion in 
Figure 7. Only 3 subjects in group 2 failed to show 
reperfusion and therefore no formal statistical analysis 
has been performed to compare the ECG score of the 
reperfusion group with the non reperfusion group. The 
non- reperfused subjects however showed Q wave 
development, and a subsequent QRS score, similar to the 
control group (Table 11). The patients in group 2 were
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further divided by the time elapsed between the onset of
cardiac pain and the time to thrombolytic therapyi group
2a<3 hours (n=16), group 2b>3 hours but <6 hours (n=14).
The presenting values for V*ST segment area were 142 + 82 
2 2 
mm and 107+70 mm respectively (N.S.). The evolved
infarct size scores were not significantly different for
the two groups. Group 2a QRS=4.2+2.8, group 2b
QRS=4.1+2.1.
Figure 8 shows a scatter diagram representing individual 
scores for Group 1 and Group 2 with respective linear 
regressions, QRS = 4. 6+0 . 027 .^ST area, and QRS =
1 .6+0 . 020 area. These regressions describing each
group separately fit the data better than a single 
regression through all points (p<0.05).
Ninety-five percent prediction intervals for QRS scores 
were calculated using the group 2 reperfusion data. These 
intervals are shown in Figure 9 with group 1 control data 
superimposed. There is a substantial number of control 
patients (51%) whose QRS score falls within the 95% 
prediction intervals for reperfused cases.
To investigate whether these intervals could be used to 
accurately predict QRS scores in individual patients,
Group 3 was used as a test group. The intervals were used 
to predict the QRS scores expected if new patients had
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reperfused. Out of 22 patients given thrombolytic 
therapy, 11 obtained a patent artery at 90 minutes after 
treatment, and 11 were classed as non reperfusions. Both 
sub groups had similar degrees of myocardial injury on
Patients obtaining reperfusion had lower QRS scores 
compared with the non reperfusion group, 4.5+3.1 v 9.3+3.4 
(p<0.01). However, Figure 10 shows that 5 of 11 non 
reperfusions fall outwith the prediction intervals for 
reperfused cases, but that 6 of 11 cases fall within this 
band. All cases except 1 which achieved reperfusion fall 
within the prediction intervals shown. The wide inter­
individual variability does not allow the prediction of a 
QRS score on an individual basis.
presentation, ST area = 147+74 mm (reperfusion group) 
2
171+76 mm (non reperfusion group) (NS).
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Mean Mean time to
Gp n M F Age Treatment Presentation
1 35 29 6 55.5 Control (n=35) 3 hrs. 28 min
+96 min
i/c Streptokinase 
> (n=13)
/
2 33 22 11 57.3 2 hrs. 40 min
V +87 min
i/v Anistreplase 
(n=20)
TABLE 10: BASELINE CHARACTERISTICS FOR GROUP 1 AND
GROUP 2
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H4 44-W  ! I I ' I H*
FIGURE 6: REPRESENTATIVE 12 LEAD ECG FROM PATIENT WITH
ACUTE ANTERIOR MYOCARDIAL INFARCTION A, AND 4 8 
HOURS FOLLOWING SUCCESSFUL REPERFUSION B.
T h e ^  ST area on the admission ECG is 218 mm2. 
The QRS score 48 hours after treatment is 3.
1ST AREA
mm ^
200 -
160 “
140 “
120  "
100  -
80 -
10
-  9
- 8 
-  7
QRS SCORE
-  5
- 4
-  3
-  2
- 1
Group 1. 
CONTROLS
Group 2. 
REPERFUSIONS
I  ST AREA
QRS SCORE
** p <0.005
FIGURE 7: RELATIONSHIP BETWEEN J^ST AREA ON PRESENTATION
AND SUBSEQUENT QRS SCORE AT 4 8 HRS POST ADMISSION 
IN GROUP 1 AND GROUP 2
Group 1 Group 2
Control
n=35
Reperfusion
n=30
Non Reperfusion 
n=3
/ ST Area 
)
115+60 126+77 279+44.7
QRS score 7.8+2.6 4.1+2.5 7 . 3+4.5
TABLE 11 : MEAN VALUES AND STANDARD DEVIATIONS FOREST
AREA AND QRS SCORES FOR GROUPS 1 AND 2 DEPENDING 
ON CORONARY ARTERY PATENCY
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4.7 DISCUSSION
This study shows that the sequential electrocardiographic 
changes are attenuated in patients with acute anterior 
myocardial infarction who achieve coronary artery 
reperfusion following thrombolytic therapy. The question 
of whether this attenuation in electrocardiographic 
infarct size could be used on an individual basis to 
predict QRS scores assuming reperfusion in patients with 
acute anterior infarction was then addressed.
Although this study was not randomised, the control and 
intervention groups show similar distribution of baseline 
characteristics including sex, age, time to presentation 
and similar levels of ST elevation on the admission ECG. 
Patients in the control group were on no drugs which could 
influence myocardial infarct size and patients with 
cardiogenic shock or cardiac failure were also excluded. 
Selection for this group was therefore biased against 
inclusion of clinical sub sets which may have had major 
myocardial damage, and hence high QRS scores. The 
electrocardiographic changes shown in this group therefore 
represent the true natural history occurring during acute 
anterior myocardial infarction. As it was considered 
unethical to perform angiography in patients not receiving 
thrombolytic therapy, the control group may include 
patients with a sub total coronary artery occlusion at the 
time of presentation or those who had spontaneous 
reperfusion (De Wood et al., 1980). Such coronary artery
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morphology may be associated with less eventual myocardial 
damage, and the inclusion of such subjects would again 
tend to bias results against finding a difference in 
evolved QRS scores.
Selwyn et al. (1978) showed that in patients with acute 
anterior myocardial infarction, the precordial area of ST 
segment elevation at 2 hours was directly related to the 
extent of developed Q waves at 24 hours after the onset of 
pain. An arbitrary time interval of 48 hours from 
presentation was chosen for the measurement of evolved 
infarct size in this study as Q wave development is 
believed to be complete at this time. Animal studies 
using an epicardial mapping system have shown a convincing 
correlation between ST segment changes, subsequent Q wave 
development, myocardial creatine phosphokinase release and 
histological evidence of necrosis (Hillis et al., 1976). 
However, opinion is divided regarding the ability of ST 
segment elevation to predict either the severity or the 
extent of myocardial necrosis in humans. In man, using 
precordial mapping techniques, both Norris et al. (1976) 
and Thompson and Katavatis (1976) found little 
relationship between ST segment elevation and subsequent 
infarct size as assessed by creatine phosphokinase 
release. Problems can arise as coronary artery occlusion 
is not the only stimulus to affect the ST segment. 
Nevertheless, Askenazi et al. (1977) have reported that
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there is a predictable distribution of leads with ST 
elevation which ultimately develop signs of necrosis, and 
have suggested that a reduction in Q wave development 
would be of value in monitoring therapy designed to 
preserve myocardium. This has been confirmed in similar 
work by Yusuf et al. (1979).
The present study confirms that a reduction in Q wave 
formation is associated with coronary artery reperfusion 
and that the reperfusion group score lower QRS values than
the control group. This is in contrast to the findings of
Mikell et al. (1986) who found that the QRS scores were
the same irrespective of whether or not the patient had
achieved successful reperfusion. This group did show an 
improvement in left ventricular ejection fraction if the 
patient had reperfused, and suggested that there was a lag 
between electrocardiographic changes and left ventricular 
recovery or function. The patients studied by this group 
had a preponderence of inferior infarctions, and this may 
explain why a difference in QRS scores was not seen. 
Previous studies have shown that both ST segment changes 
and QRS scores are more variable when applied to patients 
with inferior infarcts. This may reflect the small number 
of leads which show changes with inferior infarction, and 
therefore represent only a limited proportion of the 
underlying myocardium.
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Despite being able to show a reduction in QRS scores for 
these patients who reperfused, when prediction intervals 
were calculated for this group, the limits were so wide 
and overlap between groups such that clinical predictions 
regarding infarct size on an individual basis were not 
helpful. This degree of interindividual variability may 
be accounted for by several reasons. Hackworthy et al.
(1986) showed that collateral formation resulted in a 
smaller than expected infarct size using the same QRS 
scoring system. Only in patients with a totally occluded 
artery with no collaterals did the initial peak ST 
elevation correlate with electrocardiographic infarct 
size. Certainly the presence of collaterals may reduce 
the expected QRS score in patients with no anterograde 
flow, classed as non reperfusions. We know from de Wood 
et al. (1980) that 15% of patients presenting within a 6 
hour time window will have a sub total occlusion, and that 
there is a spontaneous reperfusion rate. Huey et al.
(1987) confirmed that patients with a natural high patency 
rate at 10-13 days post infarction had better left 
ventricular function and less development of Q waves. 
Similarly Hackworthy et al. (1986) showed a reduction in 
the expected QRS scores if related to a sub total 
occlusion.
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It is of interest in the present study that beneficial 
changes in electrocardiographic indices of myocardial 
infarct size could be demonstrated even in those subjects 
given thrombolytic therapy within a 3 to 6 hour time 
window. This suggests that functional benefit measured 
electrocardiographically may still be obtained if therapy 
can be started within 6 hours of the onset of cardiac 
pain. The potential for benefit may be present in those 
patients in whom coronary collaterals have previously 
developed or in whom acute infarction is associated with a 
sub total coronary artery stenosis rather than a complete 
occlusion (Rogers et al., 1984).
In conclusion, using conventional 12 lead 
electrocardiograms this chapter demonstrates significant 
attenuation in the developed QRS score, in patients who 
achieved reperfusion following thrombolysis for acute 
anterior myocardial infarction. Beneficial change in this 
functional marker can be obtained following successful 
reperfusion up to 6 hours from onset of pain. There is a 
wide inter-individual variability in QRS scores making 
prediction regarding infarct size on an individual basis 
unhelpful. This variability may be accounted for in part 
by degree of collateral supply, time to reperfusion, or by 
the presence of a sub total occlusion at time of
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presentation. However, the reduction in QRS scores seen 
in patients who achieve reperfusion following thrombolytic 
therapy may provide a non invasive index of myocardial 
salvage on a population basis.
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CHAPTER 5
DEVELOPMENT OF DIGITIZED ECG DATA COLLECTION AND 
VALIDATION OF SYSTEM
127
5.1. INTRODUCTION
Chapters 3 and 4 have shown that the 12 lead ECG can be a 
dynamic functional marker of myocardial reperfusion and 
salvage. The ECG measurements performed in these studies 
were made manually using hand held calipers, and the 
studies were in relatively small patient numbers or 
specific subsets - i.e. anterior infarction. Verification 
of these initial results was required in a larger patient 
group. In addition, different groups of workers use 
different methods of measurement and different parameters, 
a variety of which are shown in Table 12. It is not clear 
which are the most sensitive and specific techniques to 
follow therapeutic interventions in myocardial infarction.
In order to attempt to answer these questions, at least in 
part, a computerized data base for collection of 
electrocardiographic data has been developed. Twelve lead 
electrocardiographs were digitized and individual 
parameters stored to examine which measurements, or 
combinations of measurements, would be most useful on a 
clinical basis to detect reperfusion and to give an index 
of myocardial infarct size. This system allows storage of 
data for a large number of patients, each with several 
sequential ECG's. It was intended that the system should 
be doctor or technician run. This chapter describes the 
system that was developed, the parameters measured, and 
the validation of the technique by presenting an inter and 
intra observer variation study.
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5.2 GENERAL METHODOLOGY
The digitizer board (Summagraphics Corporation Supergrid) 
was linked to a Nodecrest computer. The individual 
thrombolytic studies undertaken in the Coronary Care Unit 
since 1984 were listed separately in data files. Each 
study has different timing of ECG sampling, and this 
allowed data to be listed in a logical and chronological 
fashion for subsequent analysis (Table 13.) This list can 
be, and has been expanded to accommodate further studies.
The 12 lead ECG to be analysed is fixed to the surface of
the digitizer board. The operator then accesses the
programme required, the appropriate study is selected, the
patient identified and the timing of the ECG inserted.
When the system was being developed, it was necessary to
plan carefully which particular ECG parameters would be
measured, and subsequently stored. Future analysis
comparing scoring systems or methods of following
intervention would depend on the initial data base, and
therefore all potentially useful data must be keyed in at
the start. While requiring a comprehensive analysis of
each ECG, it must not be so detailed and complex to be
excessively time consuming (from the initial study listing
in Table 13. there is space for 2,643 12 lead ECG's).
Measurements were made of ST segment elevation and
2
depression (both area (mm ) and height (mV)) , Q wave 
duration and amplitude, R wave duration and amplitude and 
S wave amplitude. All leads except AVR were screened for
130
the above features, and measured if present. An average 
heart rate was computed for each ECG, measured from a long 
lead II and each ECG was calibrated for m.sec and m.V by 
digitally recording 1 second and 1 mV before each separate 
12 lead ECG analysis. The average of 2-3 beats were 
measured per lead, and the isoelectric baseline identified 
for each complex. This was to prevent inaccuracies 
arising from minor baseline shifts occurring over 2-3 
beats. An example of the print-out obtained for each ECG 
is shown in Figure 11. This also provides R/Q and R/S 
ratios, allowing computation of the simplified Selvester 
QRS score (Wagner et al., 1982, and Table 5) which is 
displayed in the initial print-out. The program written 
to calculate the QRS score from the digitized ECG data is 
shown in Appendix IV.
Following an initial learning period of 2-3 weeks, the 
analysis time for each 12 lead ECG was in the order of 7- 
10 minutes, including the entry of demographic data into 
the computer.
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Study n ECG times*
1. ICSK 80 Pre, post angio, 24, 
48 hrs
2. Open APSAC 150 Pre, 2,4,6,8,10,12,24, 
48 hrs
3. APSAC/SK comparison 128 Pre, 2,4,16,18,24 hrs
4. TPA Study 1 11 Pre, 3,12,24,48 hrs
5. TPA Study 2 30 Pre, 3,12,24,48 hrs
* Time in hours refers to time following administration of 
thrombolytic agent.
ICSK = intracoronary streptokinase
APSAC = anistreplase
TPA = tissue plasminogen activator
TABLE 13: THROMBOLYTIC STUDIES LISTED ON NODECREST
COMPUTER FILE STORE. (List at end of October 
1988)
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5.3. ELECTROCARDIOGRAPHIC ANALYSIS
A clearly defined set of rules had to be established for 
identification of electrocardiographic waveforms to ensure 
reproducible results. Due to the nature of thrombolytic 
trials, many of the ECG's analysed demonstrated hyperacute 
changes with marked shifts from baseline which reguire 
clear definitions concerning from which point to measure 
the degree of ST segment deviation. These guidelines have 
been drawn up paying attention to the recommendations for 
measurement standards by both the CSE Working Party (1985) 
and the report of the American Heart Association Committee 
on Electrocardiography (1975). Further recommendations 
were obtained from the methodological paper by Hindman et 
al. (1985). Where controversy exists concerning the 
measurement of a particular waveform, the method chosen 
was the one which would be most reproducible and introduce 
least variability when being digitized. Some specific 
points are discussed below.
5.3.1 Measurement of Baseline
The American Heart Association recommends that the 
reference level for Q, R and S amplitude measurements and 
the displacement of the J point is taken from the PR 
segment, but that the reference level for measurements of 
the ST segments, the T wave and the U wave is taken on the 
TP or UP interval. This may not be easily defined as 
the heart rate increases, and has led the European Working 
group to recommend the uniform use of a horizontal
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baseline taken on the PR segment. The onset of the QRS is 
readily identified, more so than the end of the T wave, 
and so the isoelectric reference point for digitized data 
was on the PR segment prior to QRS onset.
5.3.2. Small and Inconsistent Waveforms
The CSE Working Party identified a minimum threshold which 
a wave form had to reach before being described as present 
(20 uV amplitude and 6 m.sec duration). The diagnostic 
implications of deflections smaller than this are not 
known, but identification of these waveforms may result in 
bizarre labelling of the complex, with subsequent changes 
in Q and R wave durations and the QRS score. Before 
identifying a small waveform its consistency should be 
examined in the same lead, and also across leads. For use 
with the digitizer if a wave form was inconsistently 
present and measured <0.05 mV, its presence was not 
recorded.
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5.3.3. ST Segment Analysis
Previous wor k  is controversial regarding the ideal
position from which the displaced ST segment should be
measured from the baseline. Varying distances from the J
*
point have been used - examples of which are shown in 
Table 14. Many more papers do not specify at all where 
the ST measurement is taken from. It can be seen from 
Table 14 that most published studies have made use of an 
inappropriate baseline reference point, as well as using a 
heterogenous range of positions at which to measure ST 
segment displacement. The J point, defined as the point or 
shoulder which marks the end of the QRS complex where the 
steep slopes of QRS deflection are more or less abruptly 
replaced by the more gradual slopes which precede or 
comprise the first limb of the T wave (AHA Committee 
report, 1975), was felt to be the most easily recognised 
and reproducible for digitized work. Using this point 
ensured that further variation would not be introduced by 
"estimating" 20 or 40 m.secs from the J point before 
digitizing this as ST segment displacement. The reference 
baseline point was the PR segment as discussed above.
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ST Reference
Study Measurement Point
Bar et al. 
(1987)
at the J point not specified
Blanke et al. 
(1983)
0.02 secs after 
J point
TP
Muller et al. 
(1975)
0.02 secs after 
J point
TP
Zmyslinski 
et al. (1979)
0.04 secs after 
J point
TP
Selwyn et al. 
(1977a)
0.06 secs after 
nadir of S wave
TP or PQ
TABLE 14: PUBLISHED WORK SHOWING VARIATION IN POSITION AT 
WHICH ST SEGMENT DISPLACEMENT IS MEASURED
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5.3.4. Duration Measurement
The points taken for duration of individual waveforms are 
covered fully in the set of rules which follows. However, 
in some instances slurring of waveforms resulted in 
thickened electrocardiographic upstrokes and downstrokes. 
From the work of Mazzoleni and de Maria (1983) a decision 
was made to measure duration from the middle of the 
tracing in all cases. This group showed that measuring 
from the leading or trailing edge could result in an under 
or over-estimation of the true wave duration.
5.3.5. Exclusion from Analysis
Patients who developed left axis deviation, right or left 
bundle branch block, temporary pacemaker dependence or a 
sustained idioventricular rhythm were excluded from 
analysis. If however these effects were temporary, and 
normal sinus rhythm was restored, the subsequent ECG was 
analysed.
137
5.3.6. Set of Guidelines for digitized measurement of 
ECG data
The above decisions resulted in the writing of a set of 
rules for the digitized measurement of ECG data, which are 
illustrated in the next 6 pages. This allows the analysis 
of 12 lead ECG's to be approached in a logical and 
consistent manner. With over 24 months experience using 
the digitizer this set of rules has proved easy and 
practical to adhere to.
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1. THE NORMAL ECG
R WAVE 
DURATION
R WAVE 
AMPLITUDE
Q WAVE 
AMPLITUDE
ISOELECTRIC  
POINT ,
J POINT
S WAVE 
AMPLITUDE
Q WAVE
DURATION
Duration in milliseconds 
Amplitude in millivolts.
a . Isoelectric point taken in the interval before QRS onset 
for all QRS and ST-T measurements.
b. J POINT taken for measurement of ST Segment elevation 
or depression.
FIGURE 12: SET OF GUIDELINES FOR DIGITIZED MEASUREMENTS OF
ECG DATA
2. Measurement of R and S waves - with Junctional Deviation 
i.e. ST Segment Elevation or Depression
(i) ST Segment Elevation
R WAVE 
AMPLITUDE
4ft
R WAVE 
DURATION
a) End of R wave taken at J point
b) Isoelectric point taken on PQ Segment
"  i  ST SEGMENT 
_  J y  ELEVATION
FIGURE 12: SET OF GUIDELINES FOR DIGITIZED MEASUREMENTS OF
ECG DATA
(ii) ST Segment Depression
R WAVE 
DURATION
S WAVE 
AMPLITUDE
ST
R WAVE 
DURATION
ST SEGMENT
DEPRESSION
R WAVE 
DURATION
(iii)
ST DEPRESSION
S WAVE 
AMPLITUDE
J POINT
a) Isoelectric point taken on PQ Segment
b) in (ii) the end of the R wave is depressed to coincide with the
negatively deviated J point. There is no S wave. For reproducibility 
using the digitizer the R wave duration is measured as shown -
on the down stroke as it passes through the isoelectric line.
AHA recommendations would measure R wave duration from
upstroke to J point.
c) in (iii) the ’R' wave is more depressed than the J point -
this extra deflection back to meet the J point is termed an S wave and 
the R wave duration is as shown.
FIGURE 12: SET OF GUIDELINES FOR DIGITIZED MEASUREMENTS OF
ECG DATA
3. Measurement of ST Segment Elevation and Depression 
(Amplitude and Area)
(i) ST Segment Elevation
J POINT 
/ .
ST SEGMENT
(ii) ST Segment Depression
e l e v a t i o n
a)
b)
c)
a)
ST SEGMENT 
DEPRESSION
J POINTST SEGMENT AREA
Isoelectric line taken at PQ Segment
Amplitude (mv) of ST depression/elevation taken at J point with 
reference to isoelectric point
Area of depression/elevation taken by tracing digitizer pen round 
ST-T contour. Digitizer automatically drops perpendicular to 
isoelectric line and computes area as shown by hatched lines. Elevation 
is expressed as a positive value, depression as a negative value.
(iii) ST elevation with QS complex
J POINT
ST SEG. 
ELEVATION
ST SEGMENT 
AREA
NO ST SEGMENT 
ELEVATION
Q WAVE 
DURATION
The terminal portion of the Q wave is elevated above the isoelectric line 
as a function of ST Segment elevation. There is no R wave.
ST Segment elevation is measured from the J point as shown.
For reproducibility with the digitizer Q wave duration is measured 
where down stroke and up stroke cross the isoelectric baseline and 
not at the J point.
FIGURE 12: SET OF GUIDELINES FOR DIGITIZED MEASUREMENTS OF
ECG DATA
3. Measurement of ST Segment Elevation and Depression - 
(Continued).
(IV) ST. Elevation with QR complex
NO ST SEGMENT 
ELEVATION
ST SEG. 
ELEVATION
R WAVE DURATION 
J POINT
ST SEGMENT
AREA
Q WAVE 
DURATION ^
a) If the terminal portion of the QRS complex deflects back down to the 
J point which is elevated then by definition there is an R wave 
present
(V) QR Complex with ST (VI) QRS Complex with ST
Depression
ST SEGMENT 
DEPRESSION
J POINT
Depression
ST. SEGMENT 
DEPRESSION
J POINT
a) in (V) the end of the R wave is depressed to coincide with the 
negatively deviated J point. There is no S wave. Measurements for 
ST depression are taken as shown.
b) in (VI) the deflection of the slurred terminal portion of the QRS 
complex back to meet the J point is termed an S wave. 
Measurements for ST depression are taken as shown.
FIGURE 12: SET OF GUIDELINES FOR DIGITIZED MEASUREMENTS OF
ECG DATA
4
4. Measurement of notched Complexes 
(i) Notched Q waves
Q WAVE 
DURATION
Q WAVE 
AMPLITUDE
a) A 'notch" is said to occur if there is a reversal in direction of the 
initial deflection > 0.05 m Volts.
b) The duration and amplitude of a 'notched' Q wave are measured 
from the initial deflection as shown.
FIGURE 12: SET OF GUIDELINES FOR DIGITIZED MEASUREMENTS OF
ECG DATA
5.4. INTRA AND INTER OBSERVER VARIATION
5.4.1 Aim
The purpose of this study was to validate the technique 
and ensure that both inter and intra observer variation 
was sufficiently small to allow more than one person to 
enter data (KJH and AMcK) which could be used in future 
analysis.
5.4.2. Methods
One hundred ECG's were analysed from a total of 10 
patients. The ECG's analysed in this study were chosen to 
represent the spectrum of ECG's which would be analysed in 
thrombolytic patient studies i.e. hyperacute changes of 
myocardial infarction, established infarcts and infarcts 
in evolution. This allowed the estimation of the inter 
and intra observer variation for ST segment elevation and 
depression, and Q wave duration, as well as the other 
normal parameters of a 12 lead ECG. The ECG data from 
this study are shown in Appendix V. Each of the 10 
patients had a 12 lead ECG performed in the supine 
position, and 9 identical copies made (memory facility on 
Hewlett Packard 4700A). This was necessary for the study 
as digitization of an ECG can leave marks from the pen 
which may bias a second observer or the same observer the 
second time round. The ECG's were split into 2 sections 
of 50 (10 x 5) and put into a random order before each 
section was analysed by one observer (KJH and AMcK). No 
conferring was allowed, and the data stored on computer.
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5.4.3. Analysis
Once all the ECG data had been digitized, the data were 
transferred on to magnetic tape for further analysis on 
the University mainframe computer (ICL.2980). For each of 
the 10 ECG's, 11 leads were analysed per ECG, with a total 
possibility of 9 parameters per lead (ST amplitude and 
area (elevation or depression) Q wave amplitude and 
duration, S wave amplitude, R wave amplitude and duration, 
R/S and R/Q ratios) and a further 2 parameters per ECG 
(heart rate and QRS score) . Not all leads had all 
parameters i.e. no Q wave or ST segment deviation, but 
this gives a potential number of measurements for the 10 
ECG's as 1,010 - each of which was repeated 5 times by 
each observer. Grouping the measurements either across 
all leads or across all ECG's does not make sense in 
electrocardiographic terms due to the expected degree of 
variation between ECG's (chosen specially to represent a 
spectrum of myocardial infarction), and across lead types. 
Therefore a "cell" consisting of one parameter for one 
lead for one ECG was analysed separately. Where 
parameters had not existed, as in the case of a lead 
without a Q wave, this was given a score of 0.00 and 
omitted from further analysis. The mean and standard 
deviations were calculated for each cell, and coefficients 
of variation calculated. This gives a measure of the 
inter and intra observer variation. The formula used and 
worked examples are shown in Figures 13 and ^4 
respectively. This method expresses the standard
140
deviation as a percentage of the mean. To make the vast 
number of results manageable, they have been expressed as 
the percentage of total measurements made, which fall 
within a coefficient of variation of <10% and <20%.
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INTRAOBSERVER VARIATION
CV = SD x 100% 
x
where
Example 1_
Example 2
CV = coefficient of variation
SD = Standard deviation for one cell
x = mean value of 5 replicates for one cell
ECG 3, Lead 1, observer 1, Parameter 4 
[R wave amplitude]
x = 0.8790 
SD = 0.111
cv = 0.0111 x 100%
0.8790
cv = 1.2%
ECG 1, Lead 1, observer 1 , Parameter 1
(ST deviation)
x = -0.134 (ST depression characterized as
negative. The negative change is 
ignored in calculation of cv as it 
is solely a means of differentiating 
ST segment depression from 
elevation)
SD = 0.00909
cv = 0.00909 x
0.134
cv = 6.8%
ECG 1, Lead 1,
(ST deviation)
x = -0.1394
SD = 0.00391
cv = 0.00391 x
0.1394
cv = 2.8%
Example _3
FIGURE 13: METHOD FOR DETERMINING COEFFICIENT OF VARIATION 
FOR INTRAOBSERVER VARIATION
INTER-OBSERVER VARIATION 
cv = SD x 100% 
x
cv = Vs2
cv = f i=1
( x i  - x )
n - 1
V (x.-x)2 + (x_-x  . n - 1
= . 2 )
where x
x.
overall mean for all measurements 
mean of 5 measurements for observer 1 
mean of 5 measurements for observer 2
Example
Working out inter-observer variation from 
examples 2 and 3 in Figure 13.
x = -0.1367
x ^ = -0.134
x2 = -0.1394
cv =
cv =
V (-0. 134 + 0. 1367 )2 + (-0.1394 + 0. 1367)2
-0.1367
2.7%
FIGURE 14: METHOD FOR DETERMINING COEFFICIENT OF VARIATION 
FOR INTER-OBSERVER VARIATION
5.4.4.Results: Intraobserver Variation
Of 2,020 possible cells, (both observers, all ECG's, all 
leads, all parameters) 1,565 measurements were made, the 
discrepancy reflecting leads which did not exhibit Q 
waves, S waves or ST segment deviations from baseline. 
Standard deviations of these measurements expressed as a 
percentage of the mean were <10% in 78% of cases. Only 
4% of all measurements made had coefficients of variations 
>20%. This data is displayed graphically in Figure 15.
The individual parameters were then examined to see if 
there was one particular variable which the observers 
found difficult to measure, which would result in 
persistently high coefficients of variation. From Table 
15 it can be seen that in general all measurements perform 
well. Q wave duration and amplitude have the least amount 
of cases with a coefficient of variation of <10% and this 
may reflect the difficulty in measuring small Q waves in 
evolution. However, well over 90% of both measurements 
(duration and amplitude) have a coefficient of variation 
of <20%. The QRS score has been omitted from this table 
as in contrast to other parameters measured, a score of 
zero should be taken into account as this would be the 
score expected if the ECG did not show evidence of an 
established myocardial infarction.
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FIGURE 15: INTRAOBSERVER VARIATION - SPREAD OF 
COEFFICIENTS OF VARIATION
Parameter
Coefficient of 
Total No. Variation
Measurements <10% <20% >20%
ST amplitude 
(elevation and 
depression)
133 78% 90% 10%
ST area 
(elevation and 
depression)
134 84% 96% 4%
Q wave amplitude 74 70% 97% 3%
R wave amplitude 205 96% 99% 1%
S wave amplitude 148 91% 97% 3%
Q wave duration 74 59% 93% 7%
R wave duration 205 77% 98.5% 1 .5%
Heart Rate 220 100% 100% 0%
TABLE 15: INTRAOBSERVER VARIATION: COEFFICIENTS OF 
VARIATION FOR DIFFERENT ECG PARAMETERS
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5.4.5. Results: Interobserver Variation
Results for interobserver variation have been analysed in 
a similar fashion as for intraobserver variation. Out of 
a total possible 1,010 cells per observer (1 observer, all 
ECG's, all leads, all parameters), 772 had been measured 
and coefficients of variation calculated, 80% of this 
total having a coefficient of variation <10% and only 5% 
having a coefficient of variation >20%. These results are 
shown graphically in Figure 16. Note that although ST 
segment depression is characterized and differentiated 
from ST segment elevation by a negative sign, this does 
not influence the calculation of the coefficients of 
variation which by convention are always reported as 
positive.
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FIGURE 16: INTEROBSERVER VARIATION - SPREAD OF 
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5.4.6. Computed QRS Score
The inter and intraobserver variations for the Simplified 
Selvester QRS score computed automatically for each ECG 
were examined. Significant differences in the QRS score 
obtained could arise by the arbitrary cut off levels for 
"significant" and "non significant" Q waves (e.g. Lead II, 
Q wave ^30 m.secs is significant and scores + 1, Q wave 
<30 m.secs is non scoring). If observer 1 recorded an 
average Q wave duration of 29.5 m.secs for lead II and 
observer 2 recorded an average duration of 30.3 m.secs for 
the same lead, this gives a very satisfactory 
interobserver variation of 1.1%, but a difference of 1 in 
the ultimate QRS score. The scores obtained for each of 
the 10 ECG's by each observer are shown in Table 16.
Because of the inherent difference in the 10 ECG's chosen 
for analysis, the score for each ECG was examined 
separately, a score of 5/5 meaning that all replicates of 
one ECG scored the same. When these results were grouped 
together the QRS scores were in complete agreement in 94% 
of cases for observer 1 and 78% cases for observer 2. 
Previous work by Anderson et al. (1983) has highlighted 
the problem of minor fluctuations in R wave and Q wave 
dimensions, giving rise to frequent transient 1 point 
variations and defined a "QRS change" as a score increase 
or decrease of >y2 points compared with a previous 
observation. In this study, scores+ 1 point difference 
resulted in agreement for observer 1 in 100% of cases and
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observer 2 in 88% of cases. Comparing scores between 
observers showed complete agreement in 68% of cases and +
1 in 90% of cases.
The biggest difference which occurs between scores for the 
same ECG between two observers is ECG No. 9 where observer 
1 scores 7 and observer 2 scores 2 on the first analysis. 
This primarily arises due to differences in measured Q 
wave duration. Observer 1 measures the Q wave in lead II 
as 45 msecs (score +2) but observer 2 has measured the 
same Q wave as 38 msecs (Score +1). For lead AVF observer
1 measures Q wave duration as 42.5 msecs which also scores
2 and because the Q wave is significant and the R/Q ratio
is less than 2 this adds another one to the score.
Observer 2 however has measured this Q wave as being only
24 msecs in duration, which is regarded as non significant
(cut off >, 30 msecs) and thus the R/Q ratio which has
physically been measured as the same by the 2 observers is
not taken into account, and a score of 3 is immediately
lost due to misinterpretation of Q wave duration. The
other one point difference is attributed to the R/S ratio
in V measured as 1.99 (score +1 as R/Q n<2) by observer 1 
5
and as 2.04 (score 0 as R/Q >2) by observer 2. These 
small differences which give rise to differences in the 
QRS score because of arbitrary cut off points will 
occasionally occur, and have to be accepted. The problem 
of misinterpretation of Q wave duration by almost 50% as
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in the example above is considered a miss-hit as all other 
ECG's by the same observer have much longer Q wave 
durations. With further experience this type of miss-hit 
should be recognised and rectified at the time.
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ECG NO.
REPLICATES 
1 2
(OBSERVER 1, 
3
OBSERVER 2) 
4 5
1 2/4 2,2 3,3 2,4 2,2
2 0/2 0,1 0,0 0,0 0,0
3 0,0 0,0
oo
0,0 0,0
4 3,2 3,2 3,3 3,3 3,2
5 3,3 3,3 3,4 3,3 3,3
6 0,0 0,0 0,0 o o 0,0
7 1,1 1,1 1,1 1,1 1,1
8 6,6 6,6 6,6 6,6 6,6
9 7,2 7,6 8,8 8,8 8,6
10 1,2 1,2 1,2 1,2 1,2
Observer 1 = KJH 
Observer 2 = AMcK
TABLE 16: AUTOMATED SIMPLIFIED SELVESTER QRS SCORES FOR
OBSERVER 1 AND OBSERVER 2
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5.4.7. Conclusion
This study confirms that digitizing electrocardiographic 
parameters from a 12 lead ECG for subsequent storage and 
analysis is feasible, with very good intra and 
interobserver variation. This allows the system to be 
utilized by doctors and technicians trained in 
electrocardiography, who are familiar with the rules for 
defining wave forms already discussed in this chapter. 
This facilitates the analysis of large quantities of data 
such as that generated by large clinical trials. The 
study was designed especially to examine the variation in 
technique when clearly abnormal ECG's were digitized and 
has successfully validated its application in acute 
myocardial infarction, and has been shown to be sensitive 
enough to detect the quantitative changes in 
electrocardiographic parameters seen after thrombolysis.
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CHAPTER 6
COMPARISON BETWEEN ANISTREPLASE AND STREPTOKINASE IN ACUTE
MYOCARDIAL INFARCTION
RESULTS I - DEMOGRAPHIC DATA
- ANGIOGRAPHIC PATENCY DATA
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6.1. INTRODUCTION
The next 3 chapters present the results of a randomised 
trial conducted in Stobhill Coronary Care Unit comparing 
streptokinase and anistreplase, and to which the ECG 
methodology described in the previous chapter was 
prospectively applied. The primary end point of the study 
was to compare angiographic patency rates at 90 minutes 
and at 24 hours following therapy. The 12 lead 
electrocardiographs arising from this trial were 
digitized, providing a large data base with which to 
investigate those electrocardiographic parameters best 
indicating reperfusion and myocardial salvage. The 
analysis of each 12 lead ECG on presentation also provided 
a detailed account of those ECG changes occurring in the 
early phase of acute myocardial infarction which could be 
correlated with acute angiographic anatomy. This chapter 
details the study methodology, patient demographic data 
and presents the angiographic patency results. Chapter 7 
deals with the admission ECG relating the findings to 
angiographic correlates. The results of analysis of the 
electrocardiographic markers of reperfusion and infarct 
evolution are presented in chapter 8.
6.2. AIM
The aim of this study was to investigate if there was any 
difference in patency rates between 1.5 M.U. streptokinase
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given over one hour and 30 U anistreplase given as an 
intravenous bolus dose over 5 minutes in patients with 
acute myocardial infarction of s<6 hours duration.
6.3. PATIENTS AND METHODS
A copy of the study protocol is provided in appendix I, 
with a list of inclusion and exclusion criteria. One 
hundred and twenty-eight patients (101 M, 27F, age range 
31-70, mean age 55.5 years) were recruited between April 
1987 and December 1988. Individual patient details are 
listed in appendix VI. The size of the trial was 
calculated on the numbers which would be required to show 
a significant difference between treatments with adequate 
power assuming a patency of 80% for anistreplase based on 
previous work conducted in Stobhill (Hillis et al., 1987) 
and published work suggesting a patency rate of 55% for 
streptokinase (Verstraete et al. 1985a). Following 
written informed consent, the patients were randomised in 
a double-blind, double-dummy fashion to receive either 1.5 
M.U. streptokinase intravenously over one hour or 30 U 
anistreplase (Beechams Pharmaceuticals) as an intravenous 
bolus over 5 minutes.
Patients underwent coronary angiography at 90 minutes 
following drug administration. The artery believed to be 
infarct-related, based on the admission ECG, was injected 
first, and this first injection scored according to the 
TIMI scale, a score of 0-1 denoting non-reperfusion and a
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score of 2-3 indicating a patent artery (Williams et al. , 
1986; Appendix VII). The other coronary arteries were 
then injected in standard angiographic views. At the end 
of the procedure a femoral sheath was left in situ, and 
coronary angiography was repeated 24 hours after 
treatment, with left ventriculography being performed 
where possible. The coronary angiograms were reviewed by 
the consultant in charge of the patient to facilitate 
decisions regarding further therapy, and then 
independently scored on the TIMI scale by a consultant 
cardiologist experienced in scoring coronary angiograms 
who was not involved in the study and who was blinded to 
treatment allocation. This independent score is presented 
as final patency data.
Intravenous heparin was commenced in all patients 3-4 
hours after onset of therapy titrating the dose against 
the thrombin time. If, at 24 hours the infarct-related 
artery was not patent, heparin was discontinued. If 
patency was confirmed at 24 hours, heparin was continued 
and warfarin introduced. Heparin was stopped in all cases 
for a short period after the second angiogram to allow the 
coagulation screen to normalize, enabling removal of the 
femoral sheath.
153
Results are expressed as percentages of patent arteries 
+95% confidence intervals, calculated from the total 
number of angiograms performed. Patients not undergoing 
angiography were excluded from analysis, a technique used 
in other studies of similar design (Verstraete et al., 
1987). Qualitative differences between groups were 
examined using the chi-squared test where appropriate and 
quantitative differences assessed using unpaired t-tests.
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6.4. RESULTS
6.4.1 . Baseline Characteristics
The baseline characteristics for the 128 subjects 
recruited are shown in Table 17 according to the 
thrombolytic agent received. There were no significant 
differences in the male to female ratio, mean age, infarct 
distribution or time to therapy between the two groups. 
There was a slightly higher incidence of patients in the 
streptokinase treated group having had a previous 
myocardial infarction distant to the current site (16% vs 
6%), but this did not reach statistical significance.
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STREPTOKINASE ANISTREPLASE
TOTAL NO. OF PATIENTS 63 65
FEMALE 11 (17%) 16 (25%)
SEX NS
MALE 52 (83%) 49 (75%)
MEAN AGE (yrs) 55.8+8. 55.3+8.1 NS
INFARCT RELATED ARTERY 
(by angiography)
LAD 29 (46%) 25 (38%)
RCA 27 (43%) 28 (43%)
Cx 3 (5%)
NS
9 (14%)
NOT DETERMINED 4 (6%) 3 (5%)
MEAN TIME TO THERAPY
209+80 min. 199+77 min.NS
PREVIOUS M .I. 10 (16%) 4 (6%) NS
TABLE 17: BASELINE CHARACTERISTICS OF PATIENTS
RANDOMISED TO STREPTOKINASE OR TO ANISTREPLASE
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6.4.2. Angiographic Patency
No pre-treatment angiogram was performed and so the 
results are presented as patency rates. Details of 
angiographic findings are shown in Table 18 for both 90 
minutes and 24 hours. A total of 116 angiograms were 
performed at 90 minutes post therapy and 114 at 24 hours 
following therapy, giving a total angiography rate of 91% 
and 89% respectively. Four patients died within 90 
minutes of receiving thrombolytic therapy (anistreplase 1, 
streptokinase 3). Of the remaining 8 angiograms not 
performed at 90 minutes, 3 were due to the patients being 
too haemodynamically unstable, 2 were due to extensive 
bruising round the femoral vein and artery (one from a 
Swan Ganz insertion and one from a femoral puncture for 
blood gases during earlier resuscitation), arterial access 
was not obtained in a further 2 patients and in another 1 
patient who received streptokinase there was extravasation 
of therapy 20-30 minutes after infusion onset and the 
patient was withdrawn from the study. By the 24 hour 
angiogram a further 3 patients had died (anistreplase 2, 
streptokinase 1). Of the remaining 7 angiograms not 
performed at this time, poor patient condition accounted 
for 2, problems with arterial access for 1 and haematoma 
formation round the femoral sheath in a further 2 patients 
necessitated early removal of the sheath in 1 and 
inability to pass the guide wire through the sheath in the 
other. One patient had sustained a cerebrovascular 
accident following the 90 minute angiogram and it was
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considered unethical to repeat the 24 hour angiogram, and 
the remaining patient had been withdrawn due to 
extravasation of drug.
Of the angiograms performed 32 of 58 patients (55%) 
receiving anistreplase and 31 of 58 (53%) receiving 
streptokinase had patent infarct-related arteries at 90 
minutes (95% confidence intervals 42-68% for anistreplase 
and 40-66% for streptokinase). By 24 hours, 81% of 
patients receiving anistreplase and 87.5% of patients 
receiving streptokinase had patent arteries (Figure 17). 
One patient in each treatment group had angiographic 
evidence of reocclusion at 24 hours. Both had occlusion 
of the right coronary artery, the TIMI score being reduced 
from 2 at 90 minutes to 0 at 24 hours in the patient who 
received streptokinase and from 3 to 0 in the patient who 
had anistreplase.
All patients fulfilled ECG criteria for entry into the 
study, but two patients subsequently failed to show a rise 
in cardiac enzymes (patients 58 and 80). Coronary 
angiography revealed normal coronary arteries in one 
patient (80) and minor insignificant irregularities in the 
other (58). Both patients received streptokinase and 
their exclusion does not significantly alter the patency 
rates reported (52% vs 53% NS).
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STREPTOKINASE ANISTREPLASE 
Total No. of Patients 63 65
90 MINUTE ANGIOGRAM
TIMIGRADE
0 21 22
NON REPERFUSION (47%) (45%)
^  1 6 4
NS
7 10
REPERFUSION (53%) (55%)
3 24 22
ANGIO NOT PERFORMED 5 7
24 HOUR ANGIOGRAM
TIMIGRADE
0 4 10
NON REPERFUSION (12.5%) (19%)
^  1 3 1
NS
   2 11 8
REPERFUSION (87.5%) (81%)
 3 38 39
ANGIO NOT PERFORMED 4 6
TABLE 18: ANGIOGRAPHIC DETAILS FOR PATIENTS RANDOMISED 
TO STREPTOKINASE OR ANISTREPLASE AT 90 
MINUTES AND AT 24 HOURS
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6.4.3. Influence of Time to Therapy on Patency Rates 
Figure 18 shows the patency rate at 90 minutes and 24 
hours related to the time to therapy from symptom onset. 
Very few patients (n=3) were admitted and treated within 
the first hour, the majority of patients (n=71) being 
treated between 2 and 4 hours from onset of pain.
Although from the table it appears that there is initially 
a decreasing patency rate with increasing time to therapy 
i.e. for anistreplase 67% at 61-120 min, 47% at 121-180 
minutes and 38% at 181-240 minutes, this is not borne out 
as the highest patency rate is 78% for the next time 
interval 241-300 minutes. Somewhat paradoxically looking 
at 24 hour patency rates for early (0-3 hours) and late 
groups (3-6 hours) in Table 19, it is the group presenting 
late which has the higher patency rate i.e. 89% versus 
78%. This is true irrespective of which agent is used 
i.e. 94% versus 78% for streptokinase and 84% versus 78% 
for anistreplase. However, as subdividing the treatment 
groups in this way results in smaller numbers, the 95% 
confidence intervals of these patency rates are wide and 
there is no significant difference in patency rates 
obtained dependent on time to therapy.
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FIGURE 18: PATENCY DATA RELATED TO TIME TO THERAPY FROM 
SYMPTOM ONSET AT 9 0 MINUTES AND AT 24 HOURS
TIME TO THERAPY (HOURS)
0-3I Hrs 3-6 Hrs
90 MINUTE ANGIO
Streptokinase 15/25 (60%) 16/33 (48%) NS
Anistreplase 16/28 (57%) 16/30 (53%) NS
24 HR ANGIOGRAM
Streptokinase 18/23 (78%) 31/33 (94%) NS
Anistreplase 21/27 (78%) 26/31 (84%) NS
TABLE 19: PATENCY RATE RELATED TO TIME TO THERAPY FROM 
SYMPTOM ONSET
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6.4.4. Haemodynamic Data
Satisfactory blood pressure data was obtained every 2 
minutes for the first 90 minutes post treatment in 106 
patients (anistreplase 48, streptokinase 58). Forty-two 
percent of patients who received anistreplase and 45% of 
patients who had streptokinase experienced an early fall 
in blood pressure as previously defined. This fall in 
blood pressure was rarely associated with symptoms or 
required specific treatment. In general nitrate therapy 
was stopped transiently until the blood pressure 
recovered, but none of the patients required treatment 
with dopamine or dobutamine.
6.4.5. Adverse Events
Table 20 documents those adverse events occurring in both 
treatment groups until hospital discharge. Bleeding 
problems were numerically the most important, but out of 
the 21 reported, 81% were related to the site of arterial 
puncture for coronary arteriography. There was no 
difference in incidence of bleeding between the two 
groups. However there was a higher incidence of skin rash 
in patients receiving streptokinase, and in 4 of these it 
took the form of a vasculitic rash which lasted about 2 
weeks. One patient in each treatment group received 
therapy for anaphylaxis related to the injection or 
infusion.
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The single cerebrovascular accident reported in the 
anistreplase group refers to a transient ischaemic attack 
which resolved completely in 24 hours. Two cerebro­
vascular accidents occurred in the streptokinase treatment 
group, 1 presenting after the 90 minute angiogram and the 
other at 48 hours following therapy. This latter patient 
subsequently died in cardiogenic shock but the former 
patient has made a reasonable recovery, with only a mild 
residual left hemiparesis. Neither patient underwent CT 
scanning.
163
EVENT STREPTOKINASE ANISTREPLASE
Total No. of patients 
receiving treatment 63 65
A. Skin-rash
1. Vasculitic 4 0
2. Mild, transient 2 1
B. Anaphylaxis
-related to i.v. administration 
requiring i.v. treatment 1 1
C. Bleeding
1. From catheter site 
(a) No intervention 5 2
(b) Anticoagulants stopped 
+ protamine 3 5
(c) Required transfusion 1 1
2. From other sites
(a) Venepuncture 0 1
(b) Haematemisis 1 2
D. Cerebrovascular accident 2 1*
E. Further clinical events
1. Reocclusion (ECG + enzymes) 3 2
2. Refractory arrhythmias 0 1
3. Left ventricular failure 0 1
4. Angioplasty prior to 
discharge 0 2
F. Miscellaneous
1. Sore throat 0 1
2. Extravasation of drug 
(full treatment not given) 1 0
* refers to TIA resolving within 24 hours
TABLE 20: ADVERSE EVENTS TO HOSPITAL DISCHARGE
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6.4.6 Clinical Evidence of Reocclusion
There were a total of 5 episodes with clinical evidence of 
reocclusion after the 24 hour angiogram had been 
performed, and prior to hospital discharge (Table 20). Two 
patients died, 1 had emergency angioplasty and the 
remaining 2 had no intervention and both made an 
uncomplicated recovery.
6.4.7. Mortality Rates
There were 10 deaths in total up to hospital discharge, 6 
in the streptokinase group (9.5%) and 4 in the 
anistreplase group (6%). The majority of these deaths 
occurred within the first 24 hours in patients with 
extensive infarction (anistreplase 3, streptokinase 4). 
Four of these deaths occurred within the first 90 minutes 
of treatment, 1 of which was due to cardiac tamponade from 
a ruptured posterior ventricular wall. Of the 3 deaths 
occurring between 24 hours and hospital discharge 
(anistreplase 1, streptokinase 2) 2 were due to 
reocclusion and extension of the infarct occurring at 2 
days post treatment in the patient receiving streptokinase 
and at 5 days in the patient receiving anistreplase. The 
third patient died of cardiogenic shock and also sustained 
a cerebrovascular accident.
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6.5. DISCUSSION
The results of this study show that there is no difference 
in the 90 minute patency rates between patients receiving 
30 U anistreplase and 1.5 M.U. streptokinase intravenously 
for acute myocardial infarction of N<6 hours duration. The 
percentage patency rates were 55% and 53% for the two 
treatment groups respectively. In an attempt to shorten 
the delay for thrombolytic therapy to be administered, 
none of the patients received a pre-treatment angiogram 
and therefore patency rates and not reperfusion rates are 
reported. According to the data of de Wood et al. (1980) 
partial occlusion at presentation may result in a patency 
rate which over-estimates the true reperfusion rate by at 
least 13%.
The observed patency rate of 55% with anistreplase in this 
study is similar to the data reported by the Anderson 
group of 51% reperfusion at 90 minutes (Anderson et al., 
1988) but is at variance with our previously published 
work (Hillis et al., 1987) and with the higher rates of 
64% reperfusion at 90 minutes reported by Bonnier et al. 
(1988), 72% patency by Brochier et al. (1987), and 86% 
patency by Lopez-Sendon et al. (1988). The variation in 
these results can be accounted for to some extent by 
differences in mean time to therapy, total patient numbers 
recruited and the exact timing of the 90 minute angiogram. 
Timing of this is critical as it would seem that the 
increase in reperfused coronary arteries resulting in a
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difference between 55% patency at 90 minutes and 81% at 24 
hours may well be occurring in the few hours after therapy 
when the fibrinolytic effect is at its peak. In our 
present study it was the first injection into the infarct- 
related artery which was assessed for patency status, 
although in several cases the artery was seen to reperfuse 
during serial injections. In our previous study (Hillis 
et al., 1987) coronary angiography was carried out between 
90 and 180 minutes post treatment, and this may account 
for the discrepancy in patency rates between the two 
studies.
The patency rate of 53% for 1.5 M.U. of streptokinase is 
higher than that of 35% previously reported in the TIMI 
(Phase I) Trial (TIMI Study group., 1985). This is 
probably due to the difference in mean time to therapy 
being 4.8 hours in the TIMI Phase I Trial and 3.5 hours in 
the present study. The European Co- operative Study Group 
documented a patency rate of 55% treating at a mean of 2.6 
hours from symptom onset (Verstraete et al., 1985a).
There is well documented data pooled from multiple studies 
showing a decrease in incidence of reperfusion with 
streptokinase in relation to time to treatment (Sherry, 
1987). A similar phenomenon has been suggested for 
anistreplase (Anderson et al., 1988). Subdividing the 
patients in this study into 6 groups dependant upon the 
time from symptom onset results in subsets with very small
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numbers. Nevertheless, there appears to be almost a 
biphasic reperfusion curve with a second peak occurring at 
the 241-300 minute time interval. A hypothesis to explain 
this may be that patients presenting later may have less 
clamant symptoms, and may be more likely to have a sub 
total occlusion i.e. TIMI grade I. This sub group are 
known to have a higher incidence of reperfusion following 
thrombolytic therapy (Anderson et al. , 1988). Despite 
this second peak, dividing the patients into an early (0-3 
hours) and late (3-6 hours) group showed patency rates at 
90 minutes of 60% and 48% respectively for streptokinase, 
compared with 57% and 53% respectively for anistreplase.
It is of interest that the AIMS Trial Study Group (1988) 
reported similar reduction in mortality irrespective of 
whether the patients were treated early (0-4 hrs) or late 
(4-6 hrs).
No intervention was performed other than standard 
anticoagulation with heparin in any patient between 90 min 
and 24 hours, allowing an accurate reocclusion rate to be 
calculated at the 24 hour angiogram. This is very low, 
only 1 patient in each treatment group showing evidence of 
reocclusion. This is similar to a 24 hour anistreplase 
reocclusion rate reported by Bonnier et al, (1988). 
Evidence of reocclusion prior to hospital discharge 
(confirmed by ECG and enzyme changes) took place in a 
further 3 patients (5%) who received streptokinase and 2 
patients (3%) who had received anistreplase. This seems
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to be in keeping with the incidence of reinfarction 
reported by GISSI of 4.1% (1987). Although these figures 
indicate reinfarction, a higher percentage of patients 
undetectable in this type of study design may have 
angiographic evidence of re-thrombosis and reocclusion - a 
discrepancy recognised by and reported by Geltman (1987).
A transient drop in blood pressure which was usually well 
tolerated was observed in slightly less than half of all 
patients. This is a high incidence compared to episodes 
of hypotension reported in the AIMS Study (8 out of 502 
(1.5%)) (1988). Although hypotension is a common 
occurrence, this transient drop in blood pressure does not 
require treatment and may go unnoticed, suggesting that 
the haemodynamic response to bolus anistreplase may have 
been overemphasized.
Catheter-related haemorrhage formed the most substantial 
part of bleeding complications, but only 1 person in each 
group developed a haematoma such that transfusion was 
required. Although a serum sickness type illness with 
associated vasculitic rash is now a recognised 
complication of streptokinase therapy (Weatherbee, 1984; 
Noel et al., 1987; Gemmill et al., 1988) a recent report 
suggested it also occurred with anistreplase therapy 
(Bucknall et al., 1988). Although none of the patients in 
this study receiving anistreplase developed a vasculitic
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rash, it is likely that it is the streptokinase moiety 
which is responsible, and as such anistreplase might be 
expected to be implicated in a similar type of reaction.
In conclusion, this study has shown that 30 U anistreplase 
given as an intravenous bolus is as effective in obtaining 
coronary artery patency at 90 minutes as 1.5 MU 
streptokinase given as an infusion over 1 hour. Patency 
rates at 90 minutes are 55 and 53% respectively, and 81 
and 87.5% respectively at 24 hours. There is a very low 
reocclusion rate in patients obtaining reperfusion who 
receive no other intervention other than standard anti­
coagulation with heparin and warfarin. This is true 
irrespective of which agent was used. As anistreplase is 
as effective as intravenous streptokinase at obtaining a 
patent artery within 6 hours of onset of acute myocardial 
infarction, its major advantage lies in its bolus route of 
admin-istration, making it an easy treatment to give in an 
out-of-hospital setting. Whether further saving of time 
to therapy will result in better reperfusion or patency 
rates and a decrease in mortality has still to be proven.
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CHAPTER 7
COMPARISON BETWEEN ANISTREPLASE AND STREPTOKINASE IN ACUTE
MYOCARDIAL INFARCTION
RESULTS II - THE 12 LEAD ELECTROCARDIOGRAPH IN ACUTE 
MYOCARDIAL INFARCTION
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7.1. INTRODUCTION
The accuracy of the 12 lead ECG in localising acute 
myocardial infarction has previously been discussed in 
Chapter I Section B. Initially this was based on a series 
of post mortem examinations (Myers et al. , 1948 a-b, 1949 
a-e) but has been added to by studies comparing ECG 
findings with the results of angiography early in the 
course of acute myocardial infarction (Blanke et al., 
1984b). Other workers have retrospectively studied 
patients with single vessel disease to further clarify the 
situation (Fuchs et al., 1982), but have performed 
angiography at a considerable distance from the time of 
infarction , and have used the presence or absence of Q 
waves rather than the earlier changes in ST segment 
elevation to indicate the anatomical location of the 
occlusion. Despite the number of studies which have 
performed acute angiography early in the course of 
myocardial infarction, usually in the context of 
thrombolysis, few have correlated findings with a 
comprehensive analysis of the 12 lead ECG at presentation. 
Most studies concentrate on the degree of ST segment 
elevation but the presence and extent of reciprocal ST 
segment depression and its relationship to arteriographic 
findings is not well documented. Work by Bar et al.
(1987) using ECG data from the Netherlands Interuniversity 
Group (Simoons et al., 1985) showed that the admission ECG 
was of some value in predicting which patients would 
benefit most from thrombolysis. Not suprisingly those
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patients with the highest ST segment elevation and no Q 
waves (both anterior and inferior infarction) fared best, 
but another group presenting early with high ST segment 
elevation who also had already developed Q waves had an 
impressive degree of infarct limitation. Thus, the 
admission ECG is not only of value in the diagnosis of 
acute myocardial infarction, but may highlight patients 
who would benefit especially from thrombolysis. It is 
therefore of value to study the ECG on admission, and to 
correlate the findings with acute angiographic anatomy. 
This chapter presents the observational changes in ST 
segment elevation and depression at presentation in 
patients with an acute myocardial infarction of x< 6 hours 
duration.
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7.2. PATIENTS AND METHODS
The patient group consisted of that group recruited for 
the anistreplase/streptokinase comparison study detailed 
in Chapter 6. Of the initial 128 patients only 125 had 
ECGs suitable for analysis. The 3 patients who did not 
(patients 13, 53 and 115) all had a complete right bundle 
branch block pattern, and in addition, patient No. 115 
also had left axis deviation and died soon after starting 
therapy. Twelve lead ECG's were performed on admission 
and at 2, 4, 16, 18 and 24 hours following therapy using 
the method discussed in Chapter 2. These
electrocardiograms were digitized according to the method 
described in Chapter 5, and each patient coded for age, 
sex, infarct related artery, patency data at 90 minutes 
and at 24 hours, the drug given (anistreplase or 
streptokinase), the time to therapy and finally the 
presence of a previous infarct. Data were then 
transferred to a mainframe computer (ICL2980) and analysed 
using MINITAB. If a patient developed transient bundle 
branch block or pacemaker dependence, the ECG showing this 
was not digitized, but the subsequent one was included if 
the patient had reverted to sinus rhythm with normal 
conduction.
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Each coronary angiogram was scored for degree of perfusion 
of the infarct related artery, as described in Chapter 6, 
but in addition all arteries were individually scored for 
disease using the following scale: 0, normal; 1, <50%; 
2,50-90%; 3,91-99% (complete filling); 4,99% (incomplete 
filling); 5,100%; 6,absent; 7,unknown.
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7.3 RESULTS
7.3.1. Collection of ECG data
The total potential number of ECG's arising from this 
study is 750 (i.e. 125 x 6). Of this total, 50 have not 
been digitized, in 16 of these the patient had died prior 
to the ECG being recorded. The remaining 34 ECG's were 
not digitized either because of a temporary conduction 
defect, because of poor quality tracing or because the 
ECG was not recorded. This results in a 95.5% complete 
collection of all possible data. The admission ECG has 
not been digitized in two patients, although the ECG 
series for each of these patients is otherwise complete.
In one, (patient No.35), the admission ECG was lost 
following randomisation, and in another patient (patient 
No.103), a temporary conduction defect precluded digitiz­
ation. Both patients have been eliminated from analysis.
Patients who did not have the infarct-related artery 
identified by coronary angiography are not included in the 
analysis. A small number of patients (n=5) did not 
undergo angiography at 90 minutes, but had the infarct- 
related artery identified at 24 hours, and these patients 
are included. A total of 117 admission ECG's have been 
analyzed, 51 patients having occlusion of the left 
anterior descending artery (LAD), 54 patients having 
occlusion of the right coronary artery (RCA) and 12 
patients presenting with occlusion of the cixcumflex 
artery (Cx).
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7.3.2. Distribution of ST segment shift on admission ECG 
in relation to infarct-related artery
Figures 19-21 show the percentage of all leads (excluding
AVR) showing some degree of ST segment elevation and, or
depression on the admission ECG as measured on the
digitizer and divided on the basis of the infarct-related
artery.
Figure 19 shows that for the 51 patients with LAD
occlusion, 98% have ST segment elevation in V and 100%
2
had ST segment elevation in V . A substantial percentage
3
of those patients also showed ST segment elevation in 
classically termed inferior leads (14% for lead III, 21.5% 
lead II), but by far the most common finding was of 
reciprocal ST segment depression, lead II showing ST 
segment depression in 47%, lead III in 69%, and AVF in 
67%.
For the 54 patients who had an occlusion of the RCA, 100%
of those patients had ST segment elevation in leads III
and AVF and 93% in lead II. Of particular interest was
the high percentage of leads showing reciprocal changes
on the admission ECG, 100% of patients with an RCA
occlusion had ST segment depression in AVL, 87% in lead
I, 80% in V and 78% in V (Figure 20).
2 3
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Figure 21 shows the distribution of ST segment shift on
the admission ECG for 12 patients with a Cx occlusion.
Although numbers are smaller than in the other two groups,
it can be seen that there is no simple method of
separating out Cx occlusion from RCA occlusion. 100% of
patients had ST segment elevation in II and AVF and the
incidence of reciprocal anterior ST segment depression was
84% in V and 75% in V and V . Patients with RCA 
2 1 3
occlusion never demonstrated ST segment elevation in I and
AVL but 42% and 17% of patients with Cx occlusion
demonstrated ST segment elevation in those leads
respectively. Taking ST segment elevation in Lead 1 as a
marker for Cx occlusion gives a test with a specificity of
100%, but a low sensitivity of 42%. Fifty-eight per cent.
of Cx occlusions will not have ST elevation in lead I at
presentation.
Although all patients fulfilled the ECG criteria for 
inclusion into the study (>, 1mm ST elevation in 2 limb 
leads or >, 2mm ST elevation 2 precordial leads), the data 
shown in figures 19-21 reflects any deviation from the 
isoelectric line, and may in some leads represent small 
changes which are less than the conventionally accepted 
cut-off points designating "significant" ST segment shift. 
To compare the incidence of reciprocal change between this 
data base and that reported in the literature requires 
that the same criteria for definition of reciprocal change 
is applied. Reciprocal change is most commonly described
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as more than 1 mm horizontal or sloping ST segment
depression in leads remote from the site of infarction.
Table 21 shows the decreasing incidence of reciprocal
change with increasingly stringent cut-off limits for
significant ST depression. Assuming ST depression of
X 1mm to be significant, results in a true incidence of
reciprocal change of 55% in lead III in anterior
infarction, 89% in AVL and 72% in V for inferior
2
infarction, and 75% in V for Cx occlusion. The
3
relationship between reciprocal change and coronary artery 
anatomy is discussed in Section 7.3.6.
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INFARCT
RELATED LIMITS FOR DEFINITION OF RECIPROCAL CHANGE
ARTERY LEAD NONE >y 0.5 MM >, 1 MM >, 2 MM
II 47% 39% 14% 2%
L.A.D. III 69% 65% 55% 14%
(n=51) AVF 67% 65% 39% 6%
I 87% 85% 67% 30%
AVL 100% 100% 89% 61%
V
1
V
2
50% 44% 27% 4%
R.C. A. 80% 80% 72% 48%
(n=54) V
3
78% 78% 69% 41%
V4 69% 67% 57% 22%
V
1
V
2
75% 67% 50% 33%
Cx 83% 83% 67% 50%
(n=12) V
3
75% 75% 75% 58%
V4 50% 50% 33% 17%
TABLE 21 : VARYING INCIDENCE OF RECIPROCAL CHANGE RELATED 
TO DEGREE OF ST SEGMENT DEPRESSION.
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7.3.3. Degree and location of maximum ST segment shift
Figure 22 shows a bar histogram detailing which
single lead from the 12 lead admission ECG showed the
maximum degree of ST segment elevation, and also which
one lead showed the maximum degree of reciprocal change
for each patient presenting with an acute coronary
occlusion. Figures 23-25 show the mean ( + SD)
values of ST segment elevation and depression for each of
the leads for LAD, RCA, and Cx occlusions respectively.
Results are expressed in mm rather than mV for convenience.
It can be seen that the most "dynamic" leads (i.e. those
resulting in most ST segment shift) are leads V and V
2 3
for elevation in an LAD occlusion (mean ST elevation;
4.7+2.4 mm for V , 5.5+3.2 mm for V ), and lead III in a
2 3
RCA occlusion (3.7+2.3 mm). Reciprocal changes tend to
be of similar magnitude across several leads (-2.5+^1.5 mm
for AVL, -2.5+1.5 mm for V and -2.5+0.17 mm for V in
2 3
RCA occlusion) except in Cx occlusion, where V and V
2 3
have a higher mean value of ST segment depression (i.e.
-3.3+2.6 mm and -3.6+2.4 mm respectively).
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7.3.4. Influence of time to presentation on extent of
ST segment shift
Figure 26 and 27 are scattergrams showing respectively,
the relationship between the sum of ST segment elevation
and time to therapy, and the sum of ST segment depression
and time to therapy for all patients recruited to the
study (n=123). It should be noted that the X axis
represents the time to therapy in minutes, and not the
exact time of recording of the presentation ECG. The
interval between these two events is on average about 30
minutes and is constant for all cases. The use of "time
to therapy" on the X scale should not influence any
correlation which exists, the only effect being to move
all points 30 minutes to the right.
There is no relationship between ST elevation on
admission and time to therapy (Figure 26 r=-0.031).
Figure 27 does however show an inverse relationship
between the extent of ^ S T  depression and time to therapy
(r=-0.27) suggesting that the earlier the patient
presents, the more marked will be the degree of ST segment
depression. Although this r value of -0.27 carries a p
value <0.01, it can be seen from the scattergram, and also
from the r value, that this is not a strong relationship,
and it is unwise to attach much significance to it.
Similarly, from Table 22 it can be seen that by
subdividing the groups according to the infarct-related
2
artery, or by looking at^^ST area (mm ) or the single
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lead with maximal ST segment shift, both for elevation and 
depression, results in weak correlations, suggesting 
little in the way of any true relationship. The RCA 
appears to have the strongest correlation between the 
extent of ST segment shift (both elevation and depression) 
and time to therapy.
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r value
PARAMETER
n
y > T  elev (mm)
7 > T  dep (mm)
n 2
ST elev area (mm ) 
n 2 ) ST dep area (mm )
n
Maximal ST elev (mm) 
(single lead)
n
Maximal ST dep (mm) 
(single lead)
all
patients
Infarct
LAD
related
RCA
artery
Cx
-0.03 0.01 -0.28* -0.29
-0.27** -0.21 -0.28* -0.26
-0.09 -0.11 -0.28* -0.01
-0.26** -0.25 -0.28* -0.04
00ooi -0.03 -0.31* -0.29
l
i 0 to \D 1 0.20 -0.34* -0.3
* p<0.05
** p<0.01
TABLE 22: CORRELATION COEFFICIENTS BETWEEN TIME TO
THERAPY AND ST SEGMENT SHIFT
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7.3.5. Relationship between degree of ST segment elevation 
and extent of reciprocal change.
As there was a high incidence of reciprocal change in this
infarct group (ST depression >, 1 mm in leads remote from
infarct territory in 55% LAD occlusions and 89% RCA
occlusions), the relationship between the extent of ST
segment elevation and the degree of reciprocal change was
examined. Table 23 shows correlation coefficients for
each of the ECG parameters measured. The best correlation
for all arteries arises by taking the single lead with
maximum ST elevation and comparing it with the single lead
showing maximum ST segment depression. These correlations
are shown for each of the infarct-related arteries in
Figure 28. Taking the leads previously shown to be most
dynamic (V and lead III - Figure 22) results in similarly 
3
close correlations with a better correlation coefficient 
for LAD occlusion (Table 23, r=-0.41 p<0.05).
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Parameter 
(Elevation vs Depression)
INFARCT 
LAD 
(n=51)
RELATED ARTERY 
RCA 
(n=54)
Cx
(n=12)
"^ST height (mm) 0.11 0.63** 0.60*
Single max. ST shift 0.32* 0.87** 0.82**
7 > T  area (mm2) 0.14 0.52** 0.21
Single max 
ST area (mm2) 0.26 0.90** 0.65*
Lead III vs V3 0.41* -0.62** -0.84**
*p<0.05
**p<0.01
TABLE 23: CORRELATION COEFFICIENTS FOR VARYING ECG 
PARAMETERS RELATING EXTENT OF ST SEGMENT 
ELEVATION TO DEGREE OF ST DEPRESSION.
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7.3.6. Relationship between reciprocal change and 
arteriographic findings.
Full angiographic data and an admission ECG are available
in 114 cases. The two patients with negative enzymes
(patients 58 and 80) have been excluded, as has patient
107, who underwent angiography, but the quality of the
investigation, although adequate to determine perfusion in
the infarct-related artery (IRA), precluded interpretation
of the extent of arterial disease. A vessel was
considered significantly diseased if there was a stenosis
>50% of the luminal diameter present.
Forty-three per cent of patients had single vessel 
disease, 36% double vessel disease, and 14% triple vessel 
disease (Table 24). Eight patients (7%) at the 90 minute 
angiogram are described as not having significant disease 
in any vessel. Those patients all had a rise in cardiac 
enzymes, and 7 out of 8 had a lesion in the infarct- 
related artery of <50%. One patient (No.69) had entirely 
normal arteries. In all eight cases the IRA could be 
confidently identified by slow clearing of dye from the 
infarct territory, or by persistent staining of dye at the 
site of presumed thrombus.
Reciprocal change defined as a \ 1 mm ST depression in
leads remote from the site of infarction occurred in 55% 
of LAD occlusions. In patients with RCA occlusion, 89% 
had reciprocal changes in AVL and 43 of those 48 patients
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also showed significant reciprocal change in the anterior 
leads. Table 25 shows the incidence of patients with and 
without reciprocal change related to the degree of vessel 
disease. Identification of which arteries, other than the 
IRA, were significantly diseased are shown in Table 26.
From these tables it can be seen that in patients with a 
single LAD lesion causing infarction and no other 
arterial disease, over half of these patients (16 vs 12) 
had reciprocal changes in the inferior leads, which 
clearly does not reflect coexisting disease in the 
distribution of the RCA. All patients with coexisting 
arterial disease and a RCA occlusion showed evidence of 
reciprocal change, but this is unlikely to be directly 
attributable to coexisting disease as 19 of 24 patients 
with single vessel RCA occlusions also showed marked 
reciprocal change. Of the 5 patients with RCA occlusions 
who only showed ST depression in AVL and not in the 
anterior leads, 1 had single vessel disease, 2 had 
coexisting LAD disease and 2 had coexisting Cx lesions. 
There was no relationship between the incidence of 
reciprocal change and the dominance of the arterial 
circulation. The values for Cx occlusion with and without 
coexisting disease do not show any pattern.
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Infarct
Related
Artery 3VD
EXTENT OF 
2VD
VESSEL DISEASE 
1VD OVD
LAD (n=49) 6 14 24 5
(12%) (29%) (49%) (10%)
RCA (n=53) 7 22 22 2
(13%) (41.5%) (41.5%) (4%)
Cx (n=12) 3 5 3 1
(25%) (42%) (25%) (8%)
ALL ARTERIES 
(n=114)
16
(14%)
41
(36%)
49
(43%)
8
(7%)
TABLE 24: INCIDENCE OF SINGLE, DOUBLE AND TRIPLE VESSEL 
DISEASE.
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Infarct
Related
Artery 3VD
EXTENT OF VESSEL 
2VD
DISEASE 
1VD OVD
LAD (all patients) 6 14 24 5
With reciprocal
change 2 8 16 1
No reciprocal
change 4 6 8 4
RCA (all patients) 7 22 22 2
With reciprocal
change 7 22 18 1
No reciprocal
change 0 0 4 1
Cx (all patients) 3 5 3 1
With reciprocal
change 3 3 3 0
No reciprocal
change 0 2 0 1
TABLE 25: INCIDENCE OF SINGLE, DOUBLE AND TRIPLE VESSEL
DISEASE IN PATIENTS WITH AND WITHOUT RECIPROCAL 
CHANGE ON THE ADMISSION ECG.
Infarct
Related Distribution Of R.C. R.C.
Artery Vessels Affected Present Absent
I
 IRA ONLY (IVD+OVD) 16 12
RCA+IRA 6 3
Cx+IRA 2 3
RCA+Cx+IRA 2 4
RCA ALONE (IRA <50%) 1 0
I
 IRA ONLY (IVD+OVD) 19 5
LAD+IRA 13 0
Cx+IRA 9 0
LAD+Cx+IRA 7 0
IRA ONLY (IVD+OVD) 3 1
Cx LAD+IRA 2 1
RCA+IRA 1 1
LAD+RCA+IRA 3 0
TABLE 26: DISTRIBUTION OF ADDITIONAL ARTERIAL STENOSES IN 
PATIENTS WITH AND WITHOUT RECIPROCAL CHANGE.
7.4. DISCUSSION
This chapter describes the features of the admission ECG 
in 125 patients recruited to the anistreplase/ 
streptokinase comparison study, all of whom had sustained 
an acute myocardial infarction of 4.6 hours duration. Of 
these 125 patients, 119 underwent acute angiography which 
identified the infarct-related artery allowing comparison 
between the admission ECG and coronary anatomy at the time 
of infarction.
The group of patients studied here are pre-selected in
that they all fulfilled the ECG criteria for the study
before being randomised (i.e. mm ST elevation in 2
limb leads or \2 mm ST elevation in 2 precordial leads).
This explains the high percentage of patients presenting
with a "classical" picture of infarction in this study;
100% of RCA occlusions had ST elevation in leads II and
AVF, and 100% and 98% of LAD occlusions had ST elevation
in V and V respectively. If patients presenting with 
3 2chest pain, not chosen on the basis of their ECG, but 
subsequently proven to have sustained infarction by 
positive enzymes, undergo angiography, the number of 
patients correctly showing "classical" ECG changes of 
anterior myocardial infarction drops to 93% and to 77% for 
patients correctly showing classical changes of inferior 
myocardial infarction (Blanke et al., 1984b).
Patients with an acute circumflex occlusion could not be
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differentiated from those with an acute RCA occlusion on 
the basis of the 12 lead ECG. The presence of ST segment 
elevation in lead I was 100% specific for Cx occlusion, 
but only 42% sensitive, and the values are calculated in a 
relatively small number of Cx occlusions (n=12). This 
confirms the findings of previous studies which have been 
unable to distinguish RCA from Cx occlusion based on ECG 
criteria (Fuchs et al., 1982; Blanke et al., 1984b).
This study has shown that there is no relationship between 
the extent of ST segment shift and the age of the infarct 
over the 6 hour time window examined. Bar et al. (1987) 
reporting for the Netherlands Interuniversity Cardiology 
Institute had a large proportion of patients (n=70) who 
infarcted in hospital, and who underwent very early 
electrocardiography and suggested that the degree of ST 
segment elevation is higher in the hyperacute phase than 
in a later period. Only 3 patients were randomised in 
this study within the first hour, and with previous work 
showing that the degree of ST segment elevation in 
patients with an acute infarction is stable 1-4 hours 
after the onset of pain (Foerster et al., 1977), these 
factors may well explain why no relationship has been 
detected.
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Reciprocal changes in acute myocardial infarction, 
although first described by Wolferth et al. in 1945 
continue to be the subject of much debate. There are 
several schools of thought involving the mechanism and 
significance of this concomitant ST segment depression in 
association with acute infarction. It has been suggested 
it is simply a benign electrical phenomenon (Steinhaus et 
al. , 1982;, Ferguson et al., 1984), a marker for extensive 
necrosis and bad prognosis (Pichler et al., 1983; Berland 
et al., 1986) or thirdly, an indicator of remote ischaemia 
or co-existing arterial stenoses (Salcedo et al., 1981; 
Jennings et al. , 1983). The majority of published work 
addresses the significance of anterior ST segment 
depression in the context of acute inferior myocardial 
infarction (Betocchi et al., 1983; Tendera and Campbell, 
1984; Cohen et al., 1984; Little et al., 1984). Few 
studies have examined the significance of reciprocal 
changes in anterior infarction, and those published are 
limited by small numbers (Pichler et al., 1983;
Haraphongse et al., 1984). Dewhurst et al. (1985) 
examined the early electrocardiographic results in 100 
patients sustaining a first myocardial infarction, and 
reported 'reciprocal changes' in 61% (33/54) of inferior 
infarctions and in 43% (20/46) of anterior infarctions. 
Reciprocal changes were recorded if occurring within 48 
hours of the acute event. The population of patients in 
this present study are more acute, all presenting within 6 
hours of onset of pain and this probably contributes to
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the higher incidence of reciprocal change reported here,
i.e. 89% of inferior infarctions had ST depression in AVL
and 55% of anterior infarctions had ST depression in lead
III. Tendera and Campbell (1984) divided reciprocal
changes in inferior myocardial infarction into early
(occurring within 4 hrs of chest pain onset) and late (>6
hours of chest pain), and looked specifically at incidence
of ST depression in V . Although there was a higher
2
incidence in the early group (62%) compared with the late 
group (21%) it was only those late reciprocal changes 
which helped to identify concurrent LAD stenoses or 
reduced LVEF. Although specific this was not sensitive, 
and based on a small cohort.
This finding, coupled with the overall high incidence of
reciprocal changes early in the course of myocardial
infarction reported here may support the theory that ST
depression on the admission ECG occurring soon after
symptom onset is simply a mirror image of ST segment
elevation, and may be an index of total ischaemia, rather
than specifically pinpointing co-existing disease.
Certainly the close correlation found between ST segment
elevation and depression in this study, whether examining
the relationship between ^ ~^ST elevation and depression,
single leads with maximal ST shift or simply lead III
versus V supports the electrocardiographic mirror image 
3
theory. This confirms work by Camara et al. (1983)
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performed in a smaller number of patients (n=25) 
presenting at 3.97+4.8 hours of pain onset, and which 
showed a significant correlation between ST segment 
elevation and depression in both anterior and inferior 
infarction (r=0.93, r=0.55 respectively).
The evidence based on the relationship of ECG changes to 
coronary anatomy in the 114 patients in this study, 
clearly indicates that the phenomenon of reciprocal change 
is totally independent of coexisting arterial stenoses. 
This again confirms the studies by Little et al. (1984) 
and of Berland et al. (1986) who confined their 
observations to inferior infarctions undergoing 
angiography for coronary thrombolysis.
In addition to the above data it would seem that 
resolution of ST segment depression closely follows that 
of ST elevation (Chapter 8). All these features together 
tend to support the hypothesis that reciprocal ST 
depression during early acute transmural myocardial 
infarction does not reflect remote ischaemia. Not only 
does the work of Lew et al. (1987) agree with this point, 
he and his co-workers showed that inferior wall ischaemia 
in anterior myocardial infarction, documented by thallium 
201 scintigraphy and by contrast ventriculography was 
more likely to be associated with isoelectric or elevated 
ST segments compared to anterior infarction with no 
inferior ischaemia. The group of patients whose LAD
196
artery supplied the left ventricular wall up to and
including the apex, but not the inferior wall, had a
significantly greater degree of ST segment depression in
the inferior leads compared with patients who had definite
ischaemia of their inferior wall. This led the group to
suggest that by using a ratio of ST segment depression in
AVF to ST elevation in V , less negative than -0.2 would
2
lead to identification of patients with anterior 
infarction and concomitant inferior wall ischaemia due to 
an LAD occlusion which either supplies the inferior wall 
or is the source of collateral flow to a previously 
occluded RCA. This sub group of patients are at high risk 
from extensive infarction and would benefit from early 
thrombolysis.
In conclusion, this chapter has concentrated on the acute 
ECG changes occurring in a group of patients presenting 
with myocardial infarction of s< 6 hours duration 
undergoing thrombolysis. The advantage in studying this 
group has been in being able to use the coronary angiogram 
performed post therapy and to correlate these findings 
with the admission ECG in a large number of patients. 
Although many recent thrombolytic trials perform acute 
angiography to determine success of therapy, a 
comprehensive analysis of coronary anatomy in relation to 
the ECG has not been performed. In particular this study 
has helped to clarify thinking in a number of areas.
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Firstly, that within the time window 1-6 hours, the height 
of ST segment elevation does not bear any relation to the 
age of the infarct, secondly, that there is a high 
incidence of reciprocal change early in the course of 
infarction, and thirdly, that this is not related to 
coexisting disease or remote ischaemia, but is an 
electrocardiographic mirror phenomenon.
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CHAPTER 8
COMPARISON BETWEEN ANISTREPLASE AND STREPTOKINASE 
IN ACUTE MYOCARDIAL INFARCTION
RESULTS III - ELECTROCARDIOGRAPHIC DETERMINANTS OF 
REPERFUSION AND INFARCT EVOLUTION
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8.1 INTRODUCTION
Since the initial work of this thesis was first presented 
in 1985 (Hogg et al., 1985) the publication of well 
conducted mortality studies (GISSI, ISIS II, AIMS and 
ASSET) has assured the place of thrombolysis in acute 
myocardial infarction in all hospital practices. This has 
made it even more important to know how useful the 12 lead 
ECG is as a non invasive indicator of reperfusion and of 
myocardial salvage. The work presented in Chapter 3 
introduced the concept of using a simple formula 
(Fractional Change) to calculate the percentage fall in ST 
segments and showed it to be a specific and sensitive non 
invasive test of reperfusion. Chapter 4 demonstrated that 
the QRS score was reduced in patients achieving 
reperfusion compared with a group of controls who received 
no lytic agent. The limitation of both chapters was that 
this initial work was conducted in relatively small 
patient numbers, and Chapter 4 confined itself to the 
examination of anterior infarcts only. In addition, the 
total number of non reperfusions were low (n=8 and n=3 in 
Chapters 3 and 4 respectively) making statistical 
comparison between reperfusions and non reperfusions 
impossible (chapter 4). The aim of this study was to 
investigate and validate using a large patient group 
consisting of both anterior and inferior infarctions, 
reperfusions and non-reperfusions, the results achieved in 
earlier work. In addition, the creation of an 
electrocardiographic data base backed up with acute
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angiographic findings allowed comparison of different 
methodologies. The heterogeneity of methods used between 
groups of workers (Table 12) has confused the literature, 
and the aim was to determine the simplest, most specific 
and sensitive tests to be of value to physicians treating 
patients with thrombolytic agents.
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8.2 PATIENTS AND METHODS
The patient group is that described in Chapters 6 and 7 
and listed in appendix VI. The patency data reported in 
Chapter 6 by convention was based on the first injection 
into the infarct-related artery. Some arteries were seen 
to reperfuse during the angiogram, and for this part of 
the study which relates the ECG determinants of 
reperfusion and myocardial salvage to angiographic 
findings, it is the patency at the end of the 
catheterisation procedure which is used. The list of 
patients who had a change in patency during angiography 
are shown in Table 27. Although 10 patients have a change 
of greater than 1 in the TIMI Grade, only 6 are considered 
to have reperfused during the procedure (TIMI 2 or 3) 
resulting in a patency rate of 55% for streptokinase and 
64% for anistreplase at the end of the procedure. The 95% 
confidence intervals are 42-68% and 52-76% respectively, 
showing there is no significant difference in patency 
rates between treatments.
Fractional Change was calculated on computer according to 
the formula described in Chapter 3. The ability of the 
ECG to determine reperfusion is expressed in terms of 
sensitivity and specificity using the same method as 
previously. Sensitivity measures the ability of the test 
to detect genuine cases of reperfusion and specificity 
measures the ability of the test to detect genuine cases 
of non- reperfusion. Other ECG parameters were analysed
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on a main frame computer (ICL2980) using the statistical 
package MINITAB. Data are presented as mean + SE and 
statistical comparisons between groups analysed by 
analysis of variance (ANOVA) using RUMMAGE and Bonferoni 
multiple comparisons with 95% confidence limits for 
statistical significance. For these analyses, the Q and R 
wave parameters were normally distributed and did not need 
to undergo transformation. However, the parameters of ST 
height and area required to undergo a square root 
transformation prior to ANOVA.
Each angiogram was assessed for presence or absence of 
collateral supply. Collaterals were graded according to 
the extent to which the epicardial arterial segment distal 
to the target stenosis (or acute occlusion) was 
retrogradely opacified (Rentrop et al. , 1985). Grades of 
collateral filling from the contra-lateral vessel were : 
0=none; 1=filling of side branches but no visualisation of 
epicardial vessel; 2=partial filling of epicardial 
segments; 3=complete filling of the epicardial segment 
distal to the stenosis or occlusion.
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Patient No. Drug
Timi 
First Injection
Grade
Last Injection
5 APSAC 0 2
9 APSAC 0 2
22 SK 0 1
27 APSAC 0 1
29 SK 0 1
35 SK 0 1
39 APSAC 0 2
54 APSAC 0 3
55 SK 1 2
119 APSAC 1 2
APSAC = anistreplase 
SK = streptokinase
TABLE 27: PATIENTS WITH CHANGE IN TIMI GRADE OF PERFUSION 
DURING 90 MINUTE ANGIOGRAM
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8.3 RESULTS
8.3.1. Resolution of ST Segment Shift Over 24 Hours
Figure 29 shows the pattern of resolution of ST segment
elevation (mean+SE) over a 24 hour period both for ^ S T
height and ^  *ST area, depending on coronary patency
assessed at the 90 minute angiogram from a total of 107
patients (reperfusions n=66, non reperfusions n=41).
There is no difference between baseline values on
admission, and although both groups show a significant
fall in ST segment elevation from baseline by 2 hours,
there is a significantly greater reduction in y^ST
elevation (area and height) at 2 hours in those patients
with a patent artery compared to non reperfusions ( ST
height 4.6+0.46 mm vs 10.7+1.6 mm at 2 hours, p<0.05,^^
2 2 
ST area 32^4.2 mm vs 65.3+8.7 mm at 2 hours, p<0.05).
This difference between groups is still apparent at 4
hours ( V S T  height 4.6^0.46 mm vs 7 . 5+1 .1 mm, p < 0 . 0 5 / j 
^  2 2 
ST area 34^4.2 mm vs 49.8+7.5 mm , p<0.05), but
thereafter although the patients with patent arteries tend
to have lower values, there is no significant difference
between the two groups. Although there is no difference
in the absolute value to which ST segment elevation
returns, it is the rate of fall in the first 2-4 hours
which differentiates patent from non patent arteries.
The resolution of ST segment depression is similar to that 
of ST elevation over the same time scale, but the only 
significant difference between groups is for ST
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depression (nun) at 2 hours (2.8+0.48 nun vs 4.8+1.1 mm, 
p< 0.05), suggesting that the rate of resolution of ST 
depression is not as helpful in separating out patent from 
non patent arteries at the 90 minute time point (Figure 
30). However, a significant proportion of the "non 
reperfusions" at 90 minutes (28 of 41) were found to have 
a patent artery at 24 hours, and only 13 patients did not 
reperfuse at all. The comparison between these two groups 
in shown in Figure 31 for ^ S T  elevation (mm) . The 
subgroup of patients who reperfused later than 90 minutes 
have a higher baseline value than the non reperfusions 
(16.4+2.4 mm vs 11.3+2.4 mm, p<0.05). Nevertheless the 
graph shows the gradual decline in ST segments for 
persistently occluded vessels over 24 hours. Although the 
trend is of a definite decline, none of the values at any 
time point is significantly different from baseline. This 
is in contrast to the group who reperfused late where the 
fall from baseline is statistically significant at all 
time points. Ninety percent of the total fall occurs 
within 4 hours, suggesting these patients reperfuse within 
this time scale.
These results show that patients who reperfuse or who 
obtain a patent artery early ({90 minutes)have faster 
resolution of ST segment elevation than patients shown to 
have an occluded artery, but within this latter group is a 
subset of patients who are shown to have a patent artery
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by 24 hours and who show 90% of the fall in ST segments 
within 4 hours compared with the very gradual decline seen 
in people who never reperfuse. It is this fast fall in 
the first few hours following therapy which has been 
exploited as a non-invasive means of obtaining reperfusion 
and which will be discussed in the next section.
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8.3.2. Fractional Change
Fractional Change (F.C.) values were calculated for each
of 106 patients at each of the time points. Nineteen
patients did not have a F.C. calculted, 12 of whom did not
have a 90 minute angiogram to determine patency, 2 did not
have an admission ECG and 5 had the 2 hour ECG missing.
The two patients (58 and 80) with negative enzymes were
excluded from analysis. Different ECG parameters were
used to calculate the F.C, which are as follows: 1. using
the single lead with maximal ST segment elevation; 2. ^ ST
elevation in all leads; 3. y*J5T elevation in those leads
showing elevation at presentation and 4. by following y*]sT
elevation in leads dedicated to the infarct site (i.e. II,
III, AVF for RCA occlusions, V -V for LAD occlusions and
1 4
I, II, III, AVL, AVF, V , V for Cx occlusions). In
5 6
addition the first three parameters were also used to 
calculate F.C. for ST segment depression.
The best time to calculate F.C. to maximise separation of 
the two groups (reperfusions and non reperfusions) was at 
two hours. Later time points had an unacceptably low 
specificity, and the examination of arbitrary cut-off 
points of F.C. values indicating reperfusion confirmed the 
previous finding that a F.C. value of >, 0.5 again 
maximised separation. These results are shown in Table 28 
using the single lead with maximal ST segment elevation to 
calculate F.C.
208
Using a F.C. value calculated at 2 hours following 
intravenous therapy from a single lead with maximal ST 
segment elevation and a cut-off level of >, 0.5 gives a 
sensitivity of 81% and a specificity of 60%. Scatter 
diagrams of F.C. values using this technique and of F.C. 
values calculated from ^JST elevation on all leads showing 
elevation at admission are shown in Figure 32. Table 29 
compares sensitivity and specificity using the different 
ECG parameters for calculating F.C. and shows that 
following ST segment shift in a single lead with maximal 
elevation on admission gives a result more sensitive and 
specific than any other parameter. In particular, 
exploiting the resolution of ST segment depression whether 
in a single lead or across multiple leads does not improve 
the test, and is limited in that it can only be applied to 
patients who have reciprocal change present. Ten patients 
with LAD occlusion had to be excluded from this analysis 
as no ST depression was present in any lead.
The use of a F.C. calculated at 2 hours from a single lead 
is equally good at detecting patency irrespective of the 
site of infarct. From Figure 33 it can be seen that the 
specificity for detecting non reperfusions is slightly 
higher for RCA occlusions (67% vs 55.5% for LAD 
occlusions).
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The degree of perfusion within groups on the TIMI scale 
(0-1 for non reperfusion and 2-3 for reperfusion) has no 
relation to the F.C. value (Figure 34). Although there is 
a larger number of non reperfused patients who have a TIMI 
grade of 0 (n=30) compared to those with a TIMI grade of 1 
(n=10), the percentage of patients in both groups having a 
F.C. >, 0.5 is the same, and the specificity of the test 
does not change (60% for TIMI 0 or 1). Similarly, of the 
patients who reperfused a larger percentage had a grade 3 
perfusion (n=45) compared with grade 2 perfusions (n=19). 
The sensitivity of a F.C. value  ^0.5 is 82% for TIMI 
grade 3 and 79% for TIMI grade 2. The percentage of 
patients in each group with a F.C. value } 0.75 is not 
significantly different (32% TIMI 2 vs 44% TIMI 3, NS).
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F.C. CUT OFF LIMIT*
Hours
2
Post Treatment 
Of F. 
4 16
For Calculation 
C.
18 24
SENSITIVITY 91% 89% 89% 90% 93%
0.25
SPECIFICITY 30% 24% 15% 5% 10%
SENSITIVITY 81% 77% 73% 82% 84%
0.5
SPECIFICITY 60% 48% 27% 24% 23%
SENSITIVITY 41% 53% 31% 40% 40%
0.75
SPECIFICITY 88% 71% 85% 70% 72%
* CUT OFF LIMIT = F.C. if x >, F.C. = Reperfusion
if x < F.C. = Non reperfusion
TABLE 28: THE SENSITIVITY AND SPECIFICITY OF THE F.C.
CALCULATED FROM A SINGLE LEAD SHOWING MAXIMAL 
ST ELEVATION TO DETECT REPERFUSION AND NON 
REPERFUSIONS AT DIFFERENT TIMES AND AT 
DIFFERENT PREDETERMINED CUT-OFF LEVELS.
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8.3.3. Influence of Collateral Supply on Fractional Change
Fifteen patients were seen to have collateral supply to
the distal part of the infarct related artery and 10 of
those patients had not reperfused anterogradely at the
time of the 90 minute angiogram. The extent of collateral
supply and the F.C. values (single lead at 2 hours) are
shown in Table 30. Three of 4 patients who all had a
"falsely" high F.C. had good collateral supply (one grade
3, two grade 2) while the remaining patient had grade 1
collateral supply to a non dominant Cx artery. Of the 6
patients with low F.C. values, 3 had grade 1 collateral
2
supply and 3 had grade 2. Although inconclusive with 
small numbers and depending on what is a fairly subjective 
assessment of collateral supply, satisfactory coronary 
flow via collaterals to the infarct territory may result 
in resolution of ST changes despite no anterograde flow. 
F.C. values >, 0.5 may reflect perfused myocardium and a 
value of < 0.5 may be more specific than the 60% already 
reported in this chapter for non-perfusion of the infarct 
territory.
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Patient No. IRA
90' Angio 
TIMI Grade F.C.(2 hrs)
Grade of 
Collaterals
1 RCA 0 0.68* 2
7 RCA 0 0.31 2
11 RCA 0 0.06 1
14 LAD 0 0.43 1
51 RCA 0 1.0* 3
59 RCA 1 -3.15 2
94 RCA 0 -0.26 2
117 Cx 0 0.63* 2
118 Cx 0 0.71* 1
120 LAD 0 0.21 1
* = Falsely high F.C. value at 2 hours
TABLE 30 DISTRIBUTION AND EXTENT OF COLLATERAL SUPPLY TO 
OCCLUDED INFARCT RELATED VESSELS AND FRACTIONAL 
CHANGE VALUES
8.3.4. Evolution of electrocardiographic infarct pattern 
Figures 35 and 36 show the sequential changes taking place 
in the 12 lead ECG over a 24 hour period for patients with 
and without a patent artery as assessed at the 90 minute 
angiogram. The parameters studied are both for single R 
and Q wave amplitudes in the lead identified with maximal 
ST elevation on admission, and for y^R and wave 
amplitudes taken from all leads showing ST elevation on 
admission. Figure 35 shows that by following the Q wave 
in a single lead showing maximum injury pattern on 
admission there is a significant attenuation of Q wave 
amplitude in patients with a patent artery at 90 minutes. 
This attenuation in Q wave amplitude becomes apparent at 4 
hours and the difference is maintained at all subsequent 
time intervals up to and including 24 hours, (mQ wave 
amplitude = 5.9+0.8 mm (reperfusion) vs 7.8+1.0 mm (non 
reperfusion) at 4 hours (p<0.05), and 6.4+0.7 mm vs 
9.4_+1 .3 mm at 24 hours (p<0.05)). Exactly the same 
pattern is seen for y^Q wave amplitude (m y^Q= 1 6. 6+2 mm 
(reperfusion) vs 20.2+3.2 mm (non reperfusion) at 4 hours 
(p<0.05), and 18.9+2.1 mm vs 26.4+3.8 mm at 24 hours 
(p<0.05) ) (Figure 35). By contrast although both groups 
(reperfusions and non reperfusions) show a significant 
reduction in R wave amplitude (both single R and y^R) at 
all times from baseline, there is no difference between 
the two groups (e.g. mR wave amplitude = 5.7+^0.51 mm 
(reperfusion) vs 4.8hh0.58 mm (non reperfusion) on 
admission (NS) and 1.5+0.28 mm vs 1.2+0.32 mm at 24 hours
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(NS)). This suggests that the presence of an early patent 
artery does not have any beneficial effect on R wave 
preservation.
Figures 37 and 38 show the same data sub-divided according 
to infarct related artery. Circumflex occlusions have 
been excluded from this analysis due to the small numbers 
involved. It can be seen that the majority of the 
difference in Q wave development between patients with 
and without a patent artery at 90 minutes (Figure 35) 
reflects the attenuation of Q wave development seen 
predominantly in LAD occlusions. Although patients with a 
RCA occlusion who do not reperfuse by 90 minutes have a 
tendency to develop larger Q waves than patients who 
reperfuse early, this difference is not statistically 
significant. This is true irrespective of whether 
examining a single lead with maximum injury pattern, or 
the in all leads showing ST elevation on admission
(Figure 37). Although there was no obvious difference in 
loss of R wave (single lead or ^ R )  between patients with 
and without a patent artery (Figure 36) this is not true 
when the infarct related artery is identified separately. 
Figure 38 shows that patients with a LAD occlusion who 
reperfused by 90 minutes have less R wave loss at 16, 18 
and 24 hours compared to patients with a non patent vessel 
at 90 minutes. This is not true of RCA occlusions. It 
can also be seen that the admission values for single lead
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R wave amplitudes are greater for inferior infarcts (RCA 
occlusion) than for anterior infarctions (LAD occlusions)
(P<0.05). This is due to the fact that the lead showing 
most injury pattern in anterior infarctions is either V2 
or V3 (Figure 22) which naturally have small R wave 
amplitudes compared to lead II or lead III for inferior 
infarcts.
The presentation of this data has so far assumed an 
absolute reperfusion deadline at 90 minutes. As discussed 
in Section 8.3.1. the "non reperfusions" at 90 minutes 
represent a heterogenous group, the majority (28 of 41) of 
which have reperfused by 24 hours. Table 31 shows the 
mean values available at 24 hours for each of the ECG 
parameters; single Q, single R, ^ P r , dependent on
perfusion status cross-tabulated for both angiograms. Two 
of the subdivisions are very small; all time non 
reperfusions n=12, and reocclusions between 90 minutes and 
24 hours n=3. Nevertheless there appears to be a trend 
for those patients who reperfused late to have the largest 
Q waves and smallest R waves. Figures 39 and 40 show the 
development of Q and R waves over 24 hours for those 
patients who never reperfuse, compared with those who 
reperfuse between 90 minutes and 24 hours. Surprisingly 
it is this latter group who show greater loss of R waves 
and more Q wave development. In addition, it appears that 
the group of patients in whom thrombolysis is unsuccessful 
show a tendency to have greater development of the
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electrocardiographic infarct on admission (mean Q 
amplitude = 5 . 5_+2 . 2 vs 2. 3+0. 5). This difference does not 
quite reach statistical significance when tested by ANOVA. 
However, the late reperfusers show a significant increase 
in Q wave amplitude from baseline by 2 hours (mQ amplitude 
2.3+0.5 mm to 6.1+0.96 mm, p<0.05) and at all subsequent 
time points, whereas the patients with persistently 
occluded vessels, although showing a trend to further Q 
wave development over the 24 hour period (mQ amplitude on 
admission 5.5 + 2 .2 mm to 9.0+2.9 mm at 24 hrs), this 
increase is not statistically significant from baseline. 
Figure 40 shows a trend for the late reperfusers to have a 
greater loss of R wave amplitude compared to those who do 
not reperfuse at all. The standard error bars however are 
wide and there is no significant difference between the 
two groups.
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( A  and •  ) according to 90 minute angiography.
terisks (* ) denote significant differences 
(p<0.05) between A and A  .
ECG
Parameter
90 Minute 
Angiogram
24 Hour Angiogram 
Non Reperfusion Reperfusion
Total Numbers 
In each cell
Non reperfusion
Reperfusion
12 25
65
10.0+1.5 
6.3+0.76 
29.4+5.0 
18.8+2.2 
0.5+0.21 
1.5+0.29 
13.6+1.9 
17.8+2.0
Single Q
Non reperfusion 
Reperfusion 
Non reperfusion 
Reperfusion 
Non reperfusion 
Reperfusion 
Non reperfusion 
Reperfusion
9 . 0 + 2 . 9 
7.3+4 . 3 
22.1+7.8 
20.1+14.3 
2.7+0. 9 
2.3+1 . 3 
14.8+4.6 
12.5+1.6
Single R
TABLE 31 : MEAN VALUES (+SE) AT 24 HOURS FOR SINGLE Q,
Y.Q, SINGLE R, Y R , RELATED TO PERFUSION STATUS 
CROSS-TABULATED FOR BOTH ANGIOGRAMS
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FIGURE 39: COMPARISON OF Q WAVE DEVELOPMENT BETWEEN PATIENTS 
WITH PERSISTENTLY OCCLUDED VESSELS ( # ) AT 
24 HOURS AND PATIENTS WHO REPERFUSE LATE ( Q  )
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FIGURE 40: COMPARISON OF R WAVE LOSS BETWEEN PATIENTS WITH 
PERSISTENTLY OCCLUDED VESSELS ( • ) AT 24 HOURS 
AND PATIENTS WHO REPERFUSE LATE (O )
8.3.5. QRS Scores
Figure 41 shows the development of the simplified 
Selvester QRS score over 24 hours for patients with and 
without a patent artery at 90 minutes. Although both 
groups start with similar QRS scores on admission (mean 
QRS score = 2.4+0.33 (reperfusion), mean QRS score = 
2.6^0.34 (non reperfusion) NS), patients who achieve a 
patent artery early (at or before 90 minutes) have 
significantly lower QRS scores than patients who have not 
reperfused by this time point. This difference in scores 
is apparent at 4 hours post treatment (mean QRS score 
3.9^0.44 (reperfusion) vs mean QRS = 5.1+0.67 (non 
reperfusion) p<0.05), and is maintained at each subsequent 
time point up to 24 hours (mQRS = 4.9+0.47 (reperfusion) 
vs mQRS 6.3+0.65 (non reperfusion), p<0.05). Fourteen 
patients were noted to have sustained a previous infarct 
and their baseline scores were significantly higher than 
patients presenting with a first infarction (4.7^0.96 vs 
2.5+0.23 respectively). Omitting these patients from the 
analysis does not affect the overall results. The mean 
QRS score at 24 hours for patients with no previous 
infarct and a patent artery at 90 minutes is 4.7+0.46 
compared with a mean score of 6.4j+0.7 for patients with a 
first infarct who are occluded at 90 minutes (p<0.05).
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Table 32 shows mean QRS scores ( + SE) at 24 hours for 
subgroups of patients according to patency of infarct 
related artery, both at 90 minutes and at 24 hours for all 
patients and after excluding those with previous 
infarction. The total number of patients with 
angiographic evidence of reocclusion between 90 minutes 
and 24 hours is very low (n=3). Subdivision of the 
databank into smaller groups really precludes meaningful 
statistical analysis - nevertheless it can be seen that 
rather than the group who never achieve a patent artery, 
it is the group that reperfuses late which has the 
tendency to the highest QRS scores (5.3+1.2 vs 6.6+0.87 
respectively).
The above analysis has so far incorporated all infarctions 
irrespective of which artery was responsible. Previous 
work (Chapter 4) addressed QRS scores in anterior infarcts 
only. The QRS scores on admission for LAD and RCA 
occlusions are significantly different, mean QRS =
3.9+0.39 and 1.2+0.23 respectively (p<0.05). Figure 42 
shows the development of the QRS score for LAD and RCA 
occlusion based on patency data at 90 minutes. It can be 
seen that the difference in the QRS score between 
reperfused and non reperfused groups shown in Figure 41 
for all infarcts really reflects the marked attenuation in 
the QRS score seen in patients with LAD occlusion who 
reperfuse by 90 minutes. There is no significant 
difference in QRS scores between groups for RCA occlusion,
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suggesting the use of the QRS score to show myocardial 
salvage following reperfusion is unhelpful in acute 
inferior myocardial infarction. Table 33 shows mean QRS 
scores at 24 hours related to perfusion data for both LAD 
and RCA occlusions for all patients presenting with a 
first infarction. The trend for patients who reperfuse 
late to have the highest QRS scores is again reflected 
here irrespective of which artery is involved.
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FIGURE 41: EVOLUTION OF SIMPLIFIED SELVESTER QRS SCORE OVER 
24 HOURS FOR ALL PATIENTS ACCORDING TO VESSEL 
PATENCY AT 90 MINUTES. Patients who obtain a 
patent artery early ( O  ) have lower QRS scores 
than those patients who remain occluded at 90 
minutes ( •  ). Asterisks (*) denote significant 
differences between groups
All patients
24 Hour Angiogram 
Non Reperfusion Reperfusion
Non Reperfusion 5.3^1.2 6.6+0.87
(n=12) (n=25)
90 Minute 
Angiogram*
Reperfusion 3.3+2.8 4.9+0.48
(n=3) (n=65)
Omitting patients with previous M.I.
24 Hour Angiogram 
Non Reperfusion Reperfusion
Non Reperfusion 4.8+1.2 7.1+0.93
(n=11) (n==22)
90 Minute 
Angiogram
Reperfusion 5.0+4.0 4.6+0.47
(n=2) (n=61)
TABLE 32: MEAN QRS SCORE (+ SE) AT 24 HOURS POST TREATMENT 
RELATED TO ANGIOGRAPHY BOTH AT 90 MINUTES AND AT 
24 HOURS FOR ALL PATIENTS AND AFTER EXCLUDING 
THOSE WITH PREVIOUS INFARCTION
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FIGURE 42: EVOLUTION OF SIMPLIFIED SELVESTER QRS SCORE OVER 
24 HOURS ACCORDING TO PATENCY DATA AT 90 MINUTES 
AND TO INFARCT RELATED ARTERY. Patients are 
divided into LAD ( A and A  ) and RCA ( O  and •  ) 
occlusions, reperfusions ( A and O  ) and non 
reperfusions ( ▲ and # ) according to 90 minute 
angiography. Asterisks (*) denote significant 
differences (p<0.05) between reperfusions (A) 
and non reperfusions ( A )  for LAD infarctions. 
There is no significant difference between 
reperfusion ( O )  and non reperfusions (# ) for 
RCA infarctions
LAD occlusion
24 Hour Angiogram
Non Reperfusion Reperfusion
Non reperfusion 8.3+1.75 8.7+1.08
90 Minute
(n=4) (n=12)
Angiogram 'v.
^  Reperfusion 9.0+0.0 
(n=1 )
6.7+0.82 
(n=26)
RCA occlusion
24 Hour Angiogram
Non Reperfusion Reperfusion
Non Reperfusion 3.6+1.3 4.6+1.1
S ' (n=5) (n=8)
90 Minute
Angiogram N.
^  Reperfusion 3.2+1 .2 
(n=6)
3.5+0.45 
(n=37)
TABLE 33:MEAN QRS SCORES AT 24 HOURS FOR LAD AND RCA 
OCCLUSIONS RELATED TO PERFUSION STATUS CROSS 
TABULATED FOR BOTH ANGIOGRAMS
8.4 DISCUSSION
This chapter demonstrates the sequential 
electrocardiographic changes which take place in a large 
number of patients with acute myocardial infarction 
treated with thrombolytic therapy. No attempt has been 
made to differentiate those ECG changes occurring in 
either treatment group as morphologically both treatments 
behave the same with no difference in patency rates either 
at 90 minutes or at 24 hours. The important comparison is 
between reperfused and non reperfused cornary arteries, 
and also between anterior and inferior infarctions.
Further division of these sub groups according to 
thrombolytic agent administered serves only to dilute the 
power of statistical comparison. The observational ECG 
data from this study has been examined to determine if 
practical information concerning reperfusion and 
myocardial salvage can be inferred.
Physicians treating patients with thrombolytic agents have 
long been aware of the phenomenon of rapid resolution of 
ST segment elevation reflecting reperfusion (Ganz et al., 
1981). Quantification of those changes has been 
attempted, but some of the earlier studies compared 
treatment groups with placebo groups and did not separate 
the treatment groups into those with and without a patent 
artery (Anderson et al., 1983; Anderson et al., 1984).
The results shown here confirm the very rapid drop in ST 
segments accompanying a patent artery at 90 minutes,
225
compared with non reperfused arteries, but show no 
difference in the ultimate level to which the ST segments 
fall by 24 hours. It appears that it is the rate of fall 
which discriminates patent from non patent vessels. 
Although the resolution of ST segment depression follows a 
similar pattern, there is not such a marked difference 
between groups. Calculating the F.C. or a proportional 
drop in ST segments from a single lead with maximal injury 
pattern on admission, and using a value >, 0.5 to denote a
patent artery gave a test with a sensitivity of 81% and a 
specificity of 60%. This test calculated at 2 hours using 
a single lead with maximal ST elevation was the best 
indicator of a patent artery, and has the advantages of 
simplicity. It does however fall short of the 
sensitivities and specificities reported for the initial 
study in Chapter 3 (Table 8). The reasons for this may be 
severalfold; firstly there were only 3 non reperfusions in 
the test group of the initial study and miss- 
classification of one of those dropped the specificity to 
67% from 100% in the training group. This present study 
represents a larger, and perhaps more realistic, number of 
non reperfusions; secondly with this current study the 
timing of the 90 minute angiogram was stringently adhered 
to, as was the timing of the ECGs. In the initial pilot 
study, the post treatment 12 lead ECG was performed at a 
mean time of 302+141 minutes and the angiogram for the 
intravenous anistreplase group performed between 90 and
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180 minutes post treatment. This will lead to a greater 
number of patients being seen to have reperfused, and the 
later ECG recording will take into account some of the 
natural decline of ST elevation irrespective of that 
directly attributable to reperfusion. Clearly the 90 
minute patency rate, despite being universally reported as 
a surrogate endpoint in multiple clinical trials, is not a 
morphologically sensible endpoint, as patients are still 
reperfusing after the angiogram has been completed. Of 
the group of patients designated "non reperfusion" at 90 
minutes, 28 had a patent artery by 24 hours and only 13 
were persistently occluded. In the so-called late 
reperfusions, 90% of the total fall in ST segments at 24 
hours had occurred by 4 hours, compared with a very 
gradual decline in persistently occluded vessels. The 
specificity of the test may be increased if one assumes 
that a percentage of the "false high" F.C. values at 2 
hours may represent a patent artery recanalised after the 
90 minute angiogram. Also, this study has shown that in a 
small group of patients, collateral supply to the infarct 
territory via the contralateral artery may result in a
F.C. value >, 0.5 despite the fact no anterograde
perfusion can be seen, suggesting adequate myocardial 
perfusion. The F.C. test applied equally well to all 
infarct related arteries.
Subgroup analysis of late reperfusers and all time non 
reperfusers revealed that not only did the patients who
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had unsuccessful thrombolysis have significantly less ST 
segment elevation on admission (Figure 31) but they also 
had a tendency to a greater Q wave amplitude in the lead 
with maximal ST elevation, although there was no 
significant difference in the wave amplitudes across 
all leads. This suggests that it may be possible to 
select patients on admission who are unlikely to have a 
successful response to thrombolysis; those patients seem 
to have more established infarcts in electrocardiographic 
terms, especially in leads reflecting the epicentre of the 
infarct. Previous data has shown that patients with ^ ^ST 
elevation <1.2 m.V on admission show no beneficial effects 
from streptokinase on enzymatic infarct size, left 
ventricular function or mortality, but these results were 
not specifically related to the presence or absence of 
reperfusion (Vermeer et al., 1986). This cut-off value of 
1.2 m V ^ S T  elevation is strikingly similar to the mean 
value of the^TsT elevation (11.3 mm or 1.13 mV) seen in 
patients who never reperfuse in this study. Similarly 
work by Bar et al. (1987) noted that there was no 
significant infarct limitation seen in patients with small 
amounts of ST elevation, but again the study did not 
directly relate this to perfusion status.
This study has confirmed the earlier work presented in 
Chapter 4, showing that myocardial salvage can be shown 
following early reperfusion in anterior infarction in
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terms of reduced Q wave development, attenuation of R wave 
loss, and a reduced QRS score. This is not however the 
case for inferior myocardial infarctions - a feature which 
is obscured if looking only at the results in global terms 
(Figure 35 and 41). As discussed in Chapter 4, previously 
published work has failed to show a significant difference 
in QRS scores between reperfusions and non reperfusions 
(Mikell et al., 1986; Hackworthy et al., 1988) or that a 
difference only exists when patients treated very early 
(<1.5 hours) are compared with those treated later (Koren 
et al., 1985). These groups have not examined anterior 
and inferior infarctions separately, and the failure to do 
this may have masked any difference directly attributable 
to anterior infarctions. The inability of the QRS scores 
to reflect myocardial salvage in inferior infarctions 
appears not be a function of the smaller number of leads 
indicating inferior changes as the score is weighted 
towards these leads, but reflects no significant 
difference in the component parts of the score, i.e. Q 
wave amplitude, R wave amplitude, R/Q wave ratio etc. 
(Figures 37 and 38). Without a left ventricular ejection 
fraction it is difficult to know whether this reflects a 
real absence of myocardial salvage, or the inability of 
the 12 lead ECG to adequately reflect changes in the 
inferior surface of the heart. Certainly although the 
benefit in mortality is independent of site of infarction, 
some trials have been unable to show any improvement in 
left ventricular function in inferior infarction (Western
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Washington Trial 1988, National Heart Foundation of 
Australia 1988).
Of particular interest is the observation that those 
patients who reperfuse late (>90 minutes) have a tendency 
to develop electrocardiographically bigger infarcts in 
terms of Q waves, loss of R wave amplitude and bigger QRS 
scores compared to those who reperfuse early and also to 
those who do not reperfuse at all. It is possible that 
these electrocardiographic indices may reflect an 
accelerated pattern of infarction, resulting from 
reperfusion injury.
Reperfusion injury is thought to occur when successful 
thrombolysis restores perfusion to myocardium which has 
been profoundly ischaemic, causing accelerated damage. 
Although much experimental animal and in vitro work has 
been performed to support this concept, the interaction 
between the area of infarcted myocardium, consisting of 
varying zones of profoundly ischaemic and necrotic tissue 
and the re-establishment of blood flow is very complex and 
a definitive in vivo study in the human has yet to be 
performed. In fairly gross pathological terms it is known 
that patients who have persistent coronary occlusions 
develop non haemorrhagic, pale infarcts in contrast to 
patients dying following documented reperfusion who have 
haemorrhagic infarcts. Multiple hypotheses have been
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formed to explain reperfusion injury including alteration 
in microvascular permeability (Tilton et al., 1983), 
alphadrenergic stimulation (Sheridan et al., 1980) and 
free radical production (Burrell and Blake, 1989).
Despite the molecular and biochemical level at which these 
interactions are occurring it may be that their effect 
could be picked up clinically using surface 
electrocardiography. Certainly the results presented in 
this chapter for the 12 lead ECG are an interesting and 
unexpected observation and merit further study, either 
using the 12 lead ECG or a multi-lead mapping study, which 
may better reflect changes occurring over various aspects 
of the infarction zone.
In conclusion, this chapter has presented the sequential 
ECG changes occurring in the first 24 hours after 
thrombolytic therapy for acute myocardial infarction and 
has related those changes to the clinical response 
following therapy. The data suggests that patients with a 
more established infarct pattern on admission are less 
likely to successfully reperfuse, that the rate of fall of 
ST segment elevation in the first 2 hours is a feature of 
reperfusion and has confirmed that the measurement of a
F.C. value >,0.5 hours following therapy in a single lead 
is a useful indicator of reperfusion, or perfusion, 
accepting the caveat that collateral supply from the 
contralateral artery may result in a high F.C. value 
despite no anterograde flow. This is true irrespective of
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the infarct related artery. It is only patients with 
anterior infarction (LAD occlusion) who can be shown to 
have significant attenuation of electrocardiographic 
markers of necrosis following early lysis. There is no 
significant electrocardiographic evidence of infarct 
limitation for patients with inferior infarction (RCA 
occlusion) . The observation that patients who reperfuse 
late tend to have more ECG evidence of infarction than 
patients with early reperfusion and also patients with 
persistent non reperfusion, has led to the hypothesis that 
this may represent reperfusion injury and requires further 
study in terms of confirmation of the result, and in 
following any possible resolution of ECG changes over a 
longer period than 24 hours.
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CHAPTER 9 
SUMMARY AND CONCLUSIONS
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9 . 1 SUMMARY AND CONCLUSIONS
"it is remarkable that clinically useful ECG 
information keeps coming from well conducted 
studies related to major coronary occlusion 
even after 70 years of intense 
investigation"
(Bernard R. Chaitman, 1988)
Alhough the above quotation comes from an editorial 
commenting on a paper by Huey et al. (1988) which looks at 
circumflex occlusions, it is an appropriate statement with 
which to begin to justify and discuss the work of this 
thesis. The practice of thrombolysis has advanced 
dramatically over the last decade. It is now known beyond 
doubt that thrombolysis causes reperfusion, salvages 
myocardium causing increased ejection fraction and most 
importantly of all; saves lives. It is this last factor 
which has led to its widespread use in all areas of 
hospital practice. For every trial which reports a 
definitive result concerning some aspect of thrombolysis, 
another trial poses yet more unanswered questions; what is 
the absolute time limit for administration of therapy?; 
will adjuvant therapy prevent reperfusion damage?; what is 
the best way to prevent reocclusion? Many of these 
questions that remain to be answered deal with events 
happening at a molecular and cellular level. Even 
performing invasive coronary angiography in acute 
myocardial infarction and demonstrating a patent 
epicardial vessel is no guarantee of adequate tissue
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perfusion - the so called "no-reflow" phenomenon (Kloner 
et al., 1974). Animal models and in vitro experiments 
while allowing detailed work have varying degrees of 
clinical relevance. Clinicians have for some time felt 
that surface electrocardiography is useful following 
intervention in acute myocardial infarction, but absolute 
quanitification of those changes which take place has not 
been performed. The advantages of electrocardiography are 
that it is available, reproducible, inexpensive and non 
invasive. Doctors are familiar with its interpretation 
and it is a technique which is constantly being used. If 
proven, application of simple measurements at specified 
times would provide a very useful clinical tool 
facilitating patient management, and may provide a non 
invasive means of following additional interventions.
This thesis has addressed several aspects of the 12 lead 
ECG in acute myocardial infarction, and will be summarised 
here not in the sequence of work presented chapter-by- 
chapter, but in terms of the chronological events 
occurring in acute myocardial infarction treated by 
thrombolysis, i.e. the presentation ECG and its relation 
to the infarct related artery, reperfusion and then 
myocardial salvage.
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Performing coronary angiography within 90 minutes of 
starting thrombolytic therapy, as described for the 
anistreplase/streptokinase comparison study presented in 
Chapter 6, allowed a detailed correlation between the 
distribution of ST segment shift and the infarct related 
artery. Although a pre-selected group in that all 
patients had to meet the criteria of ST segment elevation 
(^1 mm in 2 limb leads or >,2 mm in 2 precordial leads), 
many other studies relating infarct related artery to 
admission ECG changes depend on angiography performed at a 
considerable distance from the acute infarction. The 
results of the correlation confirmed the classical lead 
distribution in LAD and RCA occlusions on admission, and 
showed that ST segment elevation in I and AVL is a highly 
specific, but poorly sensitive, indicator of circumflex 
occlusion.
The importance of the presence of reciprocal change in 
acute myocardial infarction has been much debated. This 
work reports a higher incidence of reciprocal change in 
acute infarction than has previously been reported. This 
probably reflects the "younger" group of infarcts all 
presenting within 6 hours. It is clear from anatomical 
correlates that the presence of reciprocal change does not 
reflect coexisting arterial stenoses, but is an 
electrocardiographic mirror phenomenon.
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There is no means of ageing the infarction in terms of 
degree of ST segment shift (elevation or depression). 
Infarcts presenting early do not necessarily have a 
greater degree of ST segment elevation. There is wide 
interindividual variability which presumably reflects the 
site of acute occlusion, whether the occlusion is total or 
sub total, the presence and distribution of collateral 
supply, the area of myocardium at jeopardy distal to the 
thrombus and the proximity of the infarct area to the 
surface electrodes. It does however appear that patients 
who have a more established infarct pattern on admission
i.e. less ST segment elevation and a tendency to larger Q 
waves, are more likely not to respond to thrombolysis and 
to have a persistently occluded vessel at 24 hours. Work 
from this thesis and previously published work (Vermeer et 
al., 1986; Bar et al., 1987) support the view that if a 
patient presents with a myocardial infarction irrespective 
of time of onset of symptoms and has ^ S T  elevation <
1 . 2mV then the risk benefit ratio of treating with a 
thrombolytic agent increases. This sub group have not 
been shown to derive any benefit in terms of reperfusion, 
enzymatic infarct size, improvement in left ventricular 
function or a reduction in mortality.
Resolution of both ST segment elevation and depression has 
been mapped out for patients receiving thrombolysis. It 
is the rapid fall within the first 2-4 hours which 
differentiates patent from non patent arteries, although
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the level to which both groups eventually fall at 24 hours 
is not significantly different. This more rapid rate of 
fall is more obvious for resolution of ST elevation than 
for ST depression. The initial pilot study reported in 
Chapter 3 which formulated the idea for calculating a 
Fractional Change value showed that a value of >/0.5 was a 
sensitive and specific indicator of myocardial 
reperfusion. This study was performed in a smaller number 
of patients with few non reperfusions, and allowed a wider 
time window for the recording of the post-treatment ECG 
and also for angiography. When applied to the larger 
patient group randomised to anistreplase or streptokinase 
therapy, the same technique gave a sensitivity of 81% and 
a specificity of 60%. This may be a falsely low 
specificity for two reasons; one is that the Fractional 
Change is calculated from an ECG performed at 2 hours and 
the result related to angiographic patency which was 
determined 30 minutes earlier; it is clear that a lot of 
vessels continue to reperfuse after the 90 minute 
angiogram, with subsequent reduction of ST elevation, 
which would give rise to this apparently falsely high 
Fractional Change value. In addition effective collateral 
supply may have an effect on resolution of ST elevation 
and cause a high Fractional Change to result with no 
obvious anterograde flow.
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The studies conducted in this thesis show that the 
sensitivity and specificity of the Fractional Change is 
not improved if calculated from multiple leads showing ST 
elevation. Taking the single lead with maximum injury 
pattern on admission gives a Fractional Change value more 
specific and sensitive than any other lead combination.
The test is equally useful for LAD, RCA or Cx occlusions. 
The benefit of knowing whether the infarct related artery 
has reperfused or not depends on what the physician will 
do with the information. The benefits of aspirin as 
adjunctive medication by far outweigh the risks of its 
administration, the place of full body anticoagulation is 
not yet established but it is unlikely that one would want 
to subject a patient who has not reperfused to the risks 
of heparin and long-term warfarin. If a young patient is 
admitted with a large anteroseptal infarct, receives 
thrombolytic therapy and then progressively develops signs 
of cardiogenic shock, it may be that if his Fractional 
Change shows he has not reperfused, it would then be 
appropriate to consider further intervention in terms of 
angiography and intracoronary administration of a 
thrombolytic agent with mechanical perforation of the 
thrombus.
Electrocardiographic evidence of myocardial salvage was 
demonstrated in Chapter 4 in patients obtaining successful 
lysis of coronary thrombus, compared to a group of 
patients who received no medication other than simple
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analgesia. This study confined itself to anterior 
infarctions and showed that although there was a 
significant reduction in the QRS score of the established 
infarct at 48 hours in the treated group compared to the 
control group, the reduction in this evolved score related 
to a jeopardy score on admission was not predictable on an 
individual basis. Chapter 8 showed that while this 
reduction in QRS score was maintained in anterior 
infarctions who reperfused compared to those who did not, 
a similar reduction in the final QRS score was not seen 
for successful inferior infarctions (RCA occlusion) . Most 
previously reported studies using QRS scoring techniques 
have not separated out groups according to the anatomical 
site of the infarct, and as such may have masked any 
difference which did exist in anterior infarctions or 
incorrectly attributed a difference as being applicable to 
both RCA and LAD occlusions. The detailed 
electrocardiographic databank amassed for this later 
patient group presented in chapters 6-8, showed that the 
inability of the QRS score to show salvage in inferior 
infarction was not due to the smaller number of leads 
reflecting the inferior surface of the heart (II and AVF) 
compared to anterior infarctions, but was due to an 
inability of the component parts of the score (Q and R 
wave amplitudes) to show any difference depending on 
perfusion status even in leads reflecting the epicentre of 
the infarct.
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The observation that patients who reperfused after 90 
minutes tended to have bigger QRS scores, more Q wave 
development and more R wave loss was unexpected and of 
interest. Although primarily observational, it leads to 
the hypothesis that this is an electrocardiographic marker 
of reperfusion damage. Further study is required to 
verify these findings, and also to investigate if there is 
any recovery of the ECG pattern over several days - an 
electrocardiographic equivalent of myocardial stunning.
The major advantage in studying the group of patients 
recruited for the anistreplase/streptokinase comparison 
trial was being able to relate ECG changes to coronary 
anatomy defined by angiography performed acutely. This 
trial was set up to compare 30 I.U. anistreplase with 1.5 
M. I.U. streptokinase in a double-blind randomised cross­
over design using patency rates at 90 minutes and 24 hours 
as primary endpoints. The results show that there is no 
advantage of anistreplase over streptokinase in terms of 
coronary artery patency, which has been used here as a 
surrogate endpoint for coronary mortality. Justification 
for this relies on the fact that it is now ethically 
unacceptable to compare a new lytic agent with placebo. 
Comparison must be made with the standard therapy which is 
now generaly accepted as intravenous streptokinase. 
Comparative studies using mortality as an endpoint would 
need much bigger numbers than the 11 ,806 and 17,187 
required for GISSI and ISIS 2 respectively. While these
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proposed studies are underway in the form of GISSI 2 and 
ISIS 3, they take time to run and are expensive and costly 
to set up. The trial performed at Stobhill has refuted 
the claim that anistreplase is more effective than 
streptokinase in obtaining coronary patency, and by 
implication in reducing mortality. However, anistreplase 
has shown itself to be as effective as streptokinase and 
with the advantage of bolus administration, may yet find 
its niche in the thrombolytic field if out-of-hospital 
administration proves valuable.
In terms of further study - although the digitized 
database allowed a comprehensive collection of ECG 
parameters to be stored for multiple analyses, it still 
requires each 12 lead ECG to be manually digitized. 
Although the current system was well validated, an on-line 
computer system which would also signal average complexes 
from each lead of the 12 lead ECG would save a significant 
amount of time, and the signal averaging would reduce 
measurement error. A lot of the developmental work 
performed to start the digitized system, such as the set 
of rules for waveform definitions and the program to 
compute the QRS score would all be readily transferrable.
The work of this thesis has contributed to further 
understanding of the electrocardiographic changes which 
take place in acute myocardial infarction treated by 
thrombolysis, but there are so many questions still to be
242
answered that it is likely that Dr. Chaitman's quotation 
at the beginning of this chapter will be as true in a 
further 70 years time.
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APPENDIX I
PROTOCOL FOR ANISTREPLASE/STREPTOKINASE COMPARISON
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1 . STUDY OBJECTIVES
1.1. To measure and compare angiographically documented
coronary artery patency at 90 mins. following 
intravenous APSAC 30 Units or i.v. streptokinase 
1.5 million units.
1.2. To compare reocclusion rates at 24 hours after
dosing.
1.3. To compare the safety of the different compounds
with special reference to effects on blood 
pressure in the first 90 minutes after dosing.
2. STUDY MEDICATION
2.1. Intravenous APSAC
APSAC is the active site p-anisoylated derivative 
of the primary (human) lys-plasminogen- 
streptokinase complex prepared by immediate 
acylation of the serine residue in the active 
center of that complex as it is formed. The 
molecular weight is close to 131,000 Daltons.
APSAC is formulated in a mixture of clinical grade 
human albumin, D-mannitol and L-lysine. It is 
presented in vials, each containing 30 Units APSAC 
as a sterile, white lyophilized powder.
2.2. Storage
APSAC 30U vials have a shelf-life of 2 years when
o
stored at or below 5 C.
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2.3. Streptokinase
Streptokinase is presented as a freeze-dried
powder in vials containing 600,000 units of
streptokinase. Streptokinase is stable for at
least 3 years when stored at room temperature 
o
(<25 C). Solutions prepared for infusion but left 
over or not used should be discarded.
3. STUDY DESIGN
A double blind, randomised, angiographically 
controlled study of intravenous APSAC or i.v. 
streptokinase in acute myocardial infarction with 
stratification according to infarct site.
3.1. Number of patients
A minimum of 80 patients will complete the study.
3.2. Patient Entry
Patients with clinical evidence of acute 
myocardial infarction who satisfy the 
inclusion/exclusion criteria will be eligible for 
randomisation.
3.3. Stratification and Randomisation
Patients will be stratified according to the site 
of infarction. Each stratum has been separately 
pre-randomised to receive APSAC 30 Units i.v. or 
streptokinase 1.5 million Units i.v.
3.4. Coronary Angiography
Angiography will be performed at 90 mins. and at 
24 hrs after dosing.
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3.5. Blood pressure and heart rate monitoring 
Blood pressure and heart rate will be monitored 
immediately before drug and continuously 
throughout the 90 mins. post-treatment period. 
Blood pressure and heart rate will be recorded on 
the case report forms every 2 mins. until the end 
of the 90 min. angiogram.
3.6. Primary Data End Points
3.6.1. Angiographically documented patency 
(occlusion/perfusion grade 2,3) or occlusion 
(occlusion/perfusion grade 0.1) of the presumed 
infarct related vessel at 90 mins. after dosing.
3.6.2. Angiographically documented reocclusion 
(occlusion/perfusion grade 0,1) or sustained 
patency (occlusion/perfusion grade 2,3) at 24 hrs 
after dosing in those who had patent infarct 
related vessels at 90 mins.
4. PATIENTS AND METHODS
All patients with suspected acute myocardial 
infarction who satisfy the inclusion/exclusion 
criteria will be admitted.
5. INCLUSION CRITERIA 
Patients admitted to hospital;
5.1. Aged 70 yrs or under.
5.2. With chest pain or other symptoms of acute
myocardial infarction of at least 30 minutes
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duration who can be treated within 6 hours of 
symptom onset.
5.3. With ECG evidence of ST segment elevation of at 
least 0.1mV in two or more standard leads and/or 
0.2mV in two or more precordial leads.
5.4. In whom appropriate consent is obtained for 
participation in the study.
6 . EXCLUSION CRITERIA
6.1. Patients with systolic blood pressure below 95
mmHg.
"6.2. Patients on anticoagulant therapy.
6.3. Patients with a known history of haemorrhagic 
diatheses or significant recent bleeding from 
another site.
6.4. Patients with documented or suspected active 
peptic ulceration with 1 year.
6.5. Patients with a history of cerebrovascular 
accident.
6.6. Patients who have had surgery, major trauma or
head injury within the previous 4 months.
6.7. Patients who have received streptokinase or APSAC
therapy within the previous 6 months.
6.8. Patients with severe hypertension, blood pressure
above 200/120 mmHg.
6.9. Patients who have received prolonged chest 
compression prior to randomisation.
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Pregnant females or those in whom pregnancy cannot 
be ruled out. Females who are menstruating or who 
are of child bearing potential.
Patients with diabetic proliferative retinopathy. 
Patients in whom coronary angiography is contra­
indicated.
Patients who have had coronary angioplasty within 
1 month of presentation or those with a history of 
CABG or prosthetic valve insertion.
Any condition requiring immediate surgical 
intervention.
Any clinical suspicion of dissecting aneurysm. 
Transmural myocardial infarction within 3 months. 
Patients with serious or life-threatening disease 
unrelated to the circulatory system.
STRATIFICATION AND RANDOMISATION
Patients will be stratified according to the site 
of infarction on the admission ECG. Those with 
anterior or lateral infarction will be assigned to 
group A and inferior or posterior infarction to 
group I. Each of the 2 groups (A and I) has a 
separate randomisation sequence for 30 Units APSAC 
or 1.5 million units of streptokinase.
Consecutive numbers starting from 1 will be used 
within each group.
Two identification, self-adhesive labels will be 
detached from study drug pack, one to be placed in 
the record form and the other attached to a 
postcard which should be posted within 12 hours of 
patient entry. The label identifies the precise 
batch of study drug.
The double blind nature of the study will be 
ensured by a "double dummy" technique. Patients 
will receive "placebo APSAC" and "active 
streptokinase" or "active APSAC" and "placebo 
streptokinase".
8. TREATMENT
The treatment regimen will be as follows:
The vial labelled APSAC will be dissolved in 5 mis 
of water for injection or physiological saline to 
be administered intravenously over jS minutes. To 
minimize foaming, the solution must be gently 
swirled AND NOT SHAKEN.
Two and one half of the three ampoules marked 
streptokinase will be dissolved in 500ml of 5% 
Dextrose to be infused over 60 minutes.
Injection and infusion will begin at the same 
time. Solutions must be administered immediately 
after reconstitution.
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CORONARY ANGIOGRAPHY
Coronary angiography will be via a brachial or 
femoral artery approach. At lease three views 
(LCA) or two views (RCA) of the infarct related 
vessel will be taken during each procedure. One 
of these will be the optimal view for maximising 
the percent residual stenosis.
An angiogram will be performed at 90 minutes from 
the start of dosing. The catheter will then be 
withdrawn, but the sheath will be left in place 
for up to 48 hours.
Perfusion is defined as a grade 2 or 3 
(occlusion/perfusion grade) at 90 minutes. 
Patients with grade 0-1 occlusion at 90 minutes 
will not require further angiographic study and 
will be given the benefit of the best available 
treatment at the discretion of the attending 
physician. They will be recorded as "persistent 
occlusions" for the purpose of the analysis.
Only patients with patency (occlusion/perfusion 
grade 2-3) at 90 minutes will be required to 
undergo coronary angiography at 24 hours after 
dosing, but patients with non-patent arteries at 
90 minutes may undergo further angiography at the 
discretion of the physician in charge.
1 0. BLOOD PRESSURE MONITORING
Arterial pressure and heart rate will be recorded 
immediately before and continuously for 90 mins 
after dosing. Copies of all tracings will be 
reported in the relevant section of the case 
record form prior to their being placed in the 
inside cover.
Based on the result of the 90 minute post 
treatment angiogram, patients with Grade 0-1 
occlusion may be given heparin and/or other 
therapy at the discretion of the attending 
physician. Patients with Grade 2-3 perfusion 
should receive heparin in a dose of 1000-1500 
units per hour from between 4 and 6 hours after 
APSAC therapy or when the thrombin time has 
decreased to less than twice the control value.
Heparin treatment will be continued for 24 hours 
and further anticoagulation is at the physicians 
discretion.
All patients will have single lead continuous ECG 
rhythm recordings for the first 24 hrs of the 
study. Rhythm disturbances will be reported in 
the appropriate section of the case report form.
11 HEPARIN ADMINISTRATION
1 2 . ECG RECORDINGS
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Five 12 lead ECG's are required, these include one 
on admission, at 2, 4, 16, 18 and 24 hours. If 
the patients clinical condition changes 
substantially within the first 24 hours, further 
ECG's may be required.
13. CLINICAL ASSESSMENTS
13.1. Any symptoms thought to be associated with the 
procedure, the treatment or the disease will be 
noted.
13.2. Heart rate and blood pressure will be measured
before dosing and continually for the first 90
mins. after dosing. There will be further non 
invasive measurements at 6, 12 and 24 hrs. after 
dosing or more frequently if indicated by a change 
in the patient's condition.
13.3. Temperature will be monitored at 6, 12 and 24
hours after dosing. Measurements will be taken 
more frequently if indicated by changes in the 
patient's condition.
14. LABORATORY OBSERVATIONS
Blood samples will be drawn to determine Hepatitis 
B status, cardiac enzyme concentrations, clinical 
chemistry, haematology.
14.1. Hepatitis B status
A blood sample will be taken before dosing and
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tested for HBsAg.
14.2. Cardiac Enzymes Concentrations
Blood samples must be taken before dosing, at 90 
mins. and 24 hrs after dosing for the estimation 
of CPK and routine cardiac enzymes.
14.3. Clinical Chemistry and Haematology
Blood samples will be taken before dosing, at 90 
mins. and 24 hours after dosing for a routine 
screen.
14.4. Urinalysis
A urine sample will be collected at 24 hrs after 
dosing for the estimation of pH, blood, ketones, 
protein and bilirubin by means of "Dipstix".
1 5. PRECAUTIONS
15.1. Ancillary medications
No anti-platelet medication for 24 hours after 
thrombolytic therapy.
Additional drugs, such as analgesics, 
antiarrhythmics etc., should be administered in 
accordance with normal hospital practice.
15.2. Dealing with excessive production of plasmin
For the treatment of severe uncontrolled bleeding, 
it is suggested that the following steps be taken:
a) discontinue thrombolytic agent
b) application of local pressure where possible
c) reversal of the lytic state: Administer
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TRANEXAMIC ACID in a standard dose of 500 mg 
intravenously over 2 minutes (other agents may be 
used). A further 500 mg tranexamic acid may be 
administered if the bleeding is not controlled 
after the replacement of clotting factors.
d) replace clotting factors with cryoprecipitate, 
fresh frozen plasma, or whole blood.
e) replace blood loss.
16. STATISTICAL CONSIDERATION
The major efficacy variables in this protocol will 
be patency at 90 minutes and reocclusion after 
patency.
The main objectives of this study are the 
measurements of patency and reocclusion after 
APSAC and streptokinase and the effect of these 
agents on blood pressure. Results will be 
compared using relevant statistical procedures.
Information regarding adverse reactions and 
abnormal laboratory tests will be presented in the 
form of listings and tabulations.
17. DRUG ACCOUNTABILITY
17.1 On-site Storage and Distribution
All investigational drug supplies will be stored
o
in a refrigerator, maintained at 5 C at the study
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site. Shelf life for APSAC is 2 years. Access to 
the study medication must be limited to the 
principal investigator and other authorized 
members of his staff.
During periodic monitoring by Beecham staff, the 
drug supplies and case records will be reviewed 
for accuracy and completeness.
18. INFORMED CONSENT AND PATIENT PRIVACY
It is the investigator's responsibility that each 
subject or subject's legal representative signs an 
informed consent statement prior to participation 
in this study. An example of the patient 
information sheet and consent form are provided at 
the end of the protocol.
The patients will be informed of their rights to 
privacy but will be made aware that study data 
will be submitted to Beecham and to drug 
regulatory authorities for review and evaluation. 
They will also be informed that both Beecham and 
the regulatory authorities have the right to 
inspect the patient's medical records to verify 
the accuracy and completeness of the study records 
and results.
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REPORTING OF ADVERSE EVENTS
The date, time of onset, duration and severity of 
any adverse reaction will be recorded. In the 
event of a persistent severe adverse event, e.g. 
hemiplegia resulting from CVA, the outcome should 
be determined at intervals up to 1 year.
2 8 3
PATIENT INFORMATION SHEET: THROMBOLYTIC THERAPY
A heart attack or a coronary thrombosis is the term used 
for a condition in which the flow of blood to the heart 
muscle is reduced to a degree that damage occurs. The 
reduction in blood flow is usually due to a blood clot or 
thrombus obstructing the arteries leading to the heart 
muscle. After a period of time, damage is irreversible 
and the course of the illness will follow the normal 
healing process. If a patient is admitted to hospital 
early enough, then treatment may be introduced which can 
dissolve the blood clot and can restore flow of blood to 
the area of muscle under threat of permanent damage.
The standard treatment for heart attack within the 
Coronary Care Unit of Stobhill Hospital is to give this 
therapy to dissolve the blood clot - that is thrombolytic 
treatment, to those patients admitted in the early stage 
of coronary thrombosis to obtain coronary artery flow, and 
to reduce the degree of damage. This form of treatment 
cannot be given to patients who have a predisposition to 
bleeding, such as those with stomach or duodenal ulcers, 
or to patients who have had strokes or operations in the 
recent past.
The standard drug available at present for thrombolytic 
therapy is called streptokinase, and at present we are 
conducting a study to compare the effects of this drug 
with a new drug of the same family called APSAC. This 
latter drug has been shown to be very successful in 
dissolving blood clots, and has been used in a widespread 
manner in mainland europe as well as in the U.K. In this 
study you will receive an infusion of either streptokinase 
or APSAC. This treatment is in addition to all normal 
forms of treatment. Although we are studying these drugs, 
their use will not prevent the introduction of any other 
treatment which is necessary for the underlying condition. 
To compare the effects of streptokinase and APSAC we are 
studying their effects on blood clotting, and therefore 
frequent blood sampling is taken from a small plastic tube 
inserted in your arm.
As a follow up to thrombolytic therapy to assess its 
success, and to determine if any other procedures or 
treatment should be given, an x-ray test, called a 
coronary angiogram, is often helpful, and we are 
performing this as part of the present study. This 
requires the insertion of a little plastic tube into an 
artery, and therefore signed consent is required before 
the performance of this test. The actual method of the 
test will be explained separately by the Doctor who will 
perform the procedure at the time. This investigation is 
not routinely performed in all centres, and is an 
additional procedure to the administration of therapy. 
Although we may use the information gained to help in your
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management, the angiogram may not be of direct help in 
your individual case other than confirming your follow up 
treatment. After this x-ray test, a small tube will be 
left in your artery for approximately 24 hours, and our 
study requests that we perform a further angiogram at that 
time in the absence of any clinical contra-indications. 
This is an additional procedure, and would only be 
performed after further discussion and explanation.
There is no compulsion on you to enter the study, and you 
are free to withdraw from the study at any time without 
prejudice to your treatment and long-term follow up.
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ICONSENT FORM
............... (full name and
address)
freely and voluntarily consent to take part in a clinical 
research study on A Comparison of Streptokinase and APSAC in 
the Treatment of Acute Myocardial Infarction with coronary 
arteriogaphy, which so far as is known should not carry any 
unusual risk.
I have read the accompanying information sheet. The nature 
and purpose of the study has been explained to me by 
Dr...............
I have had the opportunity to ask any questions and I 
understand fully what is proposed.
I recognise that I may receive no benefit personally from the 
study. I accept that there may be other risks associated 
with the procedures which are not directly attributable to 
negligence on the part of those undertaking the procedures.
I understand that I am free to withdraw my consent at any 
time without prejudice to me or my medical care. I have 
been assured that any information obtained from me will not 
be disclosed to any other party in a manner which will reveal 
my identity.
Signature .......................  Date ......................
I confirm that I/Dr................have/has explained the
nature and purpose of the clinical research study and the 
procedure in respect of which consent has been given by the 
above named.
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APPENDIX II
PATIENT DETAILS FOR ST SEGMENT STUDY
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SITE
INITIALS AGE SEX OF M.I. TREATMENT REPERFUSIi
1. JW 64 M ANTERIOR i/c SK YES
2. JH 76 M INFERIOR i/c SK YES
3. FM 59 M INFERIOR i/c SK NO
4. MG 56 F ANTERIOR i/c SK YES
5. RC 50 M ANTERIOR i/c SK YES
6. TW 51 M INFERIOR i/c SK NO
7. JD 45 M ANTERIOR i/c SK YES
8. AE 58 M ANTERIOR i/c SK YES
9. WM 67 M ANTERIOR i/c SK YES
10. JL 68 M INFERIOR i/c SK YES
11 . CR 62 M INFERIOR i/c SK YES
12. RW 61 M INFERIOR i/c SK YES
13. MD 66 F INFERIOR i/c SK YES
14. AC 45 M INFERIOR i/c SK YES
15. GMcH 59 M ANTERIOR i/c SK YES
16. EE 58 M INFERIOR i/c SK YES
17. AY 60 M ANTERIOR i/c SK YES
18. AH 75 F INFERIOR i/v APSAC YES
19. JB 68 M ANTERIOR i/v APSAC YES
20. AM 53 M ANTERIOR i/v APSAC NOT KNOWN
21 . JC 62 M ANTERIOR i/v APSAC YES
22. DC 69 M INFERIOR i/v APSAC YES
23. CM 68 M ANTERIOR i/v APSAC YES
24. GS 49 M INFERIOR i/v APSAC NO
25. NB 64 M ANTERIOR i/v APSAC YES
26. WD 61 F INFERIOR i/v APSAC YES
27. JB 67 M INFERIOR i/v APSAC YES
28. CMcG 63 F ANTERIOR i/v APSAC YES
29. AD 67 F INFERIOR i/v APSAC YES
30. AR 39 M INFERIOR i/v APSAC YES
31 . CM 59 F ANTERIOR i/v APSAC YES
32. WD 39 M ANTERIOR i/v APSAC YES
33. JN 69 M INFERIOR i/v APSAC YES
34. JP 45 M ANTERIOR i/v APSAC YES
35. AG 56 F INFERIOR i/v APSAC YES
36. SMcM 65 F INFERIOR i/v APSAC YES
37. EC 59 F ANTERIOR i/v APSAC YES
38. PL 46 M INFERIOR i/v APSAC YES
39. IK 56 M INFERIOR i/v APSAC YES
40. MT 51 M INFERIOR i/v APSAC YES
41 . AM 58 M ANTERIOR i/v APSAC NO
42. RK 58 M ANTERIOR i/v APSAC NO
43. SM 48 F ANTERIOR i/v APSAC NO
44. RH 66 M ANTERIOR i/v APSAC NO
45. DH 49 M ANTERIOR i/v APSAC NO
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APPENDIX III
PATIENT DETAILS FOR ST/QRS STUDY
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GROUP 1
SITE
INITIALS AGE SEX OF M.I.
1. El 33 M ANTERIOR
2. WT 42 M ANTERIOR
3. CMcL 55 M ANTERIOR
4. WK 46 M ANTERIOR
5. AG 61 M ANTERIOR
6. TMcL 65 M ANTERIOR
7. MD 66 M ANTERIOR
8. AG 40 M ANTERIOR
9. HG 44 M ANTERIOR
10. AMcB 50 M ANTERIOR
11 . MC 42 F ANTERIOR
12. GM 40 M ANTERIOR
13. DG 51 M ANTERIOR
14. WW 59 M ANTERIOR
15. JH 49 M ANTERIOR
16. AMcN 67 F ANTERIOR
17. JMcH 41 M ANTERIOR
18. JI 67 F ANTERIOR
19. WD 55 M ANTERIOR
20. GM 62 M ANTERIOR
21 . TI 64 M ANTERIOR
22. FO'H 45 M ANTERIOR
23. HM 37 M ANTERIOR
24. AT 68 F ANTERIOR
25. CJ 56 M ANTERIOR
26. JC 65 F ANTERIOR
27. GW 66 M ANTERIOR
28. RB 69 M ANTERIOR
29. CS 58 M ANTERIOR
30. PMcM 51 M ANTERIOR
31 . JT 76 F ANTERIOR
32. WS 65 M ANTERIOR
33. FE 71 M ANTERIOR
34. PC 62 M ANTERIOR
35. JR 60 M ANTERIOR
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GROUP 2
INITIALS
1. WB
2. AC
3. CF
4. CMcC
5. JW
6. WK
7. MY
8. MG
9. RC
10. JD
11 . AE
12. JA
13. AY
14. CF
15. DM
16. JD
17. LL
18. JH
19. JP
20. RK
21 . EC
22. DJ
23. JC
24. JC
25. EM
26. JD
27. WM
28. JF
29. RMcC
30. WD
31 . EAM
32. JG
33. DG
SITE
AGE SEX OF M.I.
62 M ANTERIOR
53 M ANTERIOR
54 F ANTERIOR
70 F ANTERIOR
64 M ANTERIOR
53 M ANTERIOR
67 F ANTERIOR
56 F ANTERIOR
50 M ANTERIOR
45 M ANTERIOR
58 M ANTERIOR
55 M ANTERIOR
60 M ANTERIOR
52 F ANTERIOR
65 M ANTERIOR
48 F ANTERIOR
67 M ANTERIOR
45 M ANTERIOR
45 M ANTERIOR
58 M ANTERIOR
59 F ANTERIOR
47 M ANTERIOR
64 M ANTERIOR
48 M ANTERIOR
69 F ANTERIOR
49 F ANTERIOR
72 M ANTERIOR
58 M ANTERIOR
62 M ANTERIOR
38 M ANTERIOR
62 F ANTERIOR
60 M ANTERIOR
67 F ANTERIOR
TREATMENT REPERFUSION
i/c SK YES
i/c SK YES
i/c SK YES
i/c SK YES
i/c SK YES
i/c SK NO
i/c SK NO
i/c SK YES
i/c SK YES
i/c SK YES
i/c SK YES
i/c SK YES
i/c SK YES
i/V APSAC YES
i/v APSAC YES
i/v APSAC YES
i/v APSAC YES
i/v APSAC YES
i/v APSAC YES
i/v APSAC YES
i/v APSAC YES
i/v APSAC YES
i/v APSAC YES
i/v APSAC YES
i/v APSAC YES
i/v APSAC YES
i/v APSAC YES
i/v APSAC YES
i/v APSAC YES
i/v APSAC YES
i/v APSAC YES
i/v APSAC YES
i/v APSAC YES
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GROUP 3
SITE
INITIALS AGE SEX OF M.I. TREATMENT
1. JH 61 M ANTERIOR i/v APSAC
2. TMcQ 64 M ANTERIOR i/v APSAC
3. BR 49 M ANTERIOR i/v APSAC
4. JF 45 M ANTERIOR i/v SK
5. SA 47 M ANTERIOR i/v APSAC
6. KA 59 M ANTERIOR i/v SK
7. MK 52 F ANTERIOR i/v APSAC
8. WT 61 M ANTERIOR i/v SK
9. AB 48 M ANTERIOR i/v SK
10. PM 59 M ANTERIOR i/v SK
11 . JG 48 M ANTERIOR i/v SK
12. AW 68 F ANTERIOR i/v SK
13. JS 53 M ANTERIOR i/v APSAC
14. JE 40 M ANTERIOR i/v APSAC
15. JC 31 M ANTERIOR i/v APSAC
16. JM 62 M ANTERIOR i/v APSAC
17. DC 46 M ANTERIOR i/v APSAC
18. JS 57 M ANTERIOR i/v SK
19. DMcC 59 F ANTERIOR i/v APSAC
20. JO 59 M ANTERIOR i/v SK
21 . JB 55 M ANTERIOR i/v APSAC
22. RN 56 M ANTERIOR i/v APSAC
REPERFUSION
NO
YES
YES
NO
YES
NO
YES
YES
NO
NO
YES
NO
NO
NO
YES
NO
YES
YES
YES
NO
YES
NO
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APPENDIX IV 
PROGRAM FOR QRS SCORE COMPUTATION
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cn 
cn 
cn 
cn 
c.n 
cn 
ci 
C4 
c-4 
C4 
c-j 
u 
ci 
c-4 
>.a 
o\
 m 
nj 
ro 
io 
rj 
i-o 
i-j 
ro 
ro 
m 
 ^
r- 
k* 
h- 
i-*.
 
 ^
 ^
s-*-
cn 
-fs 
C--4 
f'J 
H.
 
Q 
sJ3 
0 
Nl
 
£> 
LH 
4s 
L--4 
h-J 
 ^
Q 
O 
® 
'-J 
O- 
(J!
 
-C 
i.A 
NJ 
*-■>
• 
© 
-0 
CO 
"-J 
l> 
UI
 
-fi 
C-4 
i\3 
S3 
-0 
03 
'-••.!
 
0-
 
U1 
-£■
 
C-4 
fO
1 C#
4 C
5 C
6 C
7 C 
CS 
9 
10 
1 1
:cgscr
SUBROUT INE ECGSCR(QDUR,RDUR,S,RQ,RS,SCORE)
DIMENSI ON QDUR(11),RDUR(11) ,S (11) ,RQ(11) , RS(11 )
998
C
60
60
640
70
70
760
750
80
80
WRITE(1 
WRITE(1 
WRITE (1 
WRITE ( 1 
WRITE (1
993) 
993) 
993) 
99S) 
998)
(QDUR(I) 
(RDUR(I)
1 =  1 
1 =  1
1 1 ) 
1 1 )
(S ( I ) , 
(RQ ( I )
= 1,1 1 )
1= 1 ,1 1 )
1= 1 , 1 1 )
)
LT. 30.) GOTO 20
20
28
40
40
50
50
1.0) SC0RE: 
SCORE
=SC0RE+1
GE. 30.) 
GE. 40.) 
SCORE
S C 0 R E=S C 0 R E +1 
S C Q R E = S C 0 R E +1
LT. 30.> GOTO 50
1 .0 ) 
SCORE
30
3 C 0 R E=S C O R E +1
GOTO 60
SCDRE=SCORE+l 
SCORE=SCORE+1 
GOTO 55
FORMAT(11F6.
XL=0.0001 
SCORE=0 
IF(QDUR(1) .
SCORE=l.
IF(RQ(1).LE.
WRITE(1,999)
CONTINUE 
IF(QDUR(2) .
IF(QDUR(2) .
WRITE(1,999)
CONTINUE 
IF(QDUR(4) .
3 C 0 R E=S C 0 R E +1 
IF (RQ(4) .LT.
WRITE(1,999)
CONTINUE 
IF (QDUR(5) .LT.
SCORE=SCORE+l 
QQ=QDUR(5)
IF(QQ. GE. 50.)
IF(QQ .GE. 40.) £
IF(RDUR(5).GE.XL)
S C 0 R E=S C 0 R E+2 
GOTO 60
IF (RQ (5) .LE. 2. ) SCORE=SCORE+1
IF(RQ(5) .LE. 1.) S C O R E=S C O R E+1
WRITE(1,999) SCORE 
CONTINUE
IF (QDUR(6) .GT. XL) SCORE=SCORE+l 
IF(RDUR(6).LT. 40.) GOTO 70 
SCORE=SCORE+l
IF(RDUR(6).GT.50.) 3C0RE=SC0RE+1 
IF(RS(6).GE.1.0 .OR. S(6).LE.XL) 
WRITE(1,999) SCORE 
CONTINUE
IF (QDUR(7) .LE. XL .AND. RDUR(7) 
SCORE=SCORE+l
IF(RDUR(7).GT.60.) SCORE=SCORE+l 
IF (RDUR(7) .GE. 50.) SCORE=SCORE+1 
IF(RDUR(7).LT.50.) GOTO 80 
IF(RS (7) .GE. 1.5 .OR. S(7)
WRITE(1,999) SCORE 
CONTINUE
IF(QDUR(8).GT.XL.OR.(RDUR(8)
+ SCORE=SCORE+l 
90 WRITE(1,999) SCORE
SC0RE=SC0RE+1
GT. 20.) GOTO 760
LT.XL) SCORE=SCORE+1
LE. 30. .AND. RDUR (8) .GT. XL.) )
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56 C 90 CONTINUE
57 IF (QDUR(9) .LE.28. ) GOTO 920
58 SCORE-SCORE +■1
59 IF(RDUR(9).GT.XL) GOTO 905
6(3 SC0RE=SC0RE+2
61 GOTO 108
62 905 IF(3(9).LE.XL) GOTO 910
63 IF (RQ (9).LE.1. .OR. RS(9) .LE. 1.) SCORE=SCORE+1
64 IF(RQ(9).LE.8.5 .OR. RS(9).LE.0.5) SCORE=SCORE+1
65 GOTO 108
66 910 IF(RQ(9).LE.1.0) SCORE=SCORE+1
67 IF(RQ(9).LE.8.5) SCORE=SCQRE+1
68 GOTO 100
69 920 IF (RS (9) .LE.1.0.AND.8(9) .GE.XL) SCORE=SCGRE+1
78 IF(RS(9) .LE.0.5.AND.S (9) .GE.X L) SCORE=SCORE+1
71 100 CONTINUE
72 WRITE(1,999) SCORE
73 IF(QDUR(10).LE.30.) GOTO 1030
74 SCORE=SCORE+l
75 IF(RDUR(18).GT.XL) GOTO 105
76 S C 0 R E=S C 0 R E+2
77 GOTO 110
78 185 IF(S(10).LE.XL) GOTO 1028
79 IF(RQ(10).LE.2.0 .OR. RS(18).LE.2.8) SCORE=SCCR£+1
88 IF < RQ(18) .LE.1.8 .OR. RS(13) .LE. i.0) 3C0RE=SC0RE+1
81 GOTO 110
82 1020 IF(RQ(10).LE.2.0) SCGRE=SCGRE+1
83 IF (RQ (10) .LE. 1.8) SC0RE=SC0 R E +1
84 GOTO 110
85 1038 IF(RS(10).LE.2.0.AMD.S (10).GE.XL) SCQRE=SCOEE+1
36 IF(RS(10).LE.1.0.AND.S (10).GE.XL) SCORE=SC0RE+1
87 110 CONTINUE
88 WRITE(1,999) SCORE
39 IF(QDUR(11).LE.38.) GOTO 1130
90 SCORE=SCORE+1
91 IF(RDUR(11).GT.XL) GOTO 115
nn SCORE=SC0RE+2
93 GOTO 120
94 1 15 IF (S(11) .LE.XL) GOTO 1120
95 IF(RQ(11).LE.3.0 -OR. RS(11).LE.3.0) SCORE=SCORE+l
96 IF(RQ(11).LE.1.0 .OR. RS(11).LE.1.0) SCORE=SCORE+1
97 GOTO 120
98 1 120 IF(RQ(11).LE.3.0) SCORE=SCORE+1
99 IF(RQdl) .LE. 1.0) SCORE=SCORE+l
100 GOTO 120
101 1 130 IF(RS(11).LE.3.0 .AND. S(ll).GE.XL) SCORE=SCORE+l
102 IF(RS(11).LE.1.0 .AND. S(ll).GE.XL) SCORE=SCORE+l
103 120 CONTINUE
104 WRITE(1,999) SCORE
105 999 FORMAT(9SCORE = 9 fF6.Z)
106 RETURN
107 END
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APPENDIX V
ECG DATA FROM INTRA AND INTER-OBSERVER VARIATION STUDY
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LIST OF PATIENTS USED IN INTER 
Pt. No. Initials Age Sex
1 . AS 64 F
2. PL 49 M
3. TMcK 23 M
4. WM 70 M
5. ML 49 M
6. AMcM 55 F
7. JM 52 M
8. CT 62 M
9. KH 50 M
10. ES 45 F
AND INTRA-OBSERVER VARIATION 
ECG
Evolving acute inferior 
myocardial infarction
Within normal limits
Within normal limits
Hyperacute inferior 
myocardial infarction
Acute anterior myocardial 
infarction
Inferior myocardial 
infarction
Inferolateral ischaemia
Anterior myocardial 
infarction
Inferior myocardial 
infarction
Lateral ischaemia
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APPENDIX VI
PATIENT DETAILS FROM ANISTREPLASE STREPTOKINASE COMPARISON TRIAL
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No. Initials Age Sex IRA Drug Prev. M .I
1 . JM 68 M RCA SK No
2. JMcG 66 M RCA SK No
3. DC 50 M RCA SK No
4. JC 51 M LAD SK No
5. NMcD 57 F RCA APSAC No
6. WN 42 M RCA APSAC No
7. JOC 42 M RCA APSAC No
8. WS 55 M n /a SK No
9. JH 61 M LAD APSAC No
10. CMcN 59 M RCA SK Yes
11 . TR 67 M RCA SK No
12. PW 49 M RCA APSAC No
13. EMc I 60 M LAD SK No
14. IA 64 F LAD APSAC Yes
15. TMcQ 64 M LAD APSAC No
16. WW 55 M RCA APSAC No
17. RM 59 M RCA SK No
18. BR 49 M LAD APSAC No
19. MH 52 F N/A APSAC Yes
20. JF 45 M LAD SK No
21 . SA 47 M LAD APSAC No
22. TG 45 M RCA SK No
23. RMcC 42 M RCA APSAC No
24. PK 44 M RCA SK No
25. DU 49 M Cx APSAC No
26. JH 45 M RCA SK No
27. WC 55 M RCA APSAC No
28. RR 55 M RCA APSAC No
29. KA 59 M LAD SK No
30. MK 52 F LAD APSAC No
31 . GMcM 58 F RCA APSAC No
32. NG 58 F RCA SK No
33. WT 61 M LAD SK No
34. PD 50 M LAD SK Yes
35. AB 48 M LAD SK No
36 WMcL 58 M RCA APSAC No
37. AP 68 M RCA SK Yes
38. WM 53 M LAD APSAC No
39. CM 55 M RCA APSAC No
40. EH 68 F RCA SK Yes
41 . JC 65 M LAD APSAC No
42. WD 52 M RCA SK No
43. JA 52 F RCA SK No
44. SB 66 F RCA APSAC No
45. FC 44 M LAD APSAC No
46. JL 70 M LAD APSAC No
47. GC 47 M LAD SK Yes
48. RMcD 67 M RCA SK No
49. MH 64 F Cx APSAC No
50. RE 60 M RCA APSAC No
51 . PL 58 M RCA APSAC No
52. JD 43 M RCA SK No
53. JF 68 M LAD APSAC No
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54. MMcL 59 F RCA APSAC No
55. RD 40 M RCA SK No
56. JH 54 M N/A SK Yes
57. PM 59 M LAD SK No
58. JG 48 M LAD SK No
59. AF 44 M RCA SK No
60. SW 65 F Cx SK Yes
61 . AW 68 F LAD SK No
62. MMcG 53 M RCA APSAC No
63. AO'N 58 F Cx APSAC No
64. EMcG 57 M RCA SK No
65. JB 67 M LAD APSAC No
66. WL 61 M LAD SK Yes
67. JS 53 M LAD APSAC No
68. JE 40 M LAD APSAC No
69. JC 31 M Cx APSAC No
70. AM 56 M n /a SK No
71 . JM 62 M LAD APSAC Yes
72. WMcC 59 M RCA APSAC No
73. DC 46 M LAD APSAC No
74. JS 57 M LAD SK No
75. DMcC 59 F LAD APSAC No
76. WMcL 64 M LAD APSAC No
77. CA 65 F RCA SK No
78. ED 55 M LAD SK No
79. FH 54 M RCA APSAC No
80. WA 47 M RCA SK No
81 . DP 56 M Cx SK No
82. WMcI 51 M RCA SK No
83. JO 59 M LAD SK No
84. NMcN 61 M Cx APSAC No
85. CG 60 F RCA APSAC No
86. WS 50 M RCA APSAC No
87. GH 67 M LAD SK No
88. RN 56 M LAD APSAC No
89. JB 55 M LAD APSAC No
90. GT 67 M LAD SK No
91 . GR 51 M Cx APSAC No
92. RS 58 M N/A APSAC No
93. JN 64 M RCA SK No
94. WD 54 M RCA SK No
95. JH 55 M LAD SK No
96. JA 57 F LAD SK No
97. MD 59 F LAD APSAC No
98. NU 42 M LAD SK No
99. RK 41 M LAD SK No
100. TM 46 M LAD SK Yes
101 . MM 62 F LAD APSAC No
102. JL 62 M LAD APSAC No
103. EH 45 M RCA APSAC No
104. HH 59 M Cx APSAC No
105. JW 56 M RCA APSAC No
106. EC 52 F RCA APSAC No
107. TS 54 M LAD SK No
108. JMcG 42 M RCA APSAC No
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109.
1 1 0. 
1 1 1 . 
1 1 2 .
113.
114.
115.
116.
117.
118.
119.
1 2 0 . 
121 . 
1 2 2 .
123.
124.
125.
126.
127.
128.
AB 47 F
MT 55 F
MS 55 F
RH 55 M
PM 52 M
AR 64 M
JJ 70 F
PR 61 M
DMcG 43 M
JS 61 M
PC 51 M
TJ 41 M
TM 63 M
CM 41 F
GMcD 65 M
CC 66 F
DC 65 M
RK 69 M
HT 67 M
RH 57 M
RCA SK Yes
RCA SK No
LAD SK No
RCA SK No
Cx SK No
RCA APSAC No
N/A SK No
N/A APSAC Yes
Cx APSAC No
Cx APSAC No
LAD APSAC NO
LAD SK No
RCA APSAC No
RCA APSAC No
LAD SK No
RCA APSAC No
LAD SK No
LAD SK No
LAD SK No
LAD APSAC No
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APPENDIX VII 
DEFINITION OF TIMI SCORES
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GRADE O
GRADE 1
GRADE 2
GRADE 3
DEFINITION OF TIMI SCORES 
(Williams et al., 1986)
(No reperfusion): There is no antegrade flow
beyond the point of occlusion.
(Penetration with minimal perfusion): The
contrast material passes beyond the area of
obstruction, but "hangs up" and fails to opacify
the entire coronary bed distal to the obstruction
for duration of the cine run.
(Partial perfusion): The contrast material passes 
across the obstruction and opacifies the coronary 
bed distal to the obstruction. However, the rate 
of entry of contrast material into the vessel 
distal to the obstruction or its rate of 
clearance from the distal bed (or both) are 
perceptibly slower than its entry into or 
clearance from comparable areas not perfused by 
the previously occluded vessel, e.g. the opposite 
coronary artery or the coronary bed proximal to 
the obstruction.
(Complete perfusion): Antegrade flow into the bed 
distal to the obstruction occurs as promptly as 
antegrade flow into the bed proximal to the 
obstruction, and clearance of contrast material 
from the involved bed is as rapid as clearance 
from an uninvolved bed as the same vessel or the 
opposite artery.
303
APPENDIX VIII
PUBLICATIONS AND PRESENTATIONS ARISING FROM WORK OF THESIS
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PUBLICATIONS
1 . Electrocardiographic prediction of coronary artery 
patency following thrombolytic therapy in acute 
myocardial infarction using the ST Segment as a non 
invasive marker.
Hogg KJ, Hornung RS, Howie CA, Hockings N, Dunn FG, 
Hillis WS.
Br Heart J 1988;60:275-80.
2. Electrocardiographic evidence of myocardial salvage 
following thrombolysis in acute myocardial 
infarction.
Hogg KJ, Lees KR, Hornung RS, Howie CA, Dunn FG, 
Hillis WS.
Br Heart J 1989;61:489-95.
3. Angiographic patency study of anistreplase versus 
streptokinase in acute myocardial infarction.
Hogg KJ, Gemmill JD, Burns JMA, Lifson WK, Rae AP, 
Dunn FG, Hillis WS.
Lancet 1990;335:254-258.
PRESENTATIONS
1 . ST Segment analysis as a non invasive predictive 
indicator of coronary artery reperfusion in acute 
myocardial infarction.
Hogg KJ, Hornung RS, Hockings N, Dunn FG, Hillis WS. 
Scottish Society for Experimental Medicine:
Dundee. May, 1985.
(Abstract Scottish Medical Journal 1985;30:194).
2. ST Segment analysis as a non invasive predictive 
indicator of coronary artery reperfusion in acute 
myocardial infarction.
Hogg KJ, Hornung RS, Hockings N, Dunn FG, Hillis WS. 
European Society of Cardiology.
Brighton. September, 1985.
Abstract European Heart Journal 1985;6 Suppl. 1
p.16).
3. Electrocardiographic evidence of myocardial salvage 
following thrombolysis in acute myocardial 
infarction.
Hogg KJ, Lees KR, Hornung RS, Dunn FG, Hillis WS. 
Eighth International Congress on Fibrinolysis. 
Vienna. August 1986.
(Abstract Fibrinolysis Volume 1, Suppl. 1, 1986).
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4. Thrombolysis in acute myocardial infarction with 
APSAC, electrocardiographic evidence of reduction in 
infarct size.
Hogg KJ, Lees KR, Hornung RS, Dunn FG, Hillis WS.
X World Congress of Cardiology.
Washington. September 1986.
(Abstract Proceedings of X World Congress of 
Cardiology p.35).
5. Comparative effect of anistreplase and streptokinase 
on coronary artery patency in acute myocardial 
infarction.
Hogg KJ, Gemmill JD, Lifson WK, Burns JMA, Rae AP, 
Dunn FG, Hillis WS.
American Heart Association.
New Orleans. November 1989.
(Abstract Circulation 1989;80:Suppl. 11:11-419.)
6. ECG correlates of early coronary artery patency and 
myocardial perfusion following thrombolysis.
Hogg KJ, McKenzie A, Howie CA, Gemmill JD, Rae AP, 
Dunn FG, Hillis WS.
British Cardiac Society.
Torquay. May 1990.
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